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ABSTRACT

The analgesic and anti-inflammatory effects of the nonsteroidal anti
inflammatory drugs (NSAIDs) ketoprofen (2.2 and 3.63 mg/kg) and phenylbutazone
(4.4 mg/kg) were compared in equine models of acute synovitis and chronic hoof
pain. The eicosanoids, prostaglandin Ej (PGE?) and leukotriene B4 (LTB4), increased
dramatically in synovial fluid after carrageenan-induced synovitis of the intercarpal
joint.

PGE2 concentrations in untreated horses peaked at 9 hours while LTB4

concentrations peaked in all horses at 3 hours. Synovial fluid concentrations of both
eicosanoids returned to near baseline by 48 hours. Lameness, joint temperature, and
synovial fluid volume, protein and nucleated cells increased at 3 to 12 hours with
reduction to near baseline levels by 48 hours. NSAIDs when given intravenously
decreased joint concentrations of PGE^ but LTB4 levels were unaffected by drug
administration. Both drugs decreased the signs of inflammation and lameness, but
phenylbutazone was more effective. These data suggest that leukotrienes are involved
in equine synovitis and the development of specific leukotriene inhibitors may be of
therapeutic value. The plasma half-life of ketoprofen (2.2 mg/kg) in normal horses
(0.88 hours) was higher than horses with synovitis (0.55 hours). Synovial fluid levels
of ketoprofen in horses with synovitis were 6.5 times higher than normal horses at one
hour. The area under the synovial fluid concentration curve for horses with synovitis
was greater than in normal horses. These data suggest that the inflamed joint may
serve as a site of sequestration for ketoprofen. Digital vein eicosanoid levels from

horses with hoof pain from chronic laminitis were not different than those in normal
horses. Although hoof pain and lameness could not be attributed to eicosanoids, both
effects were reduced by the systemic administration of NSAIDs. Ketoprofen at a dose
of 3.63 mg/kg (phenylbutazone equimolar dose) reduced hoof pain and lameness to
a greater extent than the 2.2 mg/kg dose and phenylbutazone. These effects were still
present at 24 hours for 3 of the 4 measures of hoof pain. These data suggest that
phenylbutazone was more potent in alleviating acute joint inflammation whereas
ketoprofen at a dosage rate of 1.65 times the therapeutic dose was more potent in
alleviating chronic pain and lameness in horses.

CHAPTER 1
GENERAL INTRODUCTION

This dissertation is organized in the journal style. A global introduction and
literature review precede separate chapters on specific themes, which are followed by
a general conclusion chapter.

The literature review (Chapter 2) encompasses three

areas that were relevant to the course of this dissertation research: inflammation, pain
and the use of nonsteroidal anti-inflammatory drugs to alleviate these conditions.
Chapters 3 through 6 describe the development of models and analytical techniques
along with the experiments used in the testing of the overall research hypothesis and
specific objectives. Chapter 7 consists of an overall summary of results, conclusions
and indications for future research.
This dissertation research was designed to bring further understanding to the
mechanisms and alleviation of pain and inflammation in the horse.

Inflammation

occurs in many forms in the horse. This pathological process results in significant
morbidity and often, mortality. Musculoskeletal inflammation in particular shortens
the working life of the horse and results in considerable pain. Our treatment options
at present are limited to a few steroidal and nonsteroidal agents that have been
approved for use in the horse. Many of these products are older drugs that were
originally used in humans. Researchers of nonsteroidal anti-inflammatory agents have
tried to identify novel drugs that are more efficacious in relieving inflammation and
pain than traditional drugs.

This research has lead to the discovery of a more
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complex array of inflammatory mediators and modulators. Since the discovery of the
pro-inflammatory leukotrienes, emphasis has been placed on developing inhibitors of
lipoxygenase and specific leukotriene antagonists.
The research hypothesis of this dissertation is that nonsteroidal anti
inflammatory drugs (NSAIDs) that inhibit the cyclooxygenase and lipoxygenase
mediated breakdown of arachidonic acid are potentially more effective alleviators of
pain and inflammation than NSAIDs that solely inhibit cyclooxygenase. The overall
objective of this research was to compare the putative cyclooxygenase and
lipoxygenase inhibitor, ketoprofen to the cyclooxygenase inhibitor, phenylbutazone in
equine models of acute joint inflammation and chronic pain. Prostaglandin Ej (PGEj)
and leukotriene B4 (LTB4) were chosen as measures of cyclooxygenase and
lipoxygenase activity, respectively, based on their potent inflammatory and pain
mediating properties. Specific objectives were as follows:
1) Develop a self-limiting, reproducible model of acute synovitis which
increases prostaglandin Ej (PGEj) and leukotriene B4 (LTB4) concentrations in
synovial fluid and produces other measurable joint inflammatory responses.
2) Compare the magnitude and time course of the anti-inflammatory and
eicosanoid inhibitory effects of ketoprofen and phenylbutazone in the acute synovitis
model.
3) Compare the ability of ketoprofen and phenylbutazone to reduce the clinical
signs of acute synovitis.
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4) Compare the time course of the anti-inflammatory effects of ketoprofen with
its plasma and synovial fluid drug concentrations.
5) Determine whether digital vein eicosanoid concentrations are greater in
horses with chronic laminitis than normal horses.
6) Providing that there are higher eicosanoid concentrations in laminitic versus

normal horses, correlate the severity of hoof pain with the eicosanoid concentrations.
7) Determine the magnitude and time course of the eicosanoid inhibitory effects
of ketoprofen and phenylbutazone in horses with chronic laminitis.
8) Objectively quantitate and compare the analgesic effects of ketoprofen and

phenylbutazone in horses with chronic hoof pain associated with chronic laminitis.

CHAPTER 2
LITERATURE REVIEW

A. Introduction
This review will focus on the specific types of inflammation and pain
associated with the experimental models used in this dissertation research. Emphasis
will be placed on the particular drugs and eicosanoids which influence inflammation.
Experimental models of joint inflammation will be discussed.

In particular,

carrageenan-induced joint inflammation and the clinical diseases of arthritis, synovitis
and chronic laminitis will be reviewed in detail. The properties of the eicosanoids,
prostaglandin Ej and leukotriene B4 will be discussed as well as the inhibition of these
substances by the nonsteroidal anti-inflammatory agents (NSAIDs), ketoprofen and
phenylbutazone. A discussion of acute and chronic pain will also be included.
B. Inflammation
Inflammation is a local, defensive process elicited by tissue insult resulting
ultimately in destruction, dilution or isolation of the offending agent and injured
tissues. This dynamic process in most cases restores homeostasis, but if unregulated
may have deleterious effects on the affected tissue or organ. Inflammation was
originally described by the first century writings of the Roman, Cornelius Celsus as:
rubor et tumor cum calore et dolore, "redness (erythema) and swelling (edema) with
heat and pain (nociception and hyperalgesia)."

The founder of modem cellular

pathology, Rudolph Virchow, added the fifth cardinal sign of inflammation, functio
4

laesa or loss of function [1]. Inflammation typically occurs in three phases: 1) an
acute transient phase characterized by local dilation of arterioles, capillaries, and
venules resulting in increased blood flow and increased vascular permeability with
exudation of fluids and plasma proteins; 2) a delayed subacute phase marked by
infiltration of leukocytes and phagocytic cells; and 3) the chronic proliferative phase
in which tissue degeneration and fibrosis lead to healing or chronic inflammation.
[2,3].
1. Stimuli
Inflammation may be elicited by a number of stimuli including: infectious
agents such as microbial organisms and parasites, ischemia, antigen-antibody
interactions, exposure to radiation or electrical energy, extreme temperatures,
mechanical trauma and noxious chemicals [3,4]. Experimentally, chemical irritants
have been used extensively to mimic the inflammatory response.
Regardless of the etiology, most forms of acute and chronic inflammation
involve the cellular and humoral components of the immune system. The inciting
cause is first recognized as a foreign antigen by surface antibodies on B lymphocytes
or via macrophage presentation to receptors on T lymphocytes. This recognition leads
to the production of pro-inflammatory substances which result in transitory
vasoconstriction followed by arteriolar and precapillary vasodilation, capillary
recruitment, and increased vascular permeability due to contraction of endothelial
cells.

Fluid and protein exudation follow as blood flow is first increased then

decreased resulting in hyperemia and congestion. Leukocytes marginate within the

vessels and adhere to vascular endothelium. Ultimately, these cells migrate to the
inflammatory locus and begin degranulating, leading to destruction of the inciting
agent and surrounding tissue. Destruction of the antigen is the responsibility of the
phagocytic cells: neutrophils; monocytes and in some cases, eosinophils. The tissue
macrophages, e.g. Kupffer cells and type-A synovial lining cells, also play important
local roles [2,4].
2. Mediators
a. Eicosanoids
Inflammation is mediated and in some cases modulated by various autocoids
or local hormones.

The eicosanoids are a family of lipid-derived autocoids that

include the prostaglandins, thromboxanes, leukotrienes and the lipoxins. Eicosanoids
are derived from 20-carbon polyunsaturated essential fatty acids [5]. Arachidonate is
the most abundant precursor of the eicosanoids and it is derived from dietary linoleic
acid. Arachidonic acid is then esterified to the phospholipids of cell membranes or
other complex lipids.
i. Release o f arachidonate
Arachidonic acid is released from cellular lipids de novo by acyl hydrolases.
This release is closely regulated and occurs in response to reduced oxygen tension,
thrombin generation, hormones, immunologic reactions, ultraviolet light, tumorproducing agents or other irritant stimuli that interact with membrane bound receptors
coupled to guanine nucleotide-binding regulatory proteins. These G proteins then
either directly activate phospholipase C and or A2 or indirectly activate these enzymes

through an increase in cytosolic calcium. Phospholipase A2 hydrolyzes the ester bond
of membrane phospholipids such as phosphatidylcholine and phosphatidylethanolamine
to release arachidonate. Phospholipase C cleaves the phosphodiester bond, resulting
in the formation of a 1,2-diglyceride leading to the release of arachidonic acid [6].
Once arachidonic acid is freed it may be acted upon by the cyclooxygenase or the
lipoxygenase enzyme systems to produce eicosanoids (Figure 1).

In addition,

arachidonic acid may be metabolized by the epoxygenase pathway in neutrophils
through a cytochrome P-450-dependent mixed-function oxidase leading to the
formation of unstable epoxides [7].
ii. Enzymes
The first enzyme in the production of prostaglandins is prostaglandin
endoperoxide synthase or as it is more commonly called, fatty acid cyclooxygenase.
This microsomal enzyme is present in all cells, except mature erythrocytes [6]. This
enzyme has two activities; one is an endoperoxide synthase activity that oxygenates
and cyclizes arachidonate acid to form the cyclic endoperoxide prostaglandin G2
(PGG2) and a peroxidase activity that converts PGG2 to prostaglandin H2 (PGHj) by
reducing the 15-hydroperoxy group to a 15-hydroxy.

Isomerases synthesize

prostaglandin E* (PGEj), prostaglandin D2 (PGD^ and prostaglandin

(P G F ^ from

PGH2. The unstable endoperoxide PGH2 is also metabolized to thromboxane A2
(TXAj) and prostacyclin (PGI2) [8], The specific prostaglandins produced vary with
different cells or tissues depending upon the synthases and isomerases present [9].
Lipoxygenase enzymes are found in the pulmonary tissue, platelets and leukocytes [6].
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Lipoxygenases are a group of membrane-associated enzymes that oxygenate
polyunsaturated fatty acids to lipid hydroperoxides [10]. The enzymes require a fatty
acid substrate with two cis double bonds separated by a methylene group and are
regulated by the presence of calcium [6].

The arachidonate metabolites of

lipoxygenase are called hydroperoxyeicosatetraenoic acids (HPETEs). This enzyme
system, like the cyclooxygenase enzyme, goes through an activation phase where it
generates metabolites that act as positive and then negative feedback regulators
[10,11]. Lipoxygenases differ in their specificity for placing the hydroperoxy group
and tissues differ in the lipoxygenases they contain. For instance, platelets have only
12-lipoxygenase while leukocytes have 5-, 12-, and in some species, 15-lipoxygenases
[12]. The HPETEs are unstable intermediates analogous to PGG2 or PGH2 and are
further degraded by a series of enzymes. HPETEs may be converted to hydroxy fatty
acids (HETEs) by a peroxidase or nonenzymatically. In a relatively newly elucidated
pathway 12-HPETE can undergo a molecular rearrangement to form the hepoxillins
while 15-HPETE may be converted by leukocytes to the lipoxins [6].

The 5-

lipoxygenase enzyme leads to the synthesis of the pro-inflammatory leukotrienes
through the metabolite, 5-HPETE. Leukotriene A synthase catalyzes the formation
of the unstable 5,6-epoxide leukotriene A4 (LTA4) from 5-HPETE. Leukotriene B4
(LTB4) or (5S, 12R)-dihydroxy-6,14-cw-8, lO-f/ww-eicosatetraenoic acid is formed
from LTA4 by LTA hydrolase.

Alternatively, LTA4 can be nonenzymatically

hydrolyzed to diastereomers of 5,6-dihydroxyeicosatetraenoic acid (5,6-diHETE), and
6,8,10-rra/w-14-c«-diastereomers of 5,12-diHETE [13]. These hydrolysis products
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have little biological importance as compared to LTB4. In a separate microsomal
pathway, LTA4 may be conjugated with glutathione at the 6 position to form the
sulfidopeptide leukotrienes: LTC4, D4, E», and F4. LTC4, LTD4 and LTE4 are also
known as the slow-reacting substances of anaphylaxis [13].
mi .

Prostaglandins

Prostaglandins are named according to substitutions on the cyclopentane ring
and numbered according to the number of double bonds in the alkyl side chains [5].
The number 1 carbon is located at the carboxyl terminus.

Prostaglandins of the

subscript 2 series are the major ones in mammals and this nomenclature denotes
derivation from arachidonic acid whereas the subscript 1 and 3 series may come from
other polyunsaturated fatty acid precursors [5,14]. Prostaglandins of the E and D type
are hydroxyketones while the F a series are 1,3 diols [6]. Many tissues have specific
prostaglandin receptors through which cell function is regulated via two second
messenger systems: regulation of intracellular synthesis of cyclic AMP by activation
or inhibition of adenylate cyclase and stimulation of phospholipase C resulting in the
formation of inositol-1,4,5-triphosphate leading to a rise in intracellular calcium.
These messenger systems in turn regulate various protein kinases which control
cellular activity [6].
By most reports, the predominant stable prostaglandin product of leukocytes
is PGEj [15]. PGEj produces long lasting dermal erythema and increased blood flow
in cutaneous vessels and superficial vessels. PGE2 produces little plasma exudation
alone, but potentiates exudation after injection of chemical irritants, histamine and

11
bradykinin [16,17]. Prostaglandins increase vascular permeability in conjunction with
serotonin and bradykinin by inducing vascular leakage in venules [18].

The effect

of PGE2 on plasma exudation has been studied in the skin of horses [19]. When PGE2
was co-administered with bradykinin the volume of plasma exudate increased
markedly. This synergistic effect was not seen with PGEj and histamine in equine
skin. PGEj has similar activities as PGEj, but it is less abundant [6]. In contrast to
other species, PGE2 is chemotactic for equine neutrophils at concentrations of 1 and
10 ng/ml [20].

The functions of T and B cells are modified by PGEj in vitro at concentrations
similar to inflammatory exudates (10-8 M). Secretion of interleukin-2 is inhibited by
PGE2 in T cells accounting for inhibition of mitogen and antigen-induced T cell
proliferation by PGEj [9]. This inhibition and the inhibitory effects of PGEj on B cell
proliferation is associated with elevated intracellular levels of cyclic AMP [9,18].
Human rheumatoid T cells are particularly susceptible to this effect of PGEj which
leads to a deficient production of interferon and other lymphokines [9]. Several other
inflammatory modulation activities have been demonstrated by PGE, and PGE2 such
as: inhibition of LTB4 production [21], inhibition of lysosomal enzyme release [22],
inhibition of 0 2 release and inhibition of neutrophil activation [23].

Thus, there

appear to be paradoxical anti-inflammatory properties as well as pro-inflammatory
effects associated with prostaglandins.
Prostanoids are not stored but are synthesized de novo and rapidly metabolized
and excreted in the urine. TXA2 and PGI2 hydrolyze in less than 2 minutes to the
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more stable compounds, TXBj and 6-keto PGFlo, respectively [9]. PGF2a can be
metabolized by a 9-keto reductase to form PGEj in some tissues [6].

PGEj is

metabolized initially to 15-keto-13, W-dihydro-PGEj [24]. This reaction is catalyzed
by 15-hydroxy prostanoate dehydrogenase and A13-reductase which are present in most
tissues, but are found in high concentrations in the liver, kidney and lung [24]. The
metabolites of prostaglandins are cleared from the circulation very quickly [25] by one
or two steps of /?- and w-oxidation in the lung and liver [24,26].
iv. Leukotrienes
Leukotrienes of the subscript 4 series are derived from arachidonic acid. Other
polyunsaturated fatty acid precursors give rise to the 3 and 5 series [5]. Receptors for
LTB4, LTC4 and LTIVLTE* have been identified which respond by activation of
phospholipase C. LTB4 receptors have been found on neutrophils and monocytes,
while receptors for LTD4 and E4 have been found on smooth muscle cells [6].
LTB4 promotes leukocyte adherence, chemotaxis and degranulation [27,28].
The chemotactic properties of LTB4 are particularly potent, both in vitro and in vivo.
This activity is dependent upon the cis-trans-trans-triene structure [13]. LTB4 has
been demonstrated to be a potent chemotactic agent for equine [20] and bovine
neutrophils [29]. In the horse, maximum chemotactic activity is reported to be
obtained at concentrations that are higher than other species [20]. LTB4 promotes the
secretion of inflammatory products by neutrophils including active oxygen molecules,
hydrogen peroxide, superoxide and hydroxyl radical and other degradative enzymes
[30]. Also, LTB4 increases vascular permeability and plasma exudation in the cheek
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pouch [13] and this effect is greatly potentiated by the co-administration of bradykinin
or PGE2 in the rabbit, guinea pig and rat [31,32]. LTC4 and LTB4 may stimulate the
production of gamma interferon.

LTB4 is a potent inhibitor of human T cell

mitogenesis. This inhibition may be accounted for by the ability of LTB4 to induce
maturation and enhance the activity of T-suppressor and cytotoxic cells [9]. LTA4 can
be transcellularly metabolized to LTB4 by erythrocytes or in blood plasma [10,33].
The w-oxidation enzymes responsible for metabolism and inactivation of these
compounds are part of the cytochrome P-450 family and like the prostaglandins utilize
P-450 reductase [10]. The neutrophil is primarily responsible for sequestering and
metabolizing LTB4 to 20-hydroxy-LTB4 which is then excreted in the urine [10].
However, complete /8-oxidation accounts for the major route of metabolism for LTB4
[34].
b. Other mediators
Vasoactive amines, kinins, cytokines, plasma-derived factors, leukocytic
products and phospholipid products play important roles in the pathogenesis of
inflammation. Many of these mediators act synergistically with the eicosanoids in
perpetuating inflammation as well as pain.
Histamine was one of the first chemicals described as an inflammatory
mediator. When released by basophils, mast cells and platelets, it initiates the early
vascular responses and maintains this effect for 30 to 60 minutes [4]. Intradermally
administered histamine produces arteriolar dilation and also results in a flare of
erythema in the surrounding tissue. The kinins, bradykinin and kallidin are liberated
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by the action of kallikrein enzymes on serum kininogen [4], Bradykinin and histamine
potentiate vascular permeability in conjunction with the eicosanoids [17]. Bradykinin
has been shown to stimulate phospholipase A2 activity and PGE2 release [35].
Serotonin and histamine increase vascular permeability exclusively at the level of the
post-capillary venules [36]. Serotonin also has vasodilatory properties. However, the
actions of serotonin differ among animal species. In rodents this amine is contained
within tissue mast cells and has permeability increasing properties. This property is
not shared by man or many other species [36].
The volume of plasma exudation following intradermally administered
histamine, bradykinin, serotonin or the E-series of prostaglandins varies between
species [19]. Histamine and bradykinin, but not serotonin, produced circular lesions
when injected intradermally into thoracic skin of horses [19]. According to this study,
histamine was more potent than bradykinin on a molar basis in producing vascular
leakage and lesion formation in the horse.
Interleukin-1 is a polypeptide produced in macrophages, synovial fibroblasts
and other cells after infection, injury or antigenic challenge.

This cytokine has

hormone-like effects systemically, but also produces distinct local effects. It acts as
a pro-inflammatory substance by inducing endogenous pyrogen fever, stimulating
cellular metabolism and promoting eicosanoid release [37].

Blockade of the

interleukin-1 receptor inhibits PGEz and LTB4 generation in human monocytes [38].
Interleukin 1 acts synergistically with many other cytokines including tumor necrosis
factor [37]. Tumor necrosis factor is also associated with eicosanoid production [39].
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Plasma derived factors such as complement also potentiate the release of the
eicosanoids from cells [18,40]. Complement fragments and prostaglandin

act

synergistically to produce intradermal edema in rabbits [36,41].
Neutrophils are known to release prostaglandins of the E type during
phagocytosis and release of lysosomal enzymes [18]. The lysosomal products of
neutrophils are classified as: cationic proteins, acid proteases and neutral proteases.
These enzymes are responsible for increased vascular permeability, chemotaxis of
monocytes and immobilization of neutrophils, degradation of basement membranes
under an acid pH, release of kinin from plasma kininogen and the degradation of
collagen, elastin, renal basement membrane, cartilage and fibrin [ 1].
The tachykinin neuropeptides, substance P, neuropeptide Y, calcitonin generelated peptide and the neurokinins A and B play important roles in the regulation of
inflammation and immune response in peripheral tissues and in the central nervous
system [42]. Substance P is most likely responsible for the local flare response after
intradermally injected histamine.

This neurokinin is also thought to mediate

neurogenic inflammation as it induces increased vascular permeability after stimulation
of C-fibers [36].
Platelet-activation factor, like the eicosanoids, is derived from membrane
phospholipids and is synthesized de novo.

This compound is produced by

inflammatory cells, platelets, endothelial cells and renal tissues.

It induces

bronchospasm, hypotension, neutropenia, thrombocytopenia, increased vascular
permeability and is chemotactic for leukocytes [6].
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3. Models of acute inflammation
Inflammatory models used to assess the potencies and duration of action of
anti-inflammatory drugs in animals include the intradermal or subcutaneous injection
of carrageenan, zymosan, Bordetella pertussis, and immune complexes [43]. Dermal
inflammation has been produced by the application of ultraviolet light [44],
inflammatory mediators [41] and compound 48/80 [41,44-46]. The mammary gland
of ruminants has been used as a unique acute inflammation model. Intramammarily
injected lipopolysaccharides in goats produced a self-limiting inflammation that
resolves within one week [47], Many of these models are also used in pain research
and in some cases they may produce a chronic inflammation.
a. Subcutaneous inflammation
Most models of subcutaneous inflammation involve the injection
carrageenan.

of

These models were developed in laboratory rodents and have been

adapted for use in the horse. Other methods of producing subcutaneous inflammation
in the horse have been reported such as the subcutaneous injection of a counterirritant
consisting of iodine, ether and soybean oil [48]. This method was used to test the
antiinflammatory effects of the metalloprotein, orgotein.
i. Carrageenan
The sulphated mucopolysaccharide carrageenan has been used experimentally
to produce local inflammation in rabbits, rats, dogs, horses and pigs [49-53]. The
major source of carrageenan is the alga Chondrus crispus which grows abundantly in
the area known as Carragheen near Waterford, Ireland. Carrageenan can also be
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extracted from the seaweed Gigartina stellata. The extracted mucopolysaccharide can
be treated with potassium chloride to form two fractions: the gel fraction,

k

-

carrageenan, and the non-gel forming X-carrageenan. A-Carrageenan is primarily
composed of sulfated D-galactose residues with a molecular weight between 3.5 and
4 x 105. A-Carrageenan is the more potent fraction in producing acute and chronic
inflammation, anticoagulation and toxicity.

Carrageenan when administered

subcutaneously appears to be very poorly absorbed systemically. However, some
absorption may occur in the rat [54].
The toxicity of intradermal carrageenan is thought to progress through a
complicated pathway that was elucidated by Vinegar, et al. [55]. The inflammatory
response to carrageenan is thought to be mediated by histamine, serotonin, bradykinin,
the eicosanoids [54] and activation of the complement system [56]. After injection of
carrageenan into the rat paw it is absorbed by mast cells resulting in cytoplasmic
injury and degranulation with initiation of the arachidonic acid cascade. Hyperemia
and an increase in tissue osmotic pressure ensues along with direct damage to
endothelial cells by carrageenan. Within 90 to 240 minutes, neutrophils infiltrate the
damaged tissue and phagocytize remaining carrageenan.

Carrageenan causes

degranulation of lysosomes resulting in cellular lysis and further arachidonic acid
release.

PGEj and bradykinin are thought to be the primary mediators of the

exudation of fluid within the first few hours of inflammation [57]. The eicosanoids
are responsible for the hyperemia, increased vascular permeability and hyperalgesia
that follows. By 12 hours the monocytes infiltrate the damaged tissue to phagocytize
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the cellular debris. These cells may also experience lysosomal rupture or they may
retain partially degraded carrageenan for extended periods [54,58].

Fibroblast

proliferation occurs after 2 to 8 days and the tissue returns to normal by 15 days post
injection [55].
Carrageenan was first used as a phlogistic agent to produce subplantar
inflammation in the rat paw by Benitz and Hall in 1959 [59], and described in detail
by Winter in 1962 [60]. Inhibition of the edema produced by subcutaneously
administered carrageenan is commonly used by the pharmaceutical industry to evaluate
NSAIDs [60]. Subplantar carrageenan in the rat hind paw model results in peak
inflammatory swelling by 4 hours after injection [61].

The same authors have

reported that subcutaneous carrageenan in the neck of rats results in peak swelling by
16 hours. In these models edema is measured in the rat paw by plethysmography and
mercury displacement and by neck circumference [62]. Other researchers have used
subcutaneous carrageenan in the rat to form an abscess that may be removed and
weighed [44].

PGEj has been measured in the rat hindpaw after carrageenan

injection. The animals were euthanized and 100 grams of tissue were then extracted
and assayed for PGE^ [63]. Carrageenan has been administered subcutaneously in the
thoracic region of horses in an effort to produce a model for NSAID evaluation.
There was an increase in lesion diameter and plasma extravasation for 5 hours after
administration [19].
Many of these workers use a 2% solution of carrageenan in water or isotonic
saline. However, the optimal strength of a solution of carrageenan in producing
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inflammatory effects was 1% as determined by Gardner [49] in guinea pig skin. He
noted little increase in inflammation with the 2% solution, while the higher viscosity
of this solution made it difficult to inject.
These subcutaneous models are limited to the measurement of edema and pain
in response to paw pressure. Other models have been developed for the measurement
of white blood cells, protein, enzymes, drugs and inflammatory mediators in the
exudate.

Polyester sponges soaked with 2% carrageenan have been implanted

subcutaneously along the ventral midline in rats [50,64-66].

The sponges are

removed, immersed in heparinized saline, centrifuged and the supernatant assayed for
PGE2. This method allows for the determination of leukocyte numbers and protein
concentration as well as drug concentration in the inflammatory exudate.
Higgins and Lees [67,68] describe two experimental models of non-immune
inflammation in the ponies using carrageenan as the inflammatory agent that were
adapted from rodent models. In one model, sterile carrageenan-impregnated polyester
sponge strips were implanted into subcutaneous neck pouches in ponies. The second
model involved the insertion of polypropylene tissue cages subcutaneously into the
necks of ponies. Carrageenan was injected intracaveally into the cages. Sponges and
exudate from the tissue cages were removed in a serial fashion and assayed for
eicosanoids, protein and cellularity. PGEj, TXBj and 6-keto-PGFla were detected in
inflamed fluid obtained from both models [69-71]. LTB4 was also detected in the
inflammatory exudates of both models [69,72,73]. Mean total leukocyte counts and
total protein were increased in both models after carrageenan stimulus. PGEj and
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LTB4 have been identified and quantified by radioimmunoassay (RIA) in carrageenaninduced inflammatory exudates from several species as seen in Tables 1 and 2.
b. Synovitis
i. Joint anatomy
Diarthrodial joints consist of articulating surfaces of bone covered by hyaline
cartilage, a synovial membrane, synovial fluid within the joint cavity, a joint capsule,
and surrounding ligamentous structures. The equine synovial membrane is more
villous than other animals and the villi may project considerably into the joint space
[74]. The synovial membrane is a modified mesenchymal tissue consisting of two
layers [75]. The intima is made up of an incomplete cell layer that overlies the
subintimal connective tissue layer. These layers constitute a selective barrier in the
joint that allows for the passage of molecules of less than approximately 12,000
daltons in molecular weight [76]. The synoviocytes of the intimal layer are usually
1 to 4 cells thick and are not connected by desmosomes or supported by a basement
membrane [77]. The synovial lining cell layer is often incomplete in the horse [74]
and human [77].

Synoviocytes are pleomorphic, but have been classified into two

types in many species, including the horse [78,79]. Type A synoviocytes resemble
macrophages structurally and functionally and may be part of the mononuclear
macrophage system [80]. Type B cells appear to be more like fibroblasts in that they
contain large amounts of endoplasmic reticulum [79] and may secrete hyaluronic acid
into the joint fluid [77].

These cell types most likely represent distinct cell

populations rather than different functional states of the same cell line as the type A

Table 1: Mean peak PGE2 concentrations from carrageenan-induced inflammation models.

METHOD/
SPECIES

TIME OF PEAK
CONCENTRATION

PEAK
CONCENTRATION
(ng/ml)

ANALYTICAL
METHOD

REF.

Tissue
cage/horse

12 hrs.

197.0

RIA

[70]

Tissue
cage/horse

8 hrs.

84.8

RIA

[69]

Tissue
cage/horse

12 hrs.

66.4

RIA

[71]

Sponge/horse

4 hrs.

12.2

RIA

[73]

Sponge/horse

12 hrs.

12.8

RIA

[70]

Sponge/rat

8 hrs.

20-30

RIA

[65]

Sponge/rat

24 hrs.

65.0

RIA

[66]

Table 2: Mean peak LTB4 concentrations from carrageenan-induced inflammation models.

METHOD/
SPECIES

TIME OF PEAK
CONCENTRATION

AVG. PEAK
CONCENTRATION
(ng/ml)

ANALYTICAL
METHOD

REF.

Tissue cage/horse

8 hrs.

1.74

RIA

[72]

Tissue cage/horse

4 hrs.

2.50

RIA

[69]

Sponge/horse

4 hrs.

9.60

RIA

[73]

Sponge/rat

6 hrs.

6.90

RIA

[65]
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cell, unlike the B cell, may be derived from the bone marrow [77]. Unlike epithelial
cells, the rate of cell division in synovial lining cells from normal joints is low [77].
Blood vessels, lymphatics and myelinated and nonmyelinated nerve fibers are found
in the subintimal layer. The majority of the nerve endings have been described in the
fibrous joint capsule with some free nerve endings in the membrane [75], The nerve
supply to the membrane appears to be primarily vasomotor in nature. However,
nociceptive fibers have been demonstrated in the synovial membrane of humans [81].
Further, the equine synovial membrane has evidence of sensory innervation with
neuropeptide transmitters located perivascularly [82].
ii.

Pathophysiology

Synovitis is characterized by inflammation of the synovium without gross
disturbance of the articular cartilage or disruption of major supporting structures.
Non-infectious synovitis results from physical or chemical damage to the soft tissue,
such as by repetitive overextension, subluxation or intra-articular injection of
chemicals [83].

Synovitis involves the classic mediators and modulators of

inflammation: histamine, serotonin, prostaglandins, leukotrienes and lysosomal
products along with the activation of the kinin, complement and clotting systems [84].
During synovitis, hypertrophy and hyperplasia of the synovium occur, and an
increased number of synovial lining cells are found in the synovial fluid [79,85,86].
An increase in vascularity of the synovial villi occurs and inflammatory cells infiltrate
the subintimal layer. Degenerative changes in equine synoviocytes that occur during
synovitis include: increase in organelles including lysosomes; dilation and vesiculation
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of the rough endoplasmic reticulum; mitochondrial condensation; dilation of the
nuclear envelope; and ultimately, loss of plasma membranes [79]. Lysosomal enzymes
and collagenase produced by synoviocytes, chondrocytes and inflammatory cells
perpetuate the synovitis and may degrade the cartilage matrix leading to arthritis [80].
Also, these lysosomal enzymes, along with hyaluronidase and oxygen-derived free
radicals produced by neutrophils and macrophages are capable of degrading hyaluronic
acid [80,83,84]. Interleukin-1 produced by macrophages and synoviocytes induces the
production of PGEj, neutral proteases and collagenase by synoviocytes and
chondrocytes [87-89]. PGE2 inhibits proteoglycan synthesis in articular cartilage [80]
and is a potent vasodilator in the synovial microcirculation [90]. Substance P also
stimulates the production of PGE2 and collagenase by rheumatoid synoviocytes [91].
This neuropeptide has been demonstrated in perivascular neural filaments from normal
equine synovia and in synovial fluid. Elevated concentrations were found in arthritic
middle (intercarpal) joints as compared to normal joints [92].
iii. Clinical signs
Clinical signs of acute synovial inflammation include: synovial effusion with
distension of the joint capsule; increased skin temperature over the joint; hypertrophy
and hyperplasia of the synovia resulting in a palpable thickening of the membrane; a
decrease in the range of motion of the joint; and lameness in the affected limb.
Synovial effusion develops as the result of an imbalance between production and
removal of synovial fluid [75].

Inflammatory mediators such as bradykinin,

prostaglandins and histamine increase synovial membrane vascular permeability [17]
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and the metabolic rate of synoviocytes [37]. As the inflammation progresses, the
permeability of the synovial membrane increases and proteins accumulate in the joint
resulting in an increase in fluid osmotic pressure. Local production of thromboxanes
from platelet aggregation cause congestion of the microvascular bed leading to
congestion and heat production [93].

As fluid accumulates within the joint, the

synovial pressure rises leading to joint instability and a reduction in the effective blood
supply to the articular cartilage. Hypoxic acidosis and lowered glucose concentration
in the fluid may result in a decreased nutritional state of the cartilage [83].
A decrease in the range of motion in these joints results from the edema,
hypertrophy and hyperplasia of the synovial membrane [83]. The effusion of synovial
fluid often results in pain and overt lameness [94]. In humans there is a positive
linear correlation between intra-articular pressure and joint pain [95].

The

inflammatory mediators released by local tissue destruction in the joint activate
nociceptors and also sensitize these receptors through lowering of activation thresholds
[96,97]. The neuromediators such as substance P from primary afferent neurons and
the interaction of norepinephrine with sympathetic postganglionic neurons in the
synovium further result in hyperalgesia and potentiation of the inflammatory response
[98].

These factors contribute to the process known as neurogenic inflammation

which is an important component of rheumatoid arthritis and other forms of joint
inflammation [99],
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iv.

Experimental induction

Synovitis has been experimentally induced in horses, ponies, calves, dogs and
rats by the intra-articular injection of a variety of chemical substances. The intraarticular injection of monosodium urate crystals in dogs [ 100, 101] and calves
[102,103] has been used as a model of the synovitis that occurs during gouty arthritis.
Autogenous hyaline cartilage has been used to produce acute synovial inflammation
in dogs [104].
The metalloprotein orgotein, which is often administered intra-articularly as
an anti-inflammatory agent, has been shown to produce a marked inflammatory
response in horses characterized by an increase in leukocytes and protein within 24
hours [86].

This inflammatory reaction lasted for up to one week.

Sodium

monoiodoacetate has been used to induce synovitis in immature horses [105].
Inflammatory changes were seen 12 hours after injection.

No articular cartilage

damage was seen after 14 days. Synovitis has been induced in horses [39] and ponies
by the intra-articular injection of E. coli lipopolysaccharide into the intercarpal joint
[106,107]. These authors suggested that this model mimics acute bacterial infection.
The horses with endotoxin-induced synovitis had peak PGE2 and tumor necrosis factor
levels two hours after injection. The ponies in the study by Firth et al. became lame
within 2 hours and the synovial fluid protein, leukocyte and alkaline phosphatase
levels increased significantly by this time post-injection [106]. Synovial fluid analyses
showed abnormalities even at 6 days post-injection. In addition, there were marked
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changes in attitude, temperature, appetite, arterial pressure, pulse and respiration.
These abnormalities persisted for up to 20 hours for some parameters.
In a series of experiments by Lowther and Gillard [108-110], carrageenan was
injected into rabbit stifles. A single injection of sterile carrageenan (0.3 ml of a 1%
solution of carrageenan in water) produced synovitis with an increase in synovial
tissue levels of cathepsin D and acid phosphatase, two lysosomal enzymes. When
more than two injections were administered into the same joint, visible cartilage
erosion was seen.

The single injection produced a decrease in the rate of

proteoglycan synthesis corresponding to a 40% loss in glycosaminoglycan content in
the articular cartilage for 3 to 7 days after injection.

The rate of synthesis of

proteoglycan increased significantly in the following days resulting in a net
replacement of proteoglycans lost during the early phase of inflammation.

The

authors also established by autoradiographic studies that very little carrageenan
penetrated the cartilage matrix. They concluded that the inflammatory response in the
synovium affects the synthetic ability of the articular cartilage. It has been postulated
that the pathophysiology of carrageenan-induced joint inflammation includes a
component of neurogenic inflammation as the pretreatment of carrageenan injected
joints with capsaicin or a substance P antagonist resulted in a significant suppression
in inflammation [ 111].
Carrageenan was used to induce synovitis in the intercarpal joint of the horse
in order to evaluate the superoxide production by stimulated neutrophils and the
inhibition of this effect by NSAIDs in vitro [52]. The authors described a dramatic
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increase in synovial fluid leukocyte numbers which peaked at 4 hours and an increase
in synovial fluid lysosome concentration which peaked at 24 hours. They did not
describe the severity or time course of the clinical effects of carrageenan-induced
synovitis such as lameness, heat production and joint effusion. Further, the quality
and quantity of the synovial fluid was not discussed.
The above described substances used to produce synovitis vary markedly in the
severity and duration of inflammation they caused. Some of these compounds have
the potential to produce cartilage damage (see arthritis section) and in some cases
result in systemic alterations.
c. Arthritis
i.

Pathophysiology

Some degree of synovitis occurs in most types of equine joint disease. In the
majority of these diseases, the synovial inflammation varies only in intensity [75].
Mcllwraith [112] has suggested that the inciting cause of degenerative joint disease is
synovitis rather than direct damage to the cartilage. The relationship between the
synovium and articular cartilage is complex and in vitro and in vivo evidence suggests
that structural and function alteration in one tissue intimately affects the other [83].
Traumatic arthritis or osteoarthritis occurs as a result of inherent instability or
trauma to the articular cartilage or subchondral bone [83]. Osteoarthritis is associated
with degeneration of the articular cartilage resulting in splitting and fragmentation
(fibrillation) with resorption and sclerosis of bone (ebumation in severe cases) and
synovitis [75,113].

In horses, the term degenerative joint disease is used to
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distinguish chronic inflammation resulting in degenerative changes from acute joint
inflammation [114].
One consistent feature of the articular cartilage in equine degenerative joint
disease is the decrease in glycosaminoglycans [76]. The loss of these proteoglycan
aggregates may be mediated by interleukin-1 and PGE^ from the synovia and
chondrocytes which activate neutral metalloproteoglycanases [80].

The inflamed

synovial membrane is also a source for the degradative lysosomal enzymes and
reactive oxygen species which lead ultimately to cartilage degeneration [76].
ii.

Experimental induction

Experimental arthritis has been induced in laboratory animals by the intraarticular injection of the polyene antibiotic filipin [115,116], fibrin complexes [117],
polycations [118], various bacterial agents, distilled water, papain, histamine,
mucopolysaccharides, physiologic saline, carbolic acid, hydrochloric acid, tincture of
iodine, xylene, turpentine, formaldehyde, and formalin [119].

Intradermal

Mycobacterium butyricum induces a polyarthritis in rats that also serves as a model
of chronic pain (see section on models of chronic pain) [ 120].
Serial intra-articular injections of carrageenan have been used to induce
articular damage in dogs [51,121-123] and rabbits [49,108]. In contrast to the other
species, the specific-pathogen free pig did not experience articular cartilage damage
after three separate weekly injections of carrageenan [53].

The reason for this

difference is not clear, although only two pigs were given repeated injections.
Arthritis has been induced in horses by surgical means [124], injection of bacteria

30
[125], amphotericin [126], serial injections of the polyene antibiotic filipin [112,127],
repeated injections of sodium monoiodoacetate [128] and combinations of the above
[129].
PGEj [130-134] and LTB4 [133,135-138] have been identified in synovial fluid
from human patients with various forms of arthritis. Monocytes from patients with
rheumatoid arthritis have been shown to produce large amounts of LTB4 [139].
Further, plasma PGE2 [140] and serum LTB4 [141] levels of patients with rheumatoid
arthritis are reportedly higher than normal controls and the time course of changes of
PGE2 in blood plasma levels reflects the disease dynamics [140]. In vitro research on
cells from humans with rheumatoid arthritis indicates that activated synovial lining
cells produce PGEj whereas LTB4 originates mainly from synovial fluid neutrophils
[142], Studies in other inflammatory exudates have also shown that the primary
arachidonic acid products of neutrophils are leukotrienes [7].

PGE2 has been

quantitated by radioimmunoassay (RIA) in synovial fluid of normal horses (26.5 pg/ml
+ /- 3.33) and those with various forms of clinical arthropathy (144.9 pg/ml + /22.19). In the arthritic horses, PGEj concentrations were reduced after treatment with
corticosteroids and antibiotics [143].
Eicosanoids have also been quantified in synovial fluid during experimental
arthritis. Synovial fluid from dogs with carrageenan-induced arthritis contained PGE^
(peak 9.5 ng/joint) and LTB4 (peak 279.2 pg/joint) as measured by reversed phase
high performance liquid chromatography (RP-HPLC) [51].
presented in Tables 3 and 4.

Additional data is

Table 3: Mean peak synovial fluid PGE2concentrations from various species.

METHOD/
SPECIES

TIME OF PEAK
CONCENTRATION

PEAK
CONCENTRATION
(ng/ml)

ANALYTICAL
METHOD

REF.

2 days

12.5

RIA

[118]

Clinical
arthritis/horse

N/A

0.144

RIA

[143]

Rheumatoid
arthritis/human

N/A

0.119

RIA

[134]

Polycation-induced
arthritis in rabbits

N/A = Data not available

Table 4: Mean peak synovial fluid LTB4 concentrations from various species.

METHOD/
SPECIES

TIME OF PEAK
CONCENTRATION

PEAK
CONCENTRATION
(ng/ml)

ANALYTICAL
METHOD

REF.

Carrageenan
arthritis/dog (10
weekly irsj.)

10 weeks

3.14

RP-HPLC

[123]

Rheumatoid
arthritis/human

N/A

0.34

RP-HPLC

[135]

Osteoarthritis/
human

N/A

0.81

Bioassay

[136]

N/A = Data not available
RP-HPLC = Reversed phase high performance liquid chromatography

33
C. Pain
Pain is defined by the International Association for the Study of Pain as "an
unpleasant sensory and emotional experience associated with actual or potential tissue
damage" [144].

Pain in animals has been described as an aversive sensory and

emotional experience which elicits protective motor actions, results in learned
avoidance and may modify species-specific traits of behavior, including social
behavior [145]. Pain is an important homeostatic mechanism that serves to warn the
organism away from the inciting cause or to inform it of a existing pathology.
Nociception, the response to the application of a noxious stimulus, involves peripheral
receptors and the transmission of the signal along neural pathways leading to the
perception of pain [145].

Nociceptors are a group of undifferentiated terminals

lacking a specialized receptor apparatus [146]. Nociceptive impulses are carried by
small myelinated afferent A-delta fibers which are associated with sharp, stabbing,
well localized pain, and unmyelinated C-fibers which are responsible for dull,
burning, diffusely localized pain [147]. These C-fibers conduct pain very slowly and
are responsible for second pain. They make up 70% of all afferents [41]. The Cfiber group also contains efferent fibers of the sympathetic nervous system which
release substance P and in this capacity they may mediate chronic pain and neurogenic
inflammation [147,148].
Two general types of central neurons are involved in nociception, nociceptive
specific neurons that respond only to painful stimuli and polymodal neurons that
respond to noxious and non-noxious stimuli. These neurons lie in the dorsal horn of
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the spinal cord and have input from A-Delta, C-fibers and in the case of polymodal
neurons, low threshold mechanosensitive Afl-fibers [147]. Impulses are carried from
these neurons to central terminals in the thalamus via axons in the spinothalamic and
spinocervicothalamic tracts [149]. The thalamus is connected to the cerebral cortex
by both ascending and descending projections which are responsible for recognition
and modification of nociceptive input [150].
1. Acute pain
Nocifensive reflexes from acute pain are manifested by the peripheral nervous
system in flexion and withdrawal responses and changes in the autonomic nervous
system such as vasospasm and inhibition of the gastrointestinal and genitourinary
tracts. These autonomic responses usually result in an increase in ventilation and
hypothalamic activity with an increase in cardiovascular and endocrine function [151].
The autonomic changes in response to painful stimuli also include increased plasma
concentrations of epinephrine and norepinephrine [152]. Cortical responses are more
complex and result in avoidance behavior.
In animals and man the threshold at which peripheral nociceptors start to
discharge does not always coincide with the pain reaction threshold.

The pain

reaction threshold is usually higher than the nociceptive threshold of the peripheral
neuron as central control centers affect the pain reaction threshold. Care must be
taken to distinguish between pain reaction and simple spinal reflexes. In animals with
complete spinal transection, pain reaction is absent but the animal may have
exaggerated spinal reflexes. Pain reaction in animals may also be manifested by
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turning the head towards the stimulus, respiratory changes, pupillary dilation,
aggression towards the stimulus and vocalization [145]. The assessment of pain in
animals is difficult without knowledge of the previous condition and behavior of the
animal. Animals may also manifest acute pain by alterations in normal behavior
including: restlessness, guarding, vocalization, self-mutilation, reluctance to move or
recumbency, abnormal posture, altered feeding or sleep cycles and aggression or
agitation [153].
2. Chronic pain
Chronic pain in humans is the most frequent cause of suffering and disability
that seriously impairs the quality of life [154,155]. Chronic pain is defined as that
which persists a month beyond the usual course of an acute disease or reasonable time
for an injury to heal, or pain that recurs at intervals for months or years [155].
Chronic pain is predominantly due to prolonged excitation of nociceptors such as
occurs in arthritis, peripheral vascular disease and chronic musculoskeletal disorders
[155]. This peripheral mechanism of chronic pain is associated with the release of
various algogenic substances in the tissue such as bradykinin, serotonin, histamine,
substance P and the prostaglandins. Central mechanisms are involved in chronic pain
syndromes associated with neuropathy [154]. In contrast to acute pain, the autonomic
responses usually decrease progressively during the course of chronic pain and may
disappear [151].
Behavioral changes in animals associated with chronic pain include: reluctance
to move or recumbency, anorexia, grooming abnormalities, depressed attitude,
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constant licking, rubbing or scratching of an area and altered feeding or sleep cycles
[153].
3. Mediators
Numerous algogenic substances are responsible for the various expressions of
pain seen in acute and chronic conditions such as: allodynia-pain resulting from a nonnoxious stimulus to normal skin; hyperalgesia-excessive sensitivity of polymodal
nociceptors; and hyperpathia-abnormally exaggerated subjective response to painful
stimuli [155]. Hydrogen ions, serotonin, histamine, bradykinin and prostaglandins
have excitatory effects on nociceptors as application of these substances to skin blisters
in humans results in pain.

These compounds have dramatic effects on

microcirculation as discussed in the inflammation section. These effects may further
add to the excitability of nociceptors [147].
Prostaglandins and leukotrienes are considered mediators of hyperalgesia rather
than pain. When administered alone they do not produce substantial pain except when
administered in high doses [156]. Prostaglandins facilitate pain evoked by physical
stimuli [157] and potentiate pain induced by histamine and bradykinin [147,156].
PGEj does not directly alter the resting discharge of nociceptive afferents, but it
produces a dose-dependent increase in the firing rate after stimulation [157]. PGE^
and PGI2 have been used to produce hyperalgesia to mechanical stimulation in the rat
hind paw. In this model, PGI2 produces immediate hyperalgesia while PGEj produces
more potent effects lasting for more than 6 hours [158]. PGE^ when injected intraarticularly in dogs produces incapacitation of the injected joint for more than four
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hours [158].

The hyperalgesic effect of prostaglandins in the inflamed rat paw can

be completely blocked by the administration of indomethacin [98]. Prostaglandins are
involved in the hyperalgesia that is produced by the local injection of bradykinin and
in norepinephrine-potentiated hyperalgesia [98,159]. It is known that prostaglandins
of the E series are released upon sympathetic nerve stimulation where they may
represent a trans-synaptic feedback process [160,161].

Prostaglandins are also

released from cholinergic synapses after stimulation of the phrenic nerve [162],
In addition to these peripheral algogenic effects, evidence exists for a central
role in the facilitation of the pain message by prostaglandins. Prostaglandins are
thought to be released centrally in response to nociceptive input.

High intensity

stimulation of peripheral nerves in the cat [163] and frog [164] result in the release
of prostaglandins in the spinal cord.

Intrathecal injections of PGEj produce

hyperalgesia and block endogenous opioid-mediated analgesia. These effects are dosedependent and are reduced by the intrathecal administration of NSAIDs [165]. These
researchers concluded that prostaglandins inhibit the bulbospinal noradrenergic
component of the endogenous pain control pathway by inhibiting the spinal release of
norepinephrine. It is clear from the literature that although prostaglandins are not
essential for nociception, when released peripherally they facilitate transmission of
nociceptive impulses and within the central nervous system they inhibit tonic
modulatory systems [163].
LTB4 produces hyperalgesia in the rat paw that is independent of
cyclooxygenase and bradykinin activity [166]. LTB4 was approximately three times
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more potent on a molar basis than bradykinin in this model.

This effect was shown

to be dependent on neutrophils as the depletion of these cells prevented the
hyperalgesic action of LTB4 [166]

Similar concentrations of PGE2 produced

hyperalgesia, but this effect was independent of neutrophils [166] and was not
synergistic with LTB4 [32]. Further studies have shown that neutrophils in response
to chemotactic factors such as LTB4, Af-formyl-methionyl-leucyl-phenylalanine
(fMLP), or C5a produce hyperalgesia by generating hyperalgesic 15-lipoxygenase
products [167,168].
The nonapeptide bradykinin is one of the most potent pain-producing
substances.

Bradykinin produces pain in man when applied intradermally,

intraarterially or intraperitoneally.

However, intramuscular administration of

bradykinin did not produce pain in man whereas hypertonic saline and histamine did
[169]. Other researchers have reported that bradykinin excites small afferent fibers
of cutaneous and muscular origin. [170]. The hyperalgesia induced by bradykinin is
dependent on norepinephrine as the effect is not seen after the intradermal injection
of bradykinin in sympathectomized rats [98], Bradykinin also facilitates the release
of the prostaglandins through phospholipase A2[159]. Administration of NSADDs
attenuates the hyperalgesic effect of bradykinin in the rat paw [166].
Substance P from sensory nerve fibers participates in neurogenic inflammation.
Orthodromic or antidromic excitation of substance P containing neurons results in
release of the mediator.

This results in an increase in capillary permeability,
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vasodilation and edema [36,147].

However, this peptide when administered locally

is not directly algogenic and does not excite nociceptors [157].
Norepinephrine is thought to mediate pain in damaged tissue (hyperalgesia) but
not in normal tissue. In rats made hyperalgesic by the application of irritants to the
hindpaw, the injection of norepinephrine significantly reduced the nociceptive
threshold, presumably through prostaglandin release [98].
4 . Models of acute pain
There are several methods described in the literature for the production of
stimuli and quantification of responses in various models of pain.

These

methodological differences make it difficult to compare nociceptive thresholds from
differing pain modalities [150]. It is known that the potency of analgesics differ
depending on the model and type of stimuli employed [171]. Furthermore, different
analgesic systems may be activated by noxious stimulation of different body regions
[172]. Therefore, caution should be used when attempting to compare data from
different pain models and regions of the body.
The ideal nociception model should distinguish between responses to noxious
and non-noxious stimuli. The nociceptive stimulus should be quantifiable, repeatable
and precise in order to minimize variability. Nociceptive responses associated with
the stimulus should be reduced dose dependently by analgesics. Further, there should
be no lasting tissue damage [144,173].

As repeated presentation of the painful

stimulus often results in response modification such as conditioning, the stimulus
should be applied in a limited fashion [144], Since animals are not able to verbally
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express pain, measurable nociceptive responses often include autonomic changes in
blood pressure, heart rate, respiratory rate, etc. and somatomotor responses such as
the tail flick, writhing, vocalization and limb withdrawal.
Acute pain models can be classified according to the type of stimulus into
chemical, electrical, mechanical and thermal methods. Various chemicals have been
used to excite peripheral nociceptors. Formalin when injected into the footpad of a
rat and cat causes measurable pain responses such as paw licking lasting for
approximately one hour [155,173]. Chemicals such as acetic acid, acetylcholine,
alloxan, bradykinin, hydrochloric acid, hypertonic saline, lipoxidase, MgS04,
oxytocin, phenylquinone, serotonin, epinephrine, tryptamine and ATP have been
injected into the peritoneal cavity of mice and rats to produce a writhing response.
Analgesic efficacies are determined by measuring the latency to the fust writhe and
the frequency of writhing [144,174]. ATP and acetylcholine are considered inducers
of inflammatory-type pain whereas MgS04 produces a non-inflammatory pain [175].
Lactic acid has been injected into the paravertebral muscles of horses as a model of
acute myositis. Pain responses such as flinching and kicking were graded after digital
pressure on the injected area [176].
Electrical stimulation of the rat tail produces three types of pain responses
according to the intensity of the stimulus. Low intensity stimulation produces a tail
withdrawal. Moderate stimulation produces a brief vocalization and higher voltages
produce vocalization after termination of stimulus [144,174]. Electrical stimulation
of the tooth pulp has been used in rats [144] and horses [177]. The tooth pulp is
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thought to be innervated exclusively by A delta and C-fibers which are nociceptive
fibers. However, non-nocifensive AB-fibers are also stimulated in this model [178].
The animal responds by lifting the head or by the jaw-opening reflex.
Selective stimulation of the mechanoceptors is accomplished by applying high
pressure. These techniques stimulate low pressure mechanoceptors in addition to the
high pressure receptors.

Some techniques use hair or nylon strings of different

diameters and lengths (Von Frey’s hairs) as stimuli [144]. Artery clips have been
applied to the tails, ears, paws, and toes of rodents and the resulting biting behavior
quantitated. Similarly, the compression of the tail or toe of the animal results in
flexor reflexes or vocalization.

These methods lack precision in the amount of

mechanical pressure applied [174]. A more precise model of mechanical pain has
been produced in sheep using a device that presses a blunt pin at a set pressure against
the dorsum of the radius [179]. A similar model has been developed for the horse
[180]. The rat paw yeast test of Randall and Selitto is used to induce hyperalgesia and
test NSAIDs [181]. The drug is administered one hour after yeast challenge and
pressure is applied to the inflamed paw until the animal struggles or vocalizes [174],
The classic thermal model is the tail-flick method in rats and mice. This
model is used as a standard screening procedure for analgesics and is highly correlated
with their effectiveness in relieving pain in humans. A radiant heat stimulus is applied
to the blackened area of the tail and the latency to tail flick is measured [173]. A
similar test involves placing the rodent’s tail in water kept at 45 to 65' C [144].
Another model of thermal pain in the rodent involves placing the animal in a closed
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container with heat applied to the floor. The responses noted include agitation, rapid
withdrawal of the paw, licking of the paws and jumping [144]. Thermal thresholds
have been measured in sheep using a heated device applied to the pinna. The sheep
responds by flicking the ear or shaking the head [179].

In the horse, thermal

stimulation of the withers and lateral fetlock has been used to evaluate pain thresholds.
The horse responds by twitching the skin over the withers or by lifting the forefoot
after stimulation of each region [182,183]. Thermal devices have been implanted over
the radial periosteum of ponies in an attempt to model deep pain. The response to
this stimulus was noted as slow and unreliable [184-186].
Reflex behaviors such as the tail-flick, toe pinch and the jaw-opening reflex
are not measures of pain reaction, but are nociceptive reflexes. Some of these simple
reflexes are considered spinal reflexes as they may be elicited in animals with spinal
transection [173].
5. Models of chronic pain
Chronic pain in humans and animals is frequently encountered in a clinical
setting and is often extremely difficult to alleviate. Most of the experiments in pain
research utilize acute rather than chronic paradigms. However, chronic pain in not
simply a prolongation of acute pain. There are distinct central changes associated
with chronic pain [41]. Therefore, knowledge gained from these acute pain models
is often not applicable to the alleviation of the chronic pain state. A few chronic pain
models have been developed in animals. The paucity of models of chronic pain in
animals is in part due to the important ethical considerations in using animals that may
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suffer needlessly.

Some of models of chronic pain have been described previously

under models of acute inflammation. Most models of arthritis produce lasting tissue
damage resulting in a perpetuation of inflammation into the chronic state. They may
then be used for the study of chronic pain [173]. In addition several models of
neuropathic pain have been developed by severing peripheral nerves [187].
a. Adjuvant models
Freund’s adjuvant models of cutaneous inflammation and polyarthritis involve
the inoculation of a paraffin oil suspension of heat-killed Mycobacterium butyricum
into the footpad or dermal tissue at the base of the tail of rats. The cutaneous model
results in inflammation within 4 hours and peaks within 1 to 2 days. The affected
limb is hyperalgesic and edematous for 1 week to 10 days [173]. In the adjuvantinduced arthritis model, animals experience a temporary polyarthritis with an
increased severity in the hindlimbs. Inflammation of the base of the tail, periorbital
region, snout, ears and penis occur as well. Behaviorally, the animals exhibit an
increased stress reaction, show frequent scratching activity and are more aggressive.
Weight loss and a decrease in spontaneous locomotion are also evident.

This

condition is fully developed 22 to 28 days post-induction and is usually associated with
a slow recovery to normal by the 55th day. Pain is inferred from the increased
scratching behavior in these animals as it is alleviated by morphine and other
analgesics [120]. Other authors have used this model to evaluate nociception by
applying pressure to the inflamed hind paw and determining the vocalization threshold
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[188] and to demonstrate self-administration of NSAIDs and narcotic analgesics
[189,190].
Several investigators have demonstrated that joints from adjuvant-induced rats
are hyperalgesic in that there is a lower threshold to mechanical stimuli and the areas
known to be involved in nociception from the peripheral receptor to the cortex are
markedly altered. A-delta and C-nociceptor afferents, which are normally sensitive
only to noxious stimuli, were stimulated by non-noxious mechanical means in this
model of rat arthritis [191].

The mechanosensitivity of the myelinated and

unmyelinated units of the medial articular nerve of the knee was also increased in this
model [192]. Similar results were found in sheep with chronic pain from foot rot.
These sheep had lowered mechanical thresholds in the affected limb. It is likely that
these effects are brought about by peripheral changes as the local injection of lidocaine
returned the thresholds to control values [179].
Central neuronal changes have been demonstrated in animals with chronic pain.
In decerebrate rats with adjuvant-induced arthritis there was an increased activity of
dorsal horn cells and a high degree of responsivity to light mechanical stimuli. The
superficial dorsal horn cells driven from inflamed areas converted from responding
only to noxious stimulation to responding to mild mechanical stimuli [193]. Dorsal
horn neurons in decerebrate rats showed an increase in cutaneous receptive field after
repeated excitation of C-fiber afferents. These neurons also began responding to low
threshold stimuli such as brush and touch [194], Recordings from the ventrobasal
complex of the thalamus in arthritic rats indicate that there is an increased proportion
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of the neurons responding to the light pressure or flexion and extension of the diseased
joints as compared to normal animals [195]. These responses were reduced by 50%
after the injection of the NSAID, diclofenac, indicating possible prostaglandin
involvement [196]. The analgesic effect of diclofenac was more potent in arthritic rats
as compared to normal animals.
The somatosensory cortex also is altered during states of chronic pain. Central
somatosensory neurons of animals with chronic inflammatory pain show a marked
increased sensitivity to moderate mechanical stimulation of inflamed tissues and
surrounding areas as compared to normal animals [197].
b. Laminitis
Laminitis is one of the major causes of chronic hoof pain in the horse [198].
Horses afflicted with the acute form of this disease experience extreme pain and are
often euthanized. The chronic form is associated with debilitation, decreased fertility,
lameness and pain which may last for the life of the animal. Equine laminitis has
multiple etiologies and the pathophysiology is complex and incompletely understood
[199]. This disease is not simply defined as inflammation of the laminae of the foot
as was once described, but is peripheral vascular disease with ischemic necrosis of the
laminae associated with hoof pain [200].

The pathology within the foot is a

manifestation of a systemic metabolic disorder that affects the cardiovascular,
endocrine and renal systems.
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/. H oof anatomy
The distal phalanx or coffin bone is covered by intermeshing dermal and
epidermal laminae which support the bone within the hoof capsule. The insensitive
laminae are composed of the epidermis except for the stratum germinativum which
with the dermis makes up the sensitive laminae [200]. The circulation of the hoof is
complex and unique owing to its role in thermoregulation and nutrition to the
proliferating epidermis. The laminar microvasculature arises from distal branches of
the digital arteries so that laminar blood flow is in a distal to proximal direction with
the dorsal laminae being the last to receive blood [201]. Numerous arteriovenous
anastomosis are found within the foot which open to decrease vascular resistance and
increase the blood flow to the limbs in order to cool the body [202].

The veins of

the hoof and lower limbs are thick muscular structures and there are no venous valves
in the foot [203].
Sensory receptors in the equine foot include lamellated corpuscles in the dermis
of the heel similar to Pacinian corpuscles and free nerve endings containing calcitonin
gene related peptide-like immunoreactivity in the solar dermis and epidermis [204].
The myelinated corpuscles in the heel are likely to be involved in relaying
proprioceptive information during locomotion. In contrast, the free nerve endings
in the solar dermis are thought to be involved in nociception and regulation of blood
flow [204].
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ii. Etiology
Numerous etiologies have been identified that produce laminitis: ingestion of
toxic quantities of wheat, com and barley grains resulting in carbohydrate overload;
ingestion of large quantities of water; ingestion of high quality, rapidly growing,
succulent grasses or legumes by obese animals; excessive weight bearing or
application of severe concussive forces to the foot; severe bacterial infection or viral
respiratory disease; exposure to black walnut shavings; ingestion of beet tops [200];
and high doses of corticosteroids [205,206].

Experimental laminitis has been

produced by the administration by aqueous extract of black walnut (JugIans nigra)
[207,208] and more commonly by the oral administration of large amounts of
carbohydrates [209].
iii. Pathophysiology
It has been hypothesized that a laminar ischemia develops acutely due to
decreased capillary perfusion from opening of arteriovenous shunts. This results in
a lowering of vascular resistance and an increase in total hoof blood flow as may be
noted clinically by an increase in hoof temperature and a bounding digital pulse that
persists through the chronic phase of the disease. Several groups have measured an
increase in total digital blood flow [210] and have demonstrated regions of
hypoperfusion within the dorsal laminae [208,211,212],

Other workers have not

supported the hypothesis that lamellar ischemia is the primary cause of acute laminitis
[213], while others have noted a decrease in total digital blood flow [208]. These
discrepancies are due primarily to the techniques used to determine blood flow and
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these results should be interpreted with caution [214]. Allen et al., concluded that
profound increases in postcapillary resistance, and capillary pressures predispose the
foot to interstitial fluid volume accumulation and increased tissue pressure in the
prodromal stages of laminitis [215]. The increased tissue pressure in this noncompliant
compartment results in hoof pain [214] which accounts for the increased plasma
catecholamine concentration seen in horses developing laminitis [199,216]. These
catecholamines further exacerbate ischemia through vasoconstriction of digital vessels
[217]. Systemic hypertension occurs in the developing phase, but it is secondary to
hoof pain and is also mediated through the sympathetic nervous system [199]. This
hypertension is thought to be a positive feedback mechanism from the digital
vasoconstriction and is often present in the chronic forms of the disease [218].
Evidence for disseminated intravascular coagulopathy exists in horses
developing laminitis as platelet numbers drop before the development of lameness
along with the development of other coagulation abnormalities [199]. Other workers
have not detected significant changes in platelet number or function in horses with
experimental laminitis [219].
Bacterial endotoxin has been incriminated as a mediator or inciting cause in
laminitis as many horses with endotoxemia develop laminitis [220] and horses with
carbohydrate overload laminitis have a increase in plasma endotoxin that is associated
with lameness [221]. Endotoxemia is associated with increase plasma levels of LTB4
[222], PGEj, TXBj and PGF2„ and the administration of NSAIDs prevents many of
the effects of experimentally induced endotoxin [223].

The association between
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endotoxin-induced eicosanoid production and the development of laminitis is theorized
but has yet to be proven due to the inability to produce laminitis with experimentallyinduced endotoxemia. Further the role of eicosanoids in equine laminitis has not been
evaluated [220].
Early histological changes in the foot include endothelial cell swelling and
edema, laminar distortion, epithelial hyperplasia, microvascular thrombosis,
congestion and hemorrhage [220,224-226]. There is no evidence of inflammatory cell
influx, but edema and vacuolation of the dermal tissue with necrosis and atrophy of
the epidermal laminae occurs [220,224]. In severe cases of laminitis, degeneration
of the laminar interdigitation occurs causing the distal phalanx to separate from this
supporting structure and rotate within the hoof capsule [201]. Ventral deviation or
distal displacement of the distal phalanx is due to the biomechanical forces exerted on
the foot including the downward load of the weight of the horse exerted on the bony
column and the proximal pull of the deep digital flexor from its insertion on the
ventral surface of the distal phalanx [220]. The tearing force exerted against the toe
during midstride also acts to separate the distal phalanx from the hoof wall [227].
The rotation forces on the distal phalanx may cause penetration of the bone through
the sole just dorsal to the apex of the frog. The degree of rotation as determined
radiographically can be used as a prognostic indicator [228]. In extremely acute
cases, the laminae surrounding the distal phalanx die resulting in a total separation
from the bone [229]. In these obviously terminal cases no rotation occurs as the bony
column sinks in the hoof capsule.
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Chronic laminitis is classified by greater than 48 hours of continual pain from
a laminitic episode or when rotation of the distal phalanx occurs [200]. Angiographic
studies in horses with chronic laminitis have shown irregular digital vascular patterns
with areas of avascularity in the cerium [230].

Hyperplasia of the dermal and

keratinizing epidermal laminae [224] occurs dorsally in the hoof wall which creates
a wedge of tissue that forces the epidermal and dermal laminae apart. This is
evidenced on the sole as ’seedy toe’ or an abnormally large white line. This wedge
is thought to perpetuate the rotation of the distal phalanx [200]. Diverging hoof
growth rings that are wider at the heels are often present giving the hoof a concave
dorsal surface. Due to the ischemic necrosis within the laminae and large white line,
these horses have an increased tendency for abscessation and cracks which may also
cause hoof pain and lameness [231]. The gait of these horses is characteristic as the
foot strikes the ground in a heel-toe fashion.

The solar surface of the foot is

particularly sensitive to the pressure of the hoof tester over the sole, midway between
the apex of the frog and the toe [231]. Horses with severe chronic laminitis often
have difficulty remaining in the standing position for any substantial length of time
due to the pain associated with weight bearing. If pain is severe, prolonged periods
of recumbency may occur which lead to the formation of decubital ulcers, reduced
body condition and impaired ventilation. Furthermore, since weight bearing by the
foot is essential for normal circulation, prolonged recumbency may lead to thrombus
formation within the digital vascular system further exacerbating laminitis [231,232].
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Analgesics temporarily reduce the pain and suffering associated with laminitis
and allow the animal to more comfortably stand and ambulate, thereby promoting
blood flow to the foot and reducing the adverse effects of long term recumbency. In
addition, some analgesics lower plasma catecholamine concentrations that are
associated with nociception and stress [152].

When released, these endogenous

amines are thought to produce vasoconstriction of the digital vasculature, resulting in
ischemia which further exacerbates laminitis [200]. According to Hood, horses that
are treated early with systemic analgesics have a lower incidence of rotation than those
treated late in the course of the disease [199].

Phenylbutazone (4.4 mg/kg) is

regarded as the single most important therapeutic agent in treating laminitis [231,233].
NSAIDs are thought to be particularly useful in treating the coagulopathy because of
their inhibitory effects on eicosanoid formation and platelet function [199,234], PGF^
and thromboxane are known to be potent constrictors of digital arteries and veins with
the veins being more responsive than the arteries [217],

Although it is known as a

vasodilator, PGEj was less potent in producing digital artery dilation as compared to
acetylcholine, acepromazine, isoxsuprine and prostacyclin [235]. During experimental
laminitis, the administration of phenylbutazone returned hypertensive horses to
normotension.

These authors found that most horses (85%) recovered from the

laminitic episode without rotation following the administration of phenylbutazone
while housed in soft sand stalls [199].
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D. Nonsteroidal anti-inflammatory agents
1. Mechanism of action
a.

Cyclooxygenase inhibition

The medicinal effect of the bark of the willow tree has been known for
centuries. The active ingredient in the bark is salicin, a bitter glycoside. It was first
used for the treatment of rheumatic fever and gout which led to the development of
the first NSAID, aspirin or acetylsalicylic acid, that was then commercially prepared
and marketed by Bayer. The NSAIDs are a chemically diverse group of compounds,
although most are weak organic acids (pKa 3.0 to 5.5 for carboxylic or enolic acids,
pKa 9-10 for phenolic acids) [236]. These drugs share common features in that most
are antipyretic, anti-inflammatory and analgesic.
In 1971 Vane [237] demonstrated that aspirin and indomethacin inhibited
prostaglandin formation in guinea pig lung in a dose dependent manner. In that same
year, Smith and Willis [238] demonstrated that the administration of two tablets of
aspirin to human volunteers resulted in deficient prostaglandin production in platelets
one hour later.

These experiments supported the increasing evidence that

prostaglandins participated in the pathogenesis of fever and inflammation. Further
work showed there to be an overall positive correlation between the concentrations of
NSAIDs that block prostaglandin synthesis in vitro and doses in which they exert
analgesic, anti-inflammatory, and antipyretic activities in animals [239,240]. Inhibition
of platelet function and prolongation of bleeding times with some NSAIDs have also
been shown to be a result of cyclooxygenase inhibition [238].
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Aspirin acetylates and irreversibly inactivates the cyclooxygenase in platelets
[241] and in human synovial microsomes [242] through covalent bonding. Other
NSAIDs such as indomethacin, meclofenamic acid and flurbiprofen inhibit
cyclooxygenase reversibly at first and then essentially irreversibly by non-covalent
binding in a stereospecific and time-dependent manner to subunits of the prostaglandin
endoperoxide synthase enzyme [243]. This time-dependent effect appears to depend
on the presence of a halogen and a carboxyl group [244].

Other drugs such as

ibuprofen and mefenamic acid are not able to inactivate the enzyme and are
considered reversible inhibitors [244] Some of these drugs such as phenylbutazone
inhibit the enzyme more efficiently when the concentration of lipid hydroperoxides is
reduced [245].
There is good correlation between the rank order of potencies in reducing
edema and prostaglandin concentrations in vivo, although the doses required to prevent
edema are usually much higher (Table 5) [64], Inhibition of lysosomal release by
NSAIDs has been documented for several compounds but the rank order of potency
of these drugs does not correlate with their anti-inflammatory activity [8].
b. Leukocyte migration
NSAIDs have been shown to inhibit leukocyte migration in carrageenaninduced inflammation in the rat [50,246]. However, the doses producing this effect
are generally much higher than those which prevent erythema and hyperalgesia [8].
However, therapeutic doses of indomethacin, piroxicam and ibuprofen reduce the
function of neutrophils in human subjects [247]. Further, doses approximating the

Table 5: Rank order of potency of NSAIDs in inhibiting carrageenan-induced edema and
prostaglandin synthesis (as determined by bioassay) in vivo in the rat. Adapted from Higgs et al.,
1976 and 1983 [8,64].

RELATIVE POTENCY
EDEMA INHIBITION

RELATIVE POTENCY
PG SYNTHESIS
INHIBITION

Aspirin

0.10

0.02

Phenylbutazone

0.73

0.39

Ibuprofen

0.85

0.20

Naproxen

1.00

1.00

Indomethacin

5.54

7.30

Ketoprofen

8.50

64.70

DRUG
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therapeutic ranges of flunixin and phenylbutazone decreased the LTB4-induced
chemotaxis of canine neutrophils ex vivo [248]. The inhibitory effects of NSAIDs on
neutrophils are not thought to be mediated by cyclooxygenase inhibition but by
uncoupling protein interactions within the plasmalemma [247]. In contrast, low doses
of phenylbutazone (0.05 mg/kg), indomethacin [50], aspirin and flurbiprofen [15]
stimulate leukocyte counts in the rat carrageenan model. This modulation of leukocyte
migration was not correlated with cyclooxygenase inhibition. There may be some
potentiation of lipoxygenase at low doses of some NSAIDs which could account for
the increased number of leukocytes. Or perhaps NSAIDS modify leukocyte migration
by another mechanism. NSAIDs have been shown to inhibit several enzyme systems
independently of cyclooxygenase such as: superoxide anion generation by a NADPH
oxidase system in neutrophils; mononuclear cell phospholipase C activity; and the
conversion of 12-HETE from 12-HPETE in platelets [247]. Further, many of these
drugs uncouple oxidative phosphorylation; alter the uptake and membrane
incorporation of arachidonate; and inhibit anion transport in the human erythrocyte,
rabbit choroid plexus and renal tubular epithelium [247].
c.

Lipoxygenase inhibition

At therapeutic doses most NSAIDs do not inhibit the formation of leukotrienes.
However, the pyrazolone derivative phenidone [249], the propionic acid derivative
benoxaprofen [250], hydroxamic acids [251] and the phenylpyrazoline analogues of
phenidone, BW755C and BW540C [252] have been shown to be both cyclooxygenase
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and lipoxygenase inhibitors. These analogues are effective in reducing inflammation
in the horse but are not available clinically [253].
It has been shown that several NSAIDs may actually potentiate in vitro
lipoxygenase product formation through shunting of the arachidonic acid substrate into
the

leukotriene

pathway

following

cyclooxygenase

inhibition

[250,254],

Cyclooxygenase blockade during acute anaphylaxis in guinea pigs augments the
production of the slow-reacting substances of anaphylaxis and LTB4 [255].

In

contrast, some prostaglandins inhibit the formation of lipoxygenase products from
activated neutrophils [21].
d.

Distribution into inflamed tissues

NSAIDs bind extensively to albumin (90 to 99%) and may achieve high
concentrations in an inflammatory site due to the increase in vascular permeability and
exudation of plasma proteins including albumin. The clinical anti-inflammatory effect
of NSAIDs in human arthritics correlates directly with the degree of plasma protein
binding [256].

NSAIDs bound to albumin are thought to be released by the

degradation of albumin by lysosomal enzymes at the site of inflammation [257]. This
one way flow of albumin serves to increase the tissue concentration of the drug [258].
Also the lowered pH of the inflamed environment serves to keep these planar, anionic
molecules unionized and thus increasing membrane permeability [247]. Ion trapping
is postulated to occur intracellularly as the environment inside the cell is relatively
alkaline compared to the acidic inflamed tissue [259-261]. The effect may also occur
in gastric and renal tubular epithelium cells which border acidic extracellular fluids
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[258,262]. The optimal pK8 for this effect is reported to be between 4 and 5 [263].
In autoradiographic studies in rats, acidic NSAIDs were found to reach high
concentration in the stomach wall, liver, blood and bone marrow, kidney cortex and
in inflamed tissue. The non-acidic NSAIDs were equally distributed throughout the
body [264]. Further, acidic salicylates reached levels in inflamed chicken joints that
were three times higher than in control joints. The inflamed joint levels approximated
the corresponding plasma levels at 2 hours post-dose [265].
e.

Pain relieving effects

NSAIDs do not produce analgesia in normal tissues and in most cases they do
not elevate simple pain thresholds in experimental models in which thermal, electrical
or mechanical stimuli are applied to normal tissues.

However, these drugs are

particularly effective in situations where an inflammatory response is present and the
area is hypersensitive to mechanical stimuli. In these situations, NSAIDs usually do
not completely block the painful response, but only reverse the hyperalgesia [163].
In electrophysiologic experiments in rats made hyperalgesic by the induction of
adjuvant arthritis, systemically administered aspirin reduced the afferent discharge
from affected joints within 20 to 30 minutes after injection [197]. Similar results were
obtained from the local application of aspirin and lysine acetylsalicylate [266]. These
experiments further add to the evidence that prostaglandins are involved in the
mediation of pain and inflammation.
Early studies in the dog spleen demonstrated that NSAIDs produce analgesia
peripherally [267,268].

Local injection of small amounts of NSAIDs into
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inflammatory lesions confirmed this peripheral site of action [269].

However,

prostaglandins are released from the spinal cord during noxious stimulation [270] and
intrathecal administration of prostaglandins lower nociceptive thresholds [269,271].
The intrathecal administration of NSAIDs reduces nociception and the simultaneous
intrathecal and peripheral administration of NSAIDs produce synergistic effects [269].
A central component of the analgesia seen with NSAIDs has been demonstrated since
intraventricular administration of these drugs reduced the hyperalgesia caused by
carrageenan in the rat hind paw [272] and in the adjuvant-induced arthritis rat model
[273]. A thalamic site of action is also likely as the administration of NSAIDs are
found to reduce the nociceptive impulses from stimulation of the sural nerve in
arthritic rats [148]. There are three possible central sites of action that have been
identified: the hypothalamus [274], the periaqueductal grey area and the thalamus
[148].

The mode of action of these drugs has been attributed to prostaglandin

inhibition in neural tissues. However, there may be other yet unknown mechanisms
as several NSAIDs such as salicylic acid, paracetamol and phenazone possess potent
analgesic and antipyretic properties but are less efficacious anti-inflammatory agents
or prostaglandin inhibitors in some models [275]. In a review of the literature by
McCormack and Brune in 1991, they were unable to find a correlation between
antinociceptive activity and inhibition of prostaglandin synthesis for the antipyretic
analgesics [258]. Further work with enantiomers of flurbiprofen have shown that the
S-enantiomer, which is almost solely active in cyclooxygenase inhibition, is
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approximately equal in antinociceptive activity as the /?-enantiomer which has almost
no cyclooxygenase inhibitory properties [276].
2. Ketoprofen
Ketoprofen [(±)-2(3-benzoylphenyl)propionic acid] was synthesized in France
by Rhone-Poulenc chemists in 1967, three years after the prototype ibuprofen [277].
This drug is approved in humans for the treatment of rheumatoid arthritis,
osteoarthritis, and mild-to-moderate pain [278]. Ketoprofen was approved for the
alleviation of musculoskeletal pain and inflammation in the horse in 1990. Few studies
have been published on the anti-inflammatory and analgesic effects in the horse.
Kinetic and metabolism studies in the horse are just now being published.
a. Pharmacokinetics
The kinetics of ketoprofen in man are well established. The terminal half-life
is 1.8 hours after an intravenous dose. The volumes of distribution in man are low,
approximately 4 L for the volume of the central compartment and 10 L for the steady
state volume [278].

The drug like most NSAIDs is highly bound (> 90%),

presumably to albumin primarily [279]. In human patients with various forms of
arthritis, the area under the curve (AUC) for total (unbound and bound ketoprofen)
was greater in serum than synovial fluid. However, the free fraction (unbound drug)
AUC was similar for both. Further, the mean residence time in the joint was about
three times that in serum which helps to explain the discrepancy of a longer duration
of therapeutic effect than serum half-life [280]. The drug is conjugated and excreted
primarily as an inactive metabolite in the urine. Further, a small percentage of the
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drug is excreted in the urine as an hydroxylated metabolite [278], Ketoprofen has
been shown to have extensive tissue penetration into human tonsils [281] and crosses
the blood-brain barrier quite rapidly [282]. This is due to the high lipid solubility of
ketoprofen which has a heptane/water partition coefficient of 3.5 at pH 7 [282].
Sams et al. have reported plasma kinetics of ketoprofen in the horse [283].
This group determined that the half life is short in the horse (90 minutes). Protein
binding was extensive with 92.8% bound at 0.5 ng//xl and 91.6% at 10 /ttg/ml. Renal
elimination of unchanged ketoprofen and a base-labile conjugate accounted for 22.4%
of total clearance and was due to both tubular secretion and filtration. Little tubular
resorption occurred as horses have alkaline urine which serves to keep the drug
ionized in the urine.

In the Sams study, approximately 42.8% of the dose was not

recovered from the urine. This was possibly due to the formation of a metabolite that
was not recovered by the extraction method. The conjugate may be a glucuronide that
has undergone intramolecular acyl migration rendering the compound resistant to /3glucuronidase hydrolysis [283]
The 2-arylpropionic acids contain a chiral center and are usually administered
as a racemate. In man, approximately 10% of the drug was found to invert from the
R to the S enantiomer upon oral administration [284]. In the horse, the ratio of the
S to R enantiomer increased over time and attained a ratio of 70:30 less than one hour
after intravenous administration

[285,286].

Cyclooxygenase inhibition is

accomplished by the S-enantiomer primarily [287,288]. Metabolic chiral inversion of
the R- to the S-enantiomer occurs after administration through the probable mediation
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of coenzyme A [289]. However, ketoprofen exhibits little stereoselectivity in its
pharmacokinetics as the enantiomers have similar plasma time-courses and do not
appear to interact with one another in man [284]. Some degree of stereoselective
binding to albumin may occur but this binding does not appear to affect the disposition
or kinetics of total (unbound and bound) enantiomer concentration in the therapeutic
range in man [284].
b.

Anti-inflammatory effects

Ketoprofen has been shown to be a potent reversible inhibitor of prostaglandin
synthase in several cyclooxygenase enzyme preparations at concentrations within the
human therapeutic range [277,278,290,291] (Table 6). Values are expressed as the
inhibitory concentration (IC^), which is defined as the concentration of inhibitor
necessary for 50 percent inhibition of the enzyme reaction. In addition, ketoprofen
is a potent inhibitor of inflammation in several models (Table 7).

Values are

expressed as effective dose (EDjq) which is defined as the dosage which gives a
pharmacological effect equal to 50% of the maximum possible effect or which gives
the expected pharmacological effect in 50% of the animals tested. As can be seen
from the following tables ketoprofen demonstrates lower effective doses and inhibitory
concentrations than many of the other commonly used NSAIDs.
There is equivocal evidence in the literature concerning the effect of ketoprofen
on the lipoxygenase pathway as can be seen in Table 8. Ketoprofen has been shown
to increase the SRS-A release in guinea pig lung but inhibited the release from human
lung [250,292,293]. The production of 5-HETE and 5,12-diHETE, a diasteromer of

Table 6: Inhibitory concentrations [IC50 (/iM)] of various NSAIDs on cyclooxygenase enzymes.

METHOD

KETOPROFEN

PHENYLBUTAZONE

IBUPROFEN

INDOMETHACIN

BW755C

REF.

Sheep
seminal
vesicles*

6.92

4.89

5.82

6.40

N/A

[291]

Mouse
peritoneal
macro
phage*

7.65

5.26

6.26

8.77

6.53

[291]

Rat
platelet

1.45

79.30

N/A

5.90

21.6

[290]

Rat
neutrophil

0.58

15.70

N/A

4.78

11.6

[290]

Rat renal
medulla

2.20

20.90

N/A

5.07

12.1

[290]

N/A = Data not available
*IC5o data expressed as -log mol/1

Table 7: Effective doses [ED50 (mg/kg)] of various NSAIDs on inhibition of acute inflammation and pain.
METHOD

KETOPROFEN

PHENYLBUTAZONE

IBUPROFEN

INDOMETHACIN

REF.

Carrageenan rat
hind paw edema

1.89

97.55

N/A

8.17

[63]

Carrageenan rat
hind paw edema

9.00

N/A

N/A

9.00

[44]

Carrageenan
abscess in rat

1.40

110.00

29.00

1.30

[44]

Inhibition of
leukocyte
migration

2.50

52.00

45.00

5.70

[15]

Contraction of rat
colon

0.002

2.00

1.50

0.016

[296]

U.V. erythema in
guinea pig

7.50

N/A

N/A

10.20

[44]

Rat paw pressure

2.40

37.00

14.00

3.50

[44]

2.30

N/A

N/A

2.20

[44]

INFLAMMATION
MODELS:
*

PAIN MODELS:

Writhing response
in mouse
N/A = Data not available

Table 8: Inhibitory concentrations [ICso (/tM)] of various NSAIDs on lipoxygenase enzymes.

KETOPROFEN

PHENYLBUTAZONE

IBUPROFEN

INDOMETHACIN

BW755C

REF.

Soybean
15-LO

225.00

123

575.00

87.50

65.50

[294]

Soybean
15-LO

No effect

N/A

N/A

No effect

38.50

[290]

Rabbit
PMN5-LO

Approx.
11.81

N/A

N/A

Potentiated

N/A

[250]

Rat platelet
12-LO

No effect

No effect

N/A

916.00

66.20

[290]

Rat PMN
5-LO

No effect

N/A

N/A

332.00

55.70

[290]

METHOD

N/A = Data not available
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LTB4, from rabbit neutrophils was inhibited by ketoprofen [250]. The lipoxygenase
inhibition appeared to be dose-related in humans [292], but not in the rabbit model
[293]. Ketoprofen and several other NSAIDs have been shown to inhibit soybean
lipoxygenase [294] while other researchers report no effect in the enzyme system
[290]. The concentrations required to inhibit lipoxygenase are generally higher than
those that inhibit prostaglandin synthase activity.

These studies underscore the

variability that other researchers have noted in the drug’s effect on lipoxygenase
activity. Such data varies depending on the source of the lipoxygenase enzyme and
the species [293,295].
Ketoprofen reduced the PGE tissue concentration in carrageenan-induced hind
paw inflammation in the rat [63]. Prostaglandin synthesis was also inhibited in the
guinea pig lung preparation as determined by the perfusion of lung effluent over rat
colon strips and measurement of the resultant contraction [296]. In human patients
with rheumatoid arthritis, ketoprofen reduced the synovial fluid concentration of PGE,
and PGF2(I three hours after intravenous administration of 100 mg of ketoprofen [297].
Ketoprofen (10 mg/kg per os) in the rat carrageenan pleurisy model decreased the
total number of monocytes and slightly increased the number of neutrophils in the
inflammatory exudate [298]. Ketoprofen (1, 3 or 9 mg/kg) when administered one
hour before induction of carrageenan-induced pleurisy reduced the volume of exudate
and leukocyte count in a dose-dependent manner. This effect was greater than that
produced by the same doses of indomethacin [299]. Alleviation of inflammation has
been demonstrated when ketoprofen was injected locally into carrageenan abscesses
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in the rat and intra-articularly in dogs with urate-induced arthritis [44]. Ketoprofen
has demonstrated anti-bradykinin activity in the guinea pig that was 8 times more
potent than indomethacin [44]. In vitro and in vivo evidence suggests that ketoprofen
stabilizes lysosomes in the rat. Interestingly, this effect was more marked in rats with
adjuvant induced arthritis than in normal animals [300].
c.

Pain relieving effects

Ketoprofen has demonstrated analgesic and anti-inflammatory effects in
rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute gout in humans
[301]. Clinical trials with ketoprofen in humans have shown that it is therapeutically
equivalent to aspirin, indomethacin and ibuprofen in rheumatoid arthritis and with
aspirin in osteoarthritis [277].

Ketoprofen when evaluated in human dental pain

models was more effective than ibuprofen and aspirin [302]. Compared to aspirin,
ketoprofen was superior in controlling osteoarthritis [277] and postpartum pain [303].
This drug provided analgesia similar to that of morphine [303] and produced a longer
duration of action than acetaminophen plus codeine [304] in clinical cases of post
operative pain. Ketoprofen is thought to have supraspinal analgesic properties [305].
Experiments with normal human volunteers and paraplegic patients

that were

stimulated by electrical impulses applied to the sural nerve have shown that
intravenous ketoprofen has rapid inhibitory effects on spinal nociceptive reflexes in
normal subjects while no significant effects were seen in the patients with chronic
spinal section [306]. The injection of ketoprofen into the cerebral ventricles in rats
with adjuvant-induced arthritis reduced the discharge of thalamic neurons after ankle
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mobilization. In addition, ketoprofen reduced the spontaneous firing rate in a dosedependent manner [307]. These data provide good evidence for the direct central
antinociceptive actions of NSAIDs.
d. Clinical studies
Ketoprofen has been evaluated in experimentally-induced endotoxemia in
neonatal calves [308]. Ketoprofen inhibited the formation of the stable metabolites
of TXA2 and prostacyclin, TXBa and 6-keto-PGFla, respectively, in plasma.
However, it failed to significantly alter the degree of leukopenia and hypoglycemia
associated with the endotoxemia in calves.
Ketoprofen was evaluated in a model of arthritis using Freund’s complete
adjuvant injected into the carpal joint of horses. Horses became lame and experienced
swelling, heat and joint pain 5 to 7 days after induction. Horses then received drugs
once daily and were evaluated for 5 days for maximum joint flexion, stride length and
lameness.

Ketoprofen

(2.2

mg/kg

intravenously

or

intramuscularly)

was

therapeutically equivalent to flunixin meglumine (1.1 mg/kg) [309]. The same group
of investigators

evaluated

ketoprofen

in

clinical

cases of non-infectious

musculoskeletal inflammation and the following were scored: lameness; pain on
palpation or compression; pain on flexion, extension or rotation; swelling; heat;
reaction after injection; and side effects. Cases included arthritis, laminitis, myositis,
cellulitis, soft tissue inflammation and minor fractures. Statistical level of significance
was set liberally at P < 0.10. There were no differences between ketoprofen and
flunixin meglumine and there were no side effects noted [309].
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In clinical colic studies in horses, significant pain relief occurred at 15 minutes
after intravenous ketoprofen administration (2.2 mg/kg) and continued for 60 minutes
after drug administration [310]. This effect lasted up to four hours in some cases
[311,312]. No difference was seen between ketoprofen (2.2 mg/kg) and flunixin
meglumine (1.1 mg/kg) in any of the parameters measured [313]. In mares with
experimentally-induced endotoxemia, ketoprofen (0.5 mg/kg) was equally as effective
as flunixin meglumine (0.25 mg/kg) in suppressing the effects of the endotoxin.
These investigators attempted to assay LTB4 in plasma during endotoxemia, but were
not successful [314].
e. Adverse effects
The safety and toxicity of this drug in the horse has been compared to several
of the currently used NSAIDs. Ketoprofen was administered intramuscularly in the
neck and gluteal regions without any noted injection site reaction [315]. Therapeutic
intravenous doses of ketoprofen (2.2 mg/kg), flunixin meglumine (1.1 mg/kg) and
phenylbutazone (4.4 mg/kg) were administered every 8 hours for 12 days and
compared in normal adult horses. Phenylbutazone caused: 1) a decrease in serum
total protein and albumin concentrations; 2) edema of the small intestine; and 3)
erosions and ulcers of the large colon. Some horses in the flunixin group and the
phenylbutazone group developed renal crest necrosis.

All NSAIDs including

ketoprofen caused erosions of the glandular mucosa of the stomach. However, only
flunixin and phenylbutazone treated horses developed ulcerations of the glandular
mucosa [316].

Ketoprofen was evaluated in a subacute safety study after the
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intravenous administration of five times the therapeutic dose (11.0 mg/kg).

No

evidence of toxicity was reported in any horses after this 15 day regime. However,
in drug tolerance studies using 25 times the therapeutic dose for 5 days, horses
experienced depression, inappetence, icterus, nephritis, hepatitis, and hemorrhagic
necrosis of the adrenal glands [309].
3. Phenylbutazone
Phenylbutazone is approved for the alleviation of musculoskeletal inflammation
in the horse and dog. Phenylbutazone is a pyrazolone derivative with a pK, of 4.8
[162].

In man, this group causes hypersensitivity reactions, diarrhea, vomiting,

mucosal ulceration, hepatitis, nephritis, sweating, aplastic anemia and agranulocytosis
[3].

The half-life in man is 72 hours owing to the extensive enterohepatic

recirculation and renal tubular resorption [162], whereas in horses the reported values
range from 4.8 [317] to 8.6 [19] hours. The reported half-life in man, like the horse
varies considerably among subjects [162]. The half life is concentration dependent
and for this reason it should not be used outside of the therapeutic range [318].
Phenylbutazone causes dose-dependent inhibition of superoxide generation at
concentrations approximating therapeutic levels in humans [319]. This property adds
to the anti-inflammatory potency of this drug [318]. It also enhances the excretion of
uric acid which is beneficial in the treatment of gout in man [3]. In ponies, therapeutic
doses decrease urinary sodium and chloride excretion with a concurrent decrease in
plasma pH, bicarbonate and carbon dioxide [320]. Phenylbutazone reduces platelet
function in ponies through both thromboxane/prostaglandin dependent and independent
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pathways [321]. However, unlike aspirin in man, phenylbutazone does not prolong
bleeding times [321].
a.

Anti-inflammatory effects

Oral phenylbutazone in dogs with experimentally-induced urate arthritis
significantly reduced the

symptoms associated with

the synovitis

[101].

Phenylbutazone (4.4 mg/kg, intravenously) when administered to ponies with
subcutaneously implanted carrageenan-soaked sponges significantly reduced the PGEj
production in inflammatory exudates for at least 24 hours but it did not have any
effect on leukocyte migration [322,323].

The same dose of phenylbutazone

significantly reduced serum TXBj concentrations for 24 hours [324]. Pre-treatment
with phenylbutazone also attenuated the endotoxin-induced rise in the stable metabolite
of prostacyclin in equine plasma [223].
Oral administration of the therapeutic dose of phenylbutazone in ponies with
carrageenan-induced inflammation also reduced prostaglandin concentrations and
reduced skin temperatures below the incision line where the sponges were implanted
[325]. The maximum depression of prostaglandin synthesis occurred at times of peak
drug exudate concentration [325]. Also in ponies, the tissue cage fluid, peritoneal
fluid and synovial fluid concentrations of phenylbutazone and the active metabolite,
oxyphenbutazone were one third to two thirds of the corresponding plasma
concentrations 6 and 12 hours after intravenous and oral doses of 4.4 mg/kg [323].
In another study by the same group, the level of phenylbutazone in inflammatory
exudates from carrageenan soaked sponges in ponies approximated plasma levels from
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4 to 12 hours after intravenous administration [326], Administration of 14C-labelled
phenylbutazone in rats with carrageenan-induced inflammation in the hind paw and
neck resulted in high concentrations in the inflamed areas and also the stomach, small
intestine and kidney. This effect was attributed to ion-trapping of the acidic drug
intracellularly in environments with a low pH.

Further, in chickens with urate-

induced arthritis, the synovial fluid concentration of phenylbutazone was higher in
inflamed joints as compared to normal joints and the concentration in these joints was
higher than corresponding plasma values [263].
b. Pain relieving effects
Phenylbutazone failed to alter normal pain thresholds in horses as tested by the
thermal evoked hoof withdrawal and skin twitch reflexes [183]. These results are in
agreement with the belief that NSAIDs do not produce a true analgesia but inhibit the
hyperalgesia associated with the sensitization of the peripheral afferent [163,271].
Drugs of the pyrazolone class are reported to be less potent analgesics than other
NSAIDs in animals [318].

In clinical studies phenylbutazone was equivalent to

naproxen in alleviating pain and joint stiffness in human patients with ankylosing
spondylitis [327]. In a clinical study involving several species of domestic and exotic
animals, phenylbutazone treatment resulted in an overall recovery rate from lameness
of 68.97% [328].
c. Adverse effects
Toxic doses of phenylbutazone produce central nervous system depression,
anorexia, diarrhea, hypoproteinemia, mucosal ulceration [329] and phlebitis [330].
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The ulcerogenic properties of this drug are more pronounced in the pony owing
probably to less efficient absorption of oral doses in the gut [318]. Inhibition of
prostaglandin plays an important role in the pathogenesis of ulcers as the co
administration of PGE2 with the toxic doses of phenylbutazone resulted in no clinical
abnormalities [329].

CHAPTER 3
QUANTIFICATION OF EICOSANOIDS IN' EQUINE PLASMA AND
SYNOVIAL FLUID

A. Introduction
The quantitation of eicosanoids in inflammatory, allergic and cardiovascular
conditions has been performed most commonly using radioimmunoassay (RIA)
[65,66,70,72,331-333].

Other quantitation techniques have been applied such as

bioassay [136,334], high performance liquid chromatography (HPLC) [335-337], gas
chromatography coupled with mass spectrometry (GC/MS) [338,339] and more
recently, enzyme-linked immunosorbent assay (ELISA) [340-343]. The ELISA
procedure offers advantages over RIA in that it is easier, faster, less expensive and
produces no radioactive waste [341,344].
The detection of eicosanoids is complicated by the fact that these substances
are very potent, having endogenous concentrations of a few pg/ml of plasma. Many
have short biological half-lives [24]. For example, the in vivo half-life of leukotriene
B4 (LTB4) in carrageenan exudate was reported as approximately 45 minutes [345].
Circulating prostaglandins are metabolized within minutes in the lung and liver [24].
Eicosanoid assays must be specific as both the prostaglandin and leukotriene
series contain many similar compounds that are produced concurrently from
polyunsaturated fatty acid precursors, mainly arachidonic acid. Many eicosanoids and
their metabolites have minor structural differences in functional groups, such as
73
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hydroxy or keto groups and double bonds, that may make isolation by extraction and
chromatography difficult [346]. Some eicosanoids are unstable and can undergo nonenzymatic degradation depending upon pH conditions or in the presence of albumin
[24]. For example, the plasma metabolite of prostaglandin Ej (PGEj), 15-keto-13,14dihydro-PGEj forms a bicyclic product by dehydration and an internal addition
reaction [347].
Further complicating analyses are sampling methods such as venipuncture and
tissue extraction which can activate phospholipase A2 resulting in ex vivo formation
of eicosanoids [348]. The coagulation process routinely produces prostaglandins while
cells such as neutrophils are capable of eicosanoid formation in whole blood.
Therefore, it is recommended that biological samples be collected into chilled tubes
containing inhibitors of prostaglandin and leukotriene synthesis and an anticoagulant
with expedient removal of the cell fraction [348].

One group of investigators

determined that collection of samples into tubes with ethylenediamine tetraacetate
(EDTA) resulted in lower prostaglandin levels than those collected with heparin [349].
This same group also determined that centrifugation of samples at room temperature
gave higher thromboxane and prostaglandin levels than samples centrifuged at 4 ' C.
Subtle differences in these sampling techniques make comparison of eicosanoid
concentrations obtained from different laboratories difficult.
Extraction of biological fluids before assaying eicosanoids is necessary to
remove other lipids that may interfere with the analysis or cause erroneously
calculated concentrations. Reports of assays without prior extraction show higher
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levels of these compounds than those found when extraction preceded the assay [350].
Several techniques for extraction have been published including various liquid/liquid
techniques using organic solvents [333] and, more recently, solid phase extraction
procedures [351-353]. Most of these methods involve acidification of the biological
sample in order to protonate the eicosanoid and increase solubility in the organic
solvents.

In some cases purification by normal or reversed phase HPLC after

extraction is necessary to isolate the compound(s) of interest before assaying by other
means.
The purpose of this study was to evaluate methods of eicosanoid extraction and
quantitation in equine plasma and synovial fluid.

Specifically, two methods for

extracting PGE2 and LTB4, and an ELISA method for quantitation of these eicosanoids
in equine synovial fluid and plasma were examined. As the PGE2 ELISA was reported
to have cross reactivity with PGEj, a method of validation and confirmation of this
assay by mass spectrometry was developed.

B. Materials and methods
1. Sample collection
a.

Plasma from digital veins

Blood samples were collected from the digital veins of normal and laminitic
horses (see also Chapter 6) using a 20 gauge, 1" needle. After 1-2 ml of blood were
discarded, 10 ml were collected into chilled evacuated siliconized glass tubes
(Vacutainer, Becton Dickinson, Rutherford, NJ) containing 3.3 /*g/ml of BW755C

76
(Wellcome Research Laboratories, Beckenham, Kent, England) as an inhibitor of ex
vivo eicosanoid synthesis [70] and 10 mg/ml of the anticoagulant, disodium
ethylenediamine tetraacetate (EDTA) [348] purchased from Sigma Chemical Co., St.
Louis, MO. Samples were centrifuged at 2,500 rpm for 15 minutes at 4° C (Beckman
J21B, Palo Alto, CA).

The platelet poor plasma was stored in polypropylene

centrifuge tubes (Sarstedt, Newton, NC) at -20 ° C for 2 days then at -70° C until
assayed [350].
b. Synovial fluid
Synovial fluid was collected from the left intercarpal joints of 24 horses with
experimentally-induced synovitis (see also Chapter 4). Synovial fluid was aseptically
withdrawn from each joint using a 20 gauge, 1" needle and 12 or 20 ml polypropylene
syringes. The fluid was immediately transferred into tubes containing the inhibitors
of eicosanoid synthesis. The use of BW755C in this project was discontinued due to
limited availability. Instead, BWA4C (Wellcome Research Laboratories, Beckenham,
Kent, England) was used as an inhibitor of ex vivo leukotriene synthesis along with
indomethacin (Biomol, Plymouth Meeting, PA) as inhibitor of ex vivo prostaglandin
synthesis. The concentration of BWA4C used was based on the studies on the in vitro
inhibition of LTB4 in guinea pig blood [343].
concentration recommended by Benedetto [348].

Indomethacin was used at a
Stock solutions containing 8.64

mg/ml of BWA4C in dimethylsulfoxide (DMSO) and 6.6 mg/ml indomethacin in
ethanol were prepared and stored at 4° C. Each chilled evacuated tube (Vacutainer,
Becton Dickinson, Rutherford, NJ) contained 6.48 /xg/ml of BWA4C, 5 /xglml of
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indomethacin, 1.5 mg/ml of EDTA (K3) and 57 fil saline. As DMSO concentrations
above 1.5% have been shown to cause hemolysis [354], saline was added to dilute the
DMSO concentration in each 2 ml tube to 1.5%, with a final concentration in 2 ml
of synovial fluid of 0.075% [354]. Tubes were then centrifuged at 2,500 rpm for 15
minutes at 4° C (Eppendorf 5415C, Brinkman Instruments, Westbury, NJ). The cellfree synovial fluid was stored in polypropylene micro-centrifuge tubes (Dot Scientific,
Inc., Flint, MI) at -20° C for 2 days and then at -70° C until assayed.
2. Extraction
Two extraction procedures were evaluated, a liquid/liquid extraction technique
and a solid phase extraction method. For the digital vein eicosanoid concentration
study, (see also Chapter 6) and for the mass spectrometry quantitation of PGEj in
inflamed synovial fluid, a liquid/liquid extraction technique was used. Synovial fluid
samples described in Chapter 4 were extracted via a solid phase extraction method.
All reagents were HPLC grade and were purchased from commercial sources. Water
was triple distilled and filtered (Modulab Polisher I™, Continental Water Systems
Corp., San Antonio, TX).
a. Liquid/liquid extraction
For plasma samples, 4 ml were extracted for both the LTB4 and PGE^ ELISA
assays. For the synovial fluid assays, 0.25 ml was used for determination of PGE2
by ELISA and 0.575 ml was used for samples to be confirmed by mass spectrometry.
One-half ml of synovial fluid was extracted for LTB4determination by ELISA. Both
plasma and synovial fluid were acidified to pH 3.5 with 1 N HC1 in polypropylene
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centrifuge tubes.

Three volumes of ethyl acetate were added to extract the

eicosanoids. After vortexing and centrifugation at 2,500 rpm for 15 minutes (Dynac,
Becton Dickenson and Company, Parsippany, NJ), the aqueous and organic layers
were separated. The ethyl acetate was evaporated under nitrogen.
b. Solid phase extraction
i. Preparation
Synovial fluid (0.5 ml) was extracted for LTB4 determination by ELISA.
Samples processed using this technique contained high concentrations of PGEj
(Chapter 4) which necessitated reduced volumes of synovial fluid or dilution in order
to stay within the limits of PGE2 quantitation (10-5000 pg/ml). Volumes of 0.25,
0.125, 0.0625 or 0.01 ml were extracted depending on the anticipated concentration
of PGE2. For synovial fluid obtained from horses with severe inflammation, serial
dilutions of synovial fluid were made with water acidified to pH 3 with 1 N HC1 (1:10
and 1:100) and the diluted sample was then extracted. Sep-Pak Plus™ cartridges
containing 360 mg of C18 were purchased from the Millipore Corporation, Milford,
MA. Pre-washed 20 ml syringe barrels (Sherwood Medical, St. Louis, MO) were
attached to the cartridges and served as reservoirs for the synovial fluid and reagents.
A modified polypropylene pipet tip was attached to the cartridge in order to direct
effluent flow. The new cartridges and syringes were washed with 20 ml of hexane
followed by 20 ml of ethyl acetate and 20 ml of methanol under vacuum from a
manifold device (Amicon, Lexington, MA) to remove impurities and immunoreactive
substances according to a modified method of Jubiz [355]. Previously used cartridges
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were washed with 40 ml of hexane, ethyl acetate and methanol before each extraction
according to a modified method of Powell [351]. Cartridges were used for extraction
a maximum of three times. Every cartridge was washed immediately before use with
20 ml of methanol and pH 3 water according to a modified method of Powell [351].
ii.

Synovial fluid extraction

The synovial fluid was acidified to pH 3.5 using 1 N HC1 in a polypropylene
centrifuge tube. Water (0.5 ml) acidified to pH 3 was added and the sample was
vortexed for 15 seconds before being transferred to the cartridge reservoir. Care was
taken not to transfer the precipitated protein as it was shown to clog the cartridge.
The sample was allowed to flow through the cartridge slowly under slight vacuum
pressure (< 5 inches of mercury). After the sample was evacuated, 6 ml of pH 3
water was added under vacuum to remove water soluble inorganic salts, amino acids,
proteins and other polar compounds in the sample [350,351]. This flush was followed
by 6 ml of hexane under vacuum to remove the neutral lipids in the sample. Finally,
the cartridges were removed from the vacuum manifold and the eicosanoids were
eluted from the cartridge with 6 ml of ethyl acetate using gentle pressure applied with
a syringe plunger. The effluent was collected into polypropylene centrifuge tubes.
The ethyl acetate was then evaporated under a stream of nitrogen gas.
c.

Recovery studies

Extraction efficiency for plasma and synovial fluid samples was determined
using 5,6,8,11,12,14,15-3H-PGE2 (200 Ci/mmole) purchased from Advanced
Magnetics (Cambridge, MA). Radioactivity in disintegrations per minute (dpm) of
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spiked samples and standards was counted on a scintillation counter (Packard Tri
Carb™, Packard Instrument Co., Downers Grove, IL). Absolute recovery of 3H-PGE2
and 3H-LTB4 was calculated by expressing the radioactivity (dpm) of 3 extracted
standards in synovial fluid or plasma as a percent of the mean radioactivity of 3 non
extracted controls. Recovery was corrected for background radioactivity. Percent
recovery was determined for both eicosanoids in plasma using the liquid/liquid
technique and synovial fluid using liquid/liquid extraction, solid phase extraction, and
also for solid phase extraction using methyl formate as the final eluting agent. The
coefficient of variation (CV) of each technique was calculated from the mean and
standard deviation (SD) of the percent recovery.
3. ELISA
Quantitation of plasma and synovial fluid eicosanoids was achieved by
commercially available PGEj and LTB4 ELISA kits

(Advanced Magnetics,

Cambridge, MA). All reagents, standards and 96-well precoated micro-titer plates
were provided in the kits. These assays were based on the principle of a competitive
ELISA where PGE2 or LTB4 in the sample (reconstituted after extraction in buffer
solution) competed with fixed amounts of alkaline phosphatase labelled PGEj or LTB4
for binding to a limited number of sites of the specific rabbit antibody (anti-PGI^ or
LTB4) bound to the microtiter well. Unbound material was removed by washing with
a buffered saline solution.

p-Nitrophenyl phosphate was added to each well as

substrate for alkaline phosphatase.

Color development was terminated following

incubation at 37° C by the addition of 0.2 N sodium hydroxide. The intensity of the
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yellow colored product formed was inversely proportional to the amount of unlabelled
eicosanoid bound to the well. Absorbance (optical density) was read at 410 nm by
a microtiter plate reader (Dynatech MR5000, Dynatech Laboratories, Alexandria,
VA).

Optical density (OD) results were normalized by subtracting the mean

absorbance of 2 blank wells (containing only p-Nitrophenyl phosphate and sodium
hydroxide) from sample ODs. Samples with the greatest color development or optical
density values (ODs) contained the least PGEj or LTB4. Absorbance was correlated
with concentration by means of a standard curve ranging from 10 to 5000 pg/ml
(Figure 2). Quantitation of unknown samples processed in duplicate was achieved by
averaging the absorbance of sample duplicates and calculation of the concentration
from the standard curve. All sample concentrations were then corrected for extraction
efficiency.
a.

Intra-assay vari.

n

An estimate of the within run precision or the variation between duplicate wells
of the same sample run in the same assay under identical conditions was determined
for PGE2 and LTB4. This represents the variability inherent in the assay, e.g.,
antibody binding, reagent stability, pipet accuracy, or plate reader accuracy. It was
defined as the CV of duplicate wells and was calculated from the mean optical density
and SD for each of 5 non-extracted standard concentrations. The CV values were
averaged for 9 PGEj assays and 4 LTB4 assays at each concentration and overall ±
SD.
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Figure 2: Standard curves from PGE2 and LTB4 ELISAs.
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b. Inter-assay variation
An estimate of the variation of non-extracted standards of PGE^ and LTB4
assayed in different kits was determined. This value includes variations in incubation
times, operator technique, manufacturing of kits and intra-assay variance. Inter-assay
variation was defined as the CVs of 5 standard concentrations run in 9 PGEz assays
and 4 LTB4 assays.

An overall CV was determined by averaging the individual

concentration CVs to get an overall CV ± SD. In addition, the correlation coefficient
of the standard curve was calculated for each assay (SigmaPlot, Jandel Corp., San
Rafael, CA). The mean correlation coefficient + SD was calculated for 9 PGEj
assays and 4 LTB4 assays.
4. PGE^ confirmation
Synovial fluid obtained from the intercarpal joint of one horse 12 hours after
induction of carrageenan synovitis was extracted using the liquid/liquid technique and
assayed for PGEz by the ELISA procedure outlined above. A separate aliquot was
also extracted using the liquid/liquid technique, subjected to purification by a HPLC
technique and then assayed for PGE2 by GC/MS [356].

The results were then

compared in an effort to confirm and validate the PGE2 ELISA. Before extraction,
PGD2 (16 ng/sample or 1.92 ng on the GC column) was added to the synovial fluid
and served as an internal standard for quantitation by GC/MS.
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a. Eicosanoid standards
PGD2 [(5Z,9o!, 13E, 15S)-9,15-Dihydroxy-1l-oxoprosta-5,13-dien-l-oic acid]
was used as the internal standard for PGE2 [(5Z, 1la , 13E, 15S)-11,15-Dihydroxy-9oxoprosta-5,13-dienoic acid]. Both were purchased from Cayman Chemical Co., Ann
Arbor, MI and were stored in ethanol at -70° C.
b. Solvents
Liquid chromatography and mass spectrometry grade solvents were obtained
from commercial sources. HPLC mobile phase A consisted of water, acetonitrile, and
trifluoroacetic acid in a ratio of 75:25:0.0008 (pH approximately 6). Mobile phase
B consisted of methanol, acetonitrile and trifluoroacetic acid at a ratio of 60:40:0.002.
Each mobile phase was filtered through a 0.45 fim membrane filter (FP Vericel™,
Gelman Sciences, Inc., Ann Arbor, MI).
c. High performance liquid chromatography (HPLC)
Synovial fluid was subjected to HPLC in order to isolate and collect PGE^
Samples were analyzed with a Hewlett Packard 1090 High Performance Liquid
Chromatograph equipped with a variable volume auto-injector and a photodiode array
detector set at 192 nm (4 nm bandwidth) with a reference spectrum of 450 nm (80 nm
bandwidth).

Instrument control, data acquisition, and peak integration were

accomplished with Hewlett-Packard HPLC ChemStation software (Waldbronn,
Germany).

A 4 mm x 30 cm reversed phase column packed with 10 /xm

octadecylsilyl derivatized silica particles (Varian, Walnut Creek, CA) maintained at
ambient temperature was used. Solvents were run using a gradient between 100%
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mobile phase A and 100% mobile phase B over 40 minutes at a flow rate of 1
ml/minute. After extraction by the liquid/liquid technique, the synovial fluid samples
were dissolved in 120 /d of Mobile Phase A and transferred to a 100 gl HPLC
autosampler vial insert (American Scientific Products, McGraw Park, IL) that allowed
for complete injection of the sample volume.
Due to the low sensitivity of the diode array detector for PGEj, a radio
chromatography detector (Series A-500, Radiomatic Instruments and Chemical Co.,
Meriden, CT) was connected in series to the HPLC in order to establish the retention
time of tritiated PGEj. The scintillation fluid, Flo-Scint II™ (Radiomatic Instrument
and Chemical Co., Meriden, CT), was pumped through the detector at 4 ml/minute.
The radioactivity of 3H-PGE2 spiked synovial fluid samples was determined in counts
per minute (cpm).

These samples were run immediately before incurred

(experimental) samples to determine the retention time of PGEj.
Samples for PGE2 confirmation were injected onto the HPLC and collected
within ± 0.75 minutes of the predetermined retention time of PGL,. This fraction
was placed under a stream of nitrogen gas to evaporate the mobile phase and then
stored at -20° C overnight.
d. Gas chromatography and mass spectrometry (GC/MS)
Standards for PGE2 were prepared using concentrations of 39.6, 79.0, 158.5,
634.0, 1268.3, and 2536.0 ng/rnl. These values represented 118.9, 237.0, 475.6 pg,
and 1.9, 3.8 and 7.6 ng of PGE2 injected on the GC column. PGD2 was added to
each standard as an internal standard at a concentration of 640 ng/ml (1.92 ng on
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column). These standards were derivatized and analyzed immediately before incurred
synovial samples in order to establish a standard curve for quantitation.
Prior to GC/MS analysis, all samples and standards were derivatized to
increase molecule volatility and thermal stability [346].

PGE2 and PGD2 were

esterified at the carboxyl terminus with pentafluorobenzyl bromide (PFB), the keto
group was oximated (MO) and then the trimethylsilyl ether (TMS) derivative was
formed at both hydroxy groups (Figure 3).

Derivatization was accomplished by

adding 10 fi\ of methanol, 50 /il of acetonitrile, 2 fd of pentafluorobenzyl bromide and
1.5 fd of diisopropylethylamine to dried samples in glass vials with teflon-lined caps.
The samples were vortexed and heated at 60° C for 15 minutes [357]. A 2% solution
of methoxyamine hydrochloride in pyridine (25 fd) was added and samples were kept
at room temperature overnight. After drying under nitrogen, 20 fd of water were
added and the samples were extracted twice with 50 fd of ethyl acetate [358]. After
drying again under nitrogen, 25 fd of N,0-bis(trimethylsilyl)-trifluoroacetamide
(BSTFA) with 1% trimethylchlorosilane (TMCS) were added and samples were heated
for 15 minutes at 60° C according to a modified method of the manufacturer. All
derivatizing reagents were purchased from Pierce Chemical Co., Rockford, IL.
Immediately following derivatization, 3 fd of each sample were injected into
a Finnigan MAT 9610 Gas Chromatograph (Sunnyvale CA) using a modified method
of Waddel et ah, 1983 [359]. A 30 M DB-5 column (J & W Scientific, Fulsom, CA)
with 0.25 fim of polymer coating and an internal diameter of 0.22 mm was used in
the splitless injector mode with a helium purge of 0.75 seconds.

The initial
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Figure 3: Structure of derivatized PGE2 and PGD2. Dotted lines indicate fragmentation sites that produced
masses (m/z) monitored by MID.
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temperature was 200° C. This was increased by 30° C per minute to a final
temperature of 300° C. The injector and transfer line temperatures were set at 220
and 300° C, respectively. The column was plumbed directly into a Finnigan MAT
TSQ 4500 Mass Spectrometer (Sunnyvale, CA).

The method of ionization was

negative ion chemical ionization (NICI) using methane as the reagent gas. The ionizer
source pressure was 0.5 Torr and the ionizer temperature was set at 150° C. Electron
energy was 70 eV and the emission current was 0.30 mA. The electron multiplier
was set at 2500 volts.
Data was acquired using multiple ion detection (MID) scanning quadrapole 3
(Q3) for masses of 524, 434, 344 and 196. This type of selective ion monitoring
enabled pg detection.

The second isomer of PGE2 and PGD2 was used for

quantitation. The base peak of the second isomer of PGE2 was 524 m/z and 434 m/z
for PGD2. The abundance of each base peak was obtained from the mass spectrum
by the computerized summing of scans from the initiation to the termination of
individual isomer peaks. Baseline noise was subtracted from the summed abundances
of each peak. Standard curves for quantitation of samples for PGEj confirmation
were prepared using the ratio of base peak abundances of PGIi, and PGD2.

C. Results
1. Sample collection
Synovial fluid samples from normal equine joints were very viscous. To
insure that the synovial fluid supernatants were free of cells that could contribute to
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ex vivo eicosanoid formation, 3 samples were evaluated for cellularity by microscopic
examination of Wright’s stained direct smears. No white blood cells or platelets were
found and slides contained scant numbers of red blood cells.
Several samples of synovial fluid from horses with acute synovitis were
subjected to two freeze/thaw cycles before extraction and ELISA in order to determine
if previously thawed samples could be refrozen and assayed at a later date. Both
PGE2 and LTB4 levels increased markedly (485.40% and 393.77%, respectively) after
two freeze thaw cycles.
2. Extraction
Percent recoveries of LTB4 and PGE2 from plasma using liquid/liquid
extraction and synovial fluid using liquid/liquid extraction, solid phase extraction, and
solid phase extraction with methyl formate as the final eluting agent are reported in
Table 9. Recoveries of PGE2 from synovial fluid and plasma using the liquid/liquid
technique modified from Coker et al., [333] were 67.95 and 43.82%, respectively.
Recovery of LTB4 from synovial fluid and plasma using this method were 98.39 and
39.13%, respectively.
Attempts were made to duplicate the solid phase extraction procedure of
Powell [351,360] using aqueous ethanol as a sample diluent and initial wash followed
by a water wash, a petroleum ether wash and elution using methyl formate. The
reported recovery of PGEj from urine and plasma using this method is > 90%.
However, in the present study this method demonstrated that recoveries of PGE2 and
LTB4 were poor, in large part due the loss of eicosanoids from the Sep-Pak upon

Table 9: Percent Recovery of PGE2 and LTB4 in synovial fluid and plasma using various techniques.

SYNOVIAL FLUID

PLASMA

LIQUID/LIQUID

SOLID PHASEETHYL
ACETATE

SOLID PHASEMETHYL
FORMATE

LIQUID/LIQUID

PGE2 % RECOVERY
CV

67.95
14.11

61.04
2.97

48.97
8.64

43.82
9.55

ltb4

98.39
7.37

57.67
12.25

65.99
11.70

39.13
10.06

% RECOVERY
CV

(ii =3)

VO

o
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application of the diluted sample fraction and the initial aqueous ethanol wash. It was
determined that higher recoveries were obtained using water at pH 3 as the sample
diluent and initial wash. Further, hexane was substituted for petroleum ether as it was
found to produce less damage to the plastic syringe plungers. Ethyl acetate was found
to give approximately equal recoveries (PGEj- 61.04%; LTB4- 57.67%) as the highly
flammable and irritating methyl formate (PGE2- 48.97%; LTB4- 65.99%) when used
with this modified method.
The cartridges and reservoirs were washed extensively before use to reduce the
immunoreactive substances that were shown to interfere with the PGEj assay. Other
researchers have also reported immunoreactive substances or other impurities from
Sep-Paks that were not thoroughly washed before use [361,362]. According to Powell,
cartridges can be re-used [351]. It was determined that cartridges could be re-used a
maximum of three times without contributing any carryover immunoreactivity if they
were washed with 40 ml each of hexane, ethyl acetate and methanol before each re
use.
3. ELISA
The limit of quantitation based on the lowest concentration of the standard
curve was 10 pg/ml for both assays.

According to performance characteristics

supplied by the manufacturer, the sensitivity of the LTB4 ELISA was 8.9 pg/ml with
minimal cross reactivity with other leukotrienes, prostaglandins and arachidonic acid
metabolites (Table 10). The reported sensitivity of PGE2 ELISA was 1.5 pg/ml. The
reactivity of this kit was low for other eicosanoids and metabolites tested except for

Table 10: Percent cross reactivity of PGE2 and LTB4 ELISAs as determined at 50% B/B0. Standards
were spiked into assay buffer (data supplied by Advanced Magnetics, Cambridge, MA).
PGEj

LTB4

PGE j

100.0 %

PGEX

50.0%

5(S),12(R)-DiHETE

6.7%

PGAj

6 .0 %

5(S),12(S) -Di-HETE

2 .0 %

PGA,

1.9%

ltc 4

< 1.0 %

PGB,

< 1. 8 % l t d 4

< 1.0 %

PGB,

< 1. 8 %

lte 4

< 1.0 %

6-keto-PGEj

< 1. 8 % 5-HETE

< 1.0 %

15-keto-l 3,14-dihydro-PGE,

< 1. 8 %

12-HETE

< 1.0 %

PGF^

< 1. 8 % 15-HETE

< 1.0 %

5-HETE

< 1.0 % p g d 2

< 1.0 %

12-HETE

< 1.0 % PGEX

< 1.0 %

6-keto-PGEla

< 1.0 % PGE,

< 1.0 %

pgd2

< 1.0 % Thromboxane B2

< 1.0 %

Arachidonic acid

< 1.0 % 20-hydroxy-LTB4

< 1.0 %

Thromboxane B2

< 1.0 % Arachidonic acid

< 1.0 %

ltb 4

100.0 %
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PGEt which had 50% reactivity with the PGE2 antibody at 50% B/B0 (sample
OD/blank OD).
a. Intra-assay variation
The intra-assay variance or the within assay precision of the PGE^ and LTB4
ELISA as expressed as the coefficient of variation are presented in Table 11.
Individual concentration and overall CVs were less than 10% as recommended by
Feldcamp and Smith [363].
b. Inter-assay variation
The between assay variability based on the coefficient of variation of 9 PGEj
assays and 4 LTB4 assays was greater than the intra-assay variation (Table 11). The
overall repeatability of these assays was 14.32% for PGE2 and 17.28% for LTB4.
These values are in the range reported for ELIS As [342,364], The mean correlation
coefficient + SD for the standard curves was 0.9869 ± 0.0102 for PGEj and 0.9850
± 0.0140 for LTB4.
3. PGEj Confirmation
A gradient of the 2 mobile phases reported by Powell [335] provided good
chromatography of PGE2 with minor column and flow rate modifications.

A

representative chromatogram of 3H-PGE2 spiked synovial fluid is shown in Figure 4.
Figure 5 shows liquid chromatograms of 10 f i g of PGE2 and PGD2 obtained with
photodiode array detection as well as a radio-chromatogram of 3H-PGE2. Photodiode
array chromatograms are expressed as milliabsorbance units (mAU) versus time,
whereas radio-chromatograms are expressed as dpm versus time. The chromatograms

Table 11: Inter- and intra-assay variance (CV) of PGEj and LTB4 ELISAs.

PGEj

LTB4

CONCENTRATION
(pg/ml)

INTER-ASSAY

INTRA-ASSAY

INTER-ASSAY

INTRA-ASSAY

10

16.89

3.00

14.50

3.50

50

15.46

2.38

9.78

3.44

250

10.77

5.32

14.73

3.44

1000

12.52

2.79

18.40

3.04

5000

15.95

4.12

28.99

6.69

OVERALL CV
(mean ± SD)

14.32
± 2.57

3.52
± 1.19

17.28
± 7.23

4.02
± 1.50

PGE2 n=9
LTB4 n=4

VO

A,I

m35

*3
DPM

239-

Figure 4: Liquid chromatogram with radio-chromatography detection of 3H-PGE2 spiked synovial fluid. The
small peak at 29 to 30 minutes (*) is likely a degradation product of PGEj.
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obtained with photodiode array detection at a wavelength of 192 nm show interference
due to the solvent gradient, making detection of small quantities of PGE^ difficult.
Thus, the retention time of PGE2 was confirmed before collection of incurred samples
using 3H-PGE2 with a radio-chromatography detector. 3H-PGE2 eluted between 0.4
and 0.12 minutes before PGE2 due to the increase in hydrophilicity associated with the
3H-labelled compound [365].

The retention times of PGE2 and PGD2 were 24.89

and 25.26 minutes, respectively. PGE2 and PGD2 differ only in the position of the
hydroxy and keto groups (PGEj-1l-hydroxy-9-keto; PGD2- 9-hydroxy-l 1-keto). This
difference accounts for the subtle difference in HPLC and GC/MS retention times.
The limit of detection for PGEj on GC/MS was 118 pg on column (39.6
ng/ml). A representative chromatogram of a standard solution of PGEj (237 pg on
column) and PGD2 (1.92 ng on column) is shown in Figure 6 . PGEj and PGD2
formed syn and anti methoxime isomers [366,367].

The first isomer of PGE^ and

PGD2 coeluted but their second isomers separated adequately with the PGD2 isomer
eluting before PGE^, as reported previously [359]. The second isomers were used for
quantitation by expressing the abundance of each base peak of PGEj to PGD2 as a
ratio. NICI of these eicosanoids resulted in fragmentation of the molecular ion (M)‘
of the compound of interest (parent compound with derivatized functional groups, total
molecular weight, 705). Cleavage of PFB from the molecular ion (M-PFB)' at the
ester linkage resulted in the 524 m/z ion. Loss of one TMS as an alcohol resulted in
the 434 m/z ion. The 344 m/z ion was produced following cleavage of the second
TMS alcohol. The 196 m/z ion represented PFB with an oxygen molecule cleaved
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from the prostaglandin. MID scans showing the intensity of the base peak of the
second isomer of PGEj (524 m/z) and the base peak of the second isomer of PGD2
(434 m/z) are shown in Figure 7. The standard curve using concentrations of PGEj
ranging from 118.9 pg to 7.61 ng on column was linear with a coefficient of
determination of 0.9981 (Figure 8).
The GC/MS chromatogram of synovial fluid obtained from a horse with
experimentally-induced synovitis for PGEz confirmation is shown in Figure 9. Scans
showing base peak abundances of PGE2 and PGD2 are shown in Figure 10. GC/MS
analysis detected 1.07 ng of PGEj (on column) which was calculated to be 15.49
ng/ml in the original synovial fluid sample.

The ELISA assay of a separate aliquot

of the same synovial fluid resulted in 20.79 ng/ml of PGE2.

D. Discussion
According to initial studies, PGE2 and LTB4 levels in synovial fluid of horses
with acute synovitis increased after repeated freeze/thaw cycles. This was not due to
cellular metabolism of arachidonic acid as these samples contained no cells capable
of eicosanoid production. The reason for this effect is not readily apparent, although
it has been seen previously in plasma but not serum [333,349].

Perhaps the

subcellular particles containing cyclooxygenase and lipoxygenase enzymes metabolized
the arachidonic acid present in membrane fragments in the synovial fluid. Or perhaps
eicosanoids bound to proteins and glycosaminoglycans in the synovial fluid are
released upon damage caused to these molecules by repeated freeze/thaw cycles.
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Owing to this effect, all samples reported in the present studies were thawed
immediately prior to extraction and assay.

Results from other laboratories have

demonstrated that eicosanoids are stable when thoroughly frozen (-20° C) for
prolonged periods of time [333].
Results from the liquid/liquid extraction technique indicated that this method
gave good recovery from small volumes of synovial fluid, whereas larger volumes of
plasma resulted in lower recovery. Solid phase extraction of synovial fluid resulted
in lower recovery of LTB4 than the liquid/liquid procedure, although the solid phase
recovery was in the range of reported extraction efficiencies.

Recovery of

leukotrienes using Sep-Paks with modified Powell methods were reported to be 73 %
[368] and 79% forLTC 4 [369] and 57% [362], 73% [345], 89% [355] and 96% [370]
for LTB4. Recovery of PGEj using solid phase extraction has been reported to be >
90% [351,368,371] which is higher than the recovery determined in this study.
Recoveries calculated from serum [368], plasma, urine [351] and tissue culture
medium [362] may not be comparable to equine synovial fluid due to the viscosity of
this matrix which could bind or trap eicosanoids.
Solid phase extraction of eicosanoids from biological matrices has largely
replaced liquid/liquid extraction owing to the specificity, efficiency and rapid
processing of samples [346]. The technique as originally described by Powell [372]
is based on the affinity of the eicosanoids for the non-polar octadecylsilyl (ODS)
packing material of the cartridge.

The cartridges function as reversed phase

chromatography columns [351]. The application of strong organic solvents such as
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hexane or petroleum ether allows for the removal of very non-polar compounds such
as triglycerides and other lipids. The application of more polar solvents such as
methyl formate or ethyl acetate elutes the eicosanoids. In the present study, this
approach allowed for a more selective extraction procedure than the liquid/liquid
extraction techniques.
Most eicosanoids are small haptens that have only one epitope and are
unsuitable for the original "sandwich" ELISA where two molecules of antibody
recognized the same antigen [344]. Most eicosanoid ELISA procedures, including the
ones described in this study, are of the competitive type where labelled antigen
competes with sample antigen for binding on the specific antibody. In immunoassay
procedures the degree of displacement of the antigen from the antigen-antibody
complex is quantified. The binding of the labelled antigen is inhibited by the antigen
of interest (PGE2 or LTB4 in the sample). However, cross-reacting substances of
similar structure and excessive amounts of unrelated compounds may interfere with
binding. Although too expensive and complicated to be used for routine analysis,
GC/MS has been used as a validation procedure for immunoassays [373]. GC/MS is
regarded as the most specific and sensitive method for analysis of eicosanoids.
Specificity is based on the gas chromatographic retention time of the compound and
detection of the characteristic fragment ions by mass spectrometry [339].
The HPLC technique used for isolation and collection of PGEj before GC/MS
has been shown to separate many cyclooxygenase and lipoxygenase metabolites that
may then be subjected to GC/MS [335,336]. However, in the present study, the use
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of radio-chromatography of tritium labelled standard was needed to confirm the
retention time of PGEj due to the relative insensitivity of the photodiode array
detector. This technique proved less expensive than using f i g quantities of PGE2 on
the photodiode array detector as the radio-chromatography detector was sensitive to
ng quantities of tritiated PGE*.
Quantitation of eicosanoids is accomplished most effectively by the highly
sensitive NICI GC/MS technique [346].

The analysis of PFB derivatives of

eicosanoids by NICI GC/MS has the advantage of producing a high yield of stable
ionized products and a low fragmentation rate [346]. The sensitivity of this method
is due to fragmentation that is primarily directed away from the prostaglandin
molecule thereby leaving the carbon skeleton intact [366]. Quantitation of eicosanoids
by GC/MS using stable isotope dilution techniques is most often accomplished using
deuterated analogues of the compound of interest acting as internal standards. These
techniques are advantageous in GC/MS due to the similar structure and properties of
the isotope and native compound [374].

The technique employed in this study,

whereby a structurally similar compound is used as an internal standard, represents
a simple and sensitive alternative to the use of deuterated compounds.
Analytical problems have been an obstacle in eicosanoid research.

Thus,

progress in this field is dependent on the advancement and validation of analytical
techniques [338]. The ELIS As used in these experiments to quantitate PGEj and
LTB4 in equine synovial fluid and plasma had not been described previously for use
in the horse. Cross reactivity information obtained from the manufacturer indicated
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that the LTB4 assay was highly specific and sensitive.

As unique interfering

substances from equine synovial fluid are unlikely, validation procedures were not
performed for LTB4. The PGE2 assay although sensitive, had 50% cross reactivity
with PGEi. The validation procedures used in the present study confirmed the results
of the PGE2 ELISA on inflamed equine synovial fluid. GC/MS analysis detected
15.49 ng/ml of PGEj in the synovial fluid while the ELISA performed on a separate
aliquot of the same sample resulted in 20.79 ng/ml.

These results are in good

agreement taking into account minor losses of sample during purification by HPLC
and derivatization before GC/MS. Therefore, the PGE2 ELISA appears to specific for
this compound in equine synovial fluid, indicating the absence of interferences from
this matrix.

CHAPTER 4
EFFECT OF KETOPROFEN AND PHENYLBUTAZONE
ON ACUTE SYNOVITIS

A. Introduction
Synovitis accompanies most forms of equine joint disease [75]. Synovitis is
characterized by inflammation of the synovium without gross disturbance of the
articular cartilage or disruption of major supporting structures [83]. Clinical signs of
acute synovial inflammation include: synovial effusion with distension of the joint
capsule; increased skin temperature over the joint; hypertrophy and hyperplasia of the
synovia resulting in a palpable thickening of the membrane; a decrease in the range
of motion of the joint; and lameness in the affected limb. Eicosanoids and other
inflammatory mediators contribute to the inflammatory response by increasing
synovial vascular permeability [17], increasing the metabolic rate of synoviocytes
[37], and causing congestion of the microvascular bed [93]. As the permeability of
the synovial membrane increases, proteins accumulate in the joint resulting in an
increase in fluid osmotic pressure.

The resulting effusion of synovial fluid often

results in pain and overt lameness [94].

In humans there is a positive linear

correlation between intra-articular pressure and joint pain [95]. The inflammatory
mediators released by local tissue destruction in the joint activate nociceptors and also
sensitize these receptors through lowering of activation thresholds [96,97]. Further,
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the release of substance P and other neuropeptides [98] may potentiate the
inflammatory response and result in neurogenic inflammation [99],
Experimentally, synovitis has been induced in horses, ponies, calves, dogs,
rabbits and rats by the intra-articular injection of a variety of chemical substances.
Models of joint inflammation have been used for screening and evaluation of anti
inflammatory agents [101] The equine joint is a unique site for an inflammatory
model due to the structure and function of the synovial membrane and the sheer size
of the joint space. The synovial membrane acts as a selective barrier in the joint in
that it allows for the passage of molecules of less than approximately 12,000 daltons
in molecular weight [76]. Transfer of small molecules to and from the synovial fluid
occurs readily due to specialized structures within the membrane such as: a synovial
lining cell layer that is 1 to 4 cells thick and often incomplete [74]; lack of
desmosomes or a basement membrane [77]; and the presence of fenestrated capillaries,
secretory and macrophagic cells, surface pores and large numbers of lymphatics [74].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered the mainstay
of treatment for non-septic joint disease in animals [76,375]. It is well documented
that these agents alleviate the pain and lameness associated with joint inflammation
[ 101] through reduction in the peripheral nociceptive impulses from the inflamed joint
[197] and through central analgesic mechanisms [148,273]. However, few studies
have described the anti-inflammatory effects of these agents in detail in experimentally
induced joint inflammation [297].
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The purpose of this study was: 1) to develop a self-limiting, reproducible
model of acute synovitis which increased prostaglandin E2 (PGE2) and leukotriene B4
(LTB4) synovial fluid concentrations along with other measurable joint inflammatory
responses; 2) compare the magnitude and time course of the anti-inflammatory and
eicosanoid inhibitory effects of ketoprofen and phenylbutazone in the acute synovitis
model; and. 3) compare the ability of ketoprofen and phenylbutazone to reduce the
clinical signs of acute synovitis. The approved therapeutic doses of ketoprofen (2.2
mg/kg) and phenylbutazone (4.4 mg/kg) were used. In addition, the phenylbutazone
molar equivalent dose of ketoprofen (3.63 mg/kg) was used in order to compare the
potency of ketoprofen and phenylbutazone. NSAIDs and saline were administered at
the same time as carrageenan induction in order to determine the anti-inflammatory
effects of the NSAIDs on developing and acute inflammation.
The intercarpal joint was chosen for induction of synovitis because of its large
volume of synovial fluid [376] as it communicates with the carpometacarpal joint in
most (90%) horses [74]. Further, this joint has three access sites: medial and lateral
to the extensor carpi radialis tendon and at the palmarolateral reflection of the
intercarpal joint capsule, distal to the accessory carpal bone [377]. As most of the
horses used in this study were retired racing Thoroughbreds, the left carpus was used
because of the increased incidence of joint pathology in the right carpus [378,379].
Inflammation was induced in each horse only once due to the potential for permanent
cartilage damage with successive carrageenan injections [108]. Further, it has been
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documented that the prior injection of carrageenan in the rat paw causes hyperalgesia
to develop much faster when the contralateral paw is injected [272].

B. Materials and methods
1. Experimental animals
Twenty-four mares and geldings (5 American Quarter Horses and 19
Thoroughbreds) weighing from 410 to 554 kg and ranging from 6 to 13 years of age
were used. Prior to induction of synovitis, horses were judged to be healthy and
sound based on physical examination, lameness evaluation, complete blood count, left
intercarpal synovial fluid clinical pathology analysis and radiographic examination of
the left carpus.

Horses with radiographic or synovial fluid pathology of the

intercarpal joint were excluded.
All horses were vaccinated at least three weeks prior against eastern and
western equine encephalomyelitis, influenza, tetanus (Equi-Flu EWT™, Coopers,
Mundelein, IL) and rhinopneumonitis (Rhinomune™, SmithKline Beecham Animal
Health, Exton, PA).

The horses were dewormed with oxibendazole (Equipar™,

Coopers, Mundelein, IL). Horses were housed in 10.9 x 12.5 feet stalls and were
maintained on 5 pounds of a pelleted ration (Purina Horse Chow 100™, Purina Mills
Inc., St. Louis, MO) containing: a minimum of 10% protein; 2% fat; a maximum of
25 % fiber; and a vitamin/trace mineral supplement twice daily with mixed grass hay
(11% protein, 1.4% fat, 24% fiber) and water provided ad libitum.
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2. Drugs and reagents
a. NSAID solutions for administration
Ketoprofen (Ketofen™) was obtained commercially from Aveco Company,
Inc., Fort Dodge, IA. Each ml of the sterile solution contained: 100 mg ketoprofen;
L-arginine, 70 mg; citric acid to adjust pH to approximately 7; and benzyl alcohol,
0.25 ml as a preservative. Phenylbutazone (Butazolidin™) was obtained commercially
from Coopers Animal Health, Inc., Kansas City, KS. Each ml of the sterile solution
contained: phenylbutazone, 200 mg; sodium hydroxide to adjust pH to between 9.5
and 10.0; and benzyl alcohol, 10.45 mg as a preservative.
b. Carrageenan solution
Carrageenan (type IV; molecular weight, approximately 300,000) was
purchased from Sigma Chemical Co., St. Louis, MO.

This type of non-gelling

carrageenan was isolated from two seaweed species, Gigartina aciclulaire and
Gigartina pistillata. It was sterilized in powder form using ethylene oxide (H.W.
Andersen Products, Haw River, NC) and then mixed to a suspension with sterile
0.9% saline according to a modified method of Higgins and Lees to produce a 1%
solution [70].

All horses were induced using the same batch of carrageenan as

different batches are known to vary in their inflammatory potency [380]. Cultures of
the 1 % solution were made in duplicate on blood agar (aerobic culture medium) and
in thioglycollate broth (anaerobic culture medium) weekly for the duration of this
study [381].

These cultures were maintained at 37° C for three days and were

examined for microbial growth daily. The solution was thoroughly mixed and (0.3
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ml) was drawn up in a sterile 1 ml syringe using a 25 gauge, 1 inch needle on the
morning of each experimental day.
3. Experimental protocol
a. Overview
In the beginning of each experimental session, horses were evaluated for
lameness and then brought into the environmentally controlled laboratory and
restrained in an equine stanchion.

The left carpal joint was radiographed and

measured. The horse was then sedated and after 5 minutes, blood was collected and
heart rate, respiratory rate and rectal temperature were determined. A thermography
apparatus was applied to the joint and then it was scrubbed in preparation for
arthrocentesis. In baseline sessions, synovial fluid was collected. Then at time 0,
carrageenan was injected into the joint and ketoprofen (2.2 mg/kg and 3.63 mg/kg),
phenylbutazone (4.4 mg/kg) or saline was administered intravenously. Horses were
subsequently evaluated according to this protocol at 1, 3, 6 , 9, 12, 24 and 48 hours
after administration.
b. Horse preparation
Each horse was washed and shaved over the entire carpal region 24 hours prior
to drug administration.

Indwelling catheters (14 gauge, 5.7 cm) (Quick-Cath™,

Baxter Healthcare Corp., Deerfield, IL) were aseptically placed bilaterally in the
jugular veins of each horse before each session.

114
c.

Synovial fluid collection and induction o f synovitis

Horses were sedated with intravenous detomidine HC1 (Dormosedan™, Norden
Laboratories, Lincoln, NE) at doses of 10 jig/kg before the baseline collection, and
5.0 ^ig/kg before each post-treatment arthrocentesis to reduce the risk of iatrogenic
joint hemorrhage and trauma.

In addition, all horses were nose twitched during

arthrocentesis. Before each arthrocentesis the entire left carpal area was scrubbed
with Hibiclens™ (Stuart Pharmaceuticals, Wilmington, DE) and alcohol at least three
times with a final scrub directly over the site for arthrocentesis. Sterile needles (20
gauge, 1 inch), syringes (12 ml or 20 ml) and gloves were used to collect fluid from
the intercarpal joint while the limb was held in the flexed position by another
examiner. Immediately following the collection of the baseline synovial fluid sample,
0.3 ml of 1% solution of sterile carrageenan was injected into the left intercarpal joint
(dorsolateral aspect) using sterile technique [52].

An independent examiner

administered the NSAIDs or saline via the left jugular catheter immediately following
carrageenan injection.
Synovial fluid was then collected from the intercarpal joint at 1, 3, 6 , 9, 12,
and 24 hours after drug and carrageenan administration.

Fluid was collected

altematingly from the dorsolateral and dorsomedial aspect of the intercarpal joints.
In addition, the palmarolateral access site was used intermittently when the joint
become effused. Sites for arthrocentesis were rotated in order to minimize iatrogenic
hemorrhage into the joint capsule. At each time point, the maximum volume of
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synovial fluid available was withdrawn in order to reduce the degree of discomfort in
the horse caused by joint effusion.
All synovial fluid samples were aliquoted for ketoprofen determination,
bacterial culture, clinical pathology analysis and eicosanoid determination. Fluid (at
least 1.5 ml) for the PGEj and LTB4 assay was placed immediately into chilled
evacuated tubes containing 1.5 mg/ml of ethylenediamine tetraacetate K3 (EDTA)
(Vacutainer, Becton Dickinson, Rutherford, NJ) with 6.48 /tg/ml of BWA4C, 5 pig/ml
of indomethacin, and 57 fA saline. Tubes were then centrifuged at 2,500 rpm for 15
minutes at 4° C (Eppendorf 5415C, Brinkman Instruments, Westbury, NJ). The cellfree synovial fluid was stored in polypropylene micro-centrifuge tubes (Dot Scientific,
Inc., Flint, MI) at -20° C for 2 days, then at -70° C until assayed. Fluid for clinical
pathology analysis (at least 0.75 ml) was placed into 2 ml evacuated tubes containing
3 mg/ml of EDTA (Vacutainer, Becton Dickinson, Rutherford, NJ).

Fluid for

ketoprofen determination was processed according to methods described in Chapter
5.
Synovial fluid volume was recorded and the fluid was graded for hemorrhage
based on the following scale:
Grade 1: A slight amount of blood contamination, often obtained upon exiting
the joint.
Grade 2: Moderate blood contamination upon exiting the joint or fluid that
had a moderate red or brownish-red haze indicating formation of unconjugated
bilirubin from the breakdown of erythrocytes.
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Grade 3: Very hazy, opaque, red or brownish-red fluid.
Grade 4: Fluid containing a large quantity of frank blood or evidence of
clotting.
d. Blood collection
All NSAIDS and detomidine were administered via the left jugular catheter.
The right jugular catheter was used for blood collection before drug and carrageenan
administration (baseline) and at 1, 3, 6, 9, 12, 24 and 48 hours after drug injection
for determination of complete blood counts.

Blood was also collected for

determination of plasma ketoprofen concentrations as outlined in Chapter 5. The
patency of each catheter was maintained after each blood collection with 3 ml of 100
IU/ml of heparinized saline. Before blood was collected, 2-3 ml was discarded to
remove any residual heparin from the catheter. Blood (7 ml) was collected with a 18
gauge, 1.5 inch needle and a 20 ml syringe and then placed immediately into 7 ml
evacuated glass tubes containing 10.5 mg of EDTA as an anticoagulant (Vacutainer,
Becton Dickinson, Rutherford, NJ) and stored at 4° C until analysis.
e. Lameness evaluation
Horses were evaluated at a walk and trot on a concrete surface and graded for
lameness as follows [377]:
Grade 1: The horse exhibited a normal gait at a walk. The trot showed a
slightly shortened weight bearing phase for the left forelimb with an audible
cadence abnormality. There was even head and neck lifting for each foot.
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Grade 2: The walk showed stride changes with no abnormal head or neck
lifting. The trot showed obvious lameness with uneven head and neck lifting.
Grade 3: The lameness was obvious at a walk and trot with prominent head
and neck lifting as the left forelimb was weight bearing.
Grade 4: The horse experienced difficulty bearing weight on the left forelimb.
f

Radiography

The left carpus was radiographed (Min X-Ray 300, Evanston, IL) laterally
while held in rigid flexion by the examiner, in order to obtain the angle of maximum
flexion of the joint, using 20.3 x 25.4 cm film cassettes and TML diagnostic film (TMat™, Eastman Kodak Co., Rochester, NY). After development of the radiographic
film (RP X-Omat Processor, Eastman Kodak Co., Rochester, NY) lines were drawn
on the radiographic image along the long axis of the radius and third metacarpal bones
at the measured midpoint of each diaphysis. The angle formed by the intersection of
these lines dorsal to the carpus was measured with a standard protractor to provide
an estimate of the range of motion of the carpus.
g.

Joint circumference and effusion grade

The circumference of the intercarpal joint was measured in cm using a standard
tape measure.

To ensure measurement consistency, the joint was marked with

fingernail polish in three places (medial, lateral and palmar) in the beginning of each
experimental session. Each horse was subjectively evaluated for carpal effusion based
on the following scale:
Grade 1: Slight effusion around the site of carrageenan injection.
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Grade 2: Moderate effusion of the intercarpal joint only without distention of
the palmarolateral joint pouch.
Grade 3: Marked effusion of the intercarpal joint with distension of the
palmarolateral joint pouch.

Some swelling proximal and distal to the

intercarpal joint.
Grade 4: Severe swelling of the entire carpal region.
h. Temperature, heart and respiratory rates
Rectal temperature was obtained from a rectal probe (Model RET-1, Sensortek,
Clifton, NJ) and digital thermometer (Model TH-6D, Sensortek, Clifton, NJ). Heart
and respiratory rates (bpm) were obtained by auscultation.
i. Carpal thermography
A contact thermography system (Novatherm, Med Tech Products, Inc.,
Dayton, OH) was used to detect thermal emissions from the dorsal surface of the left
carpus. The detector consisted of a liquid crystalline latex membrane wrapped around
a pressurized frame with a viewing window. Eight membranes were used with mean
detection temperatures of 22, 24, 26, 28, 30, 32, 34 and 36° C. Each membrane had
an approximate temperature range of 4° C. Color changes in the membrane were
correlated with temperatures by color calibration scales on each membrane
(approximately 0.8° C change per color). Membranes were held against the dorsal
surface of the carpus for 60 seconds, withdrawn and immediately photographed
(Polaroid auto-focus single lens camera with Polaroid instant film (779, ASA 640),
Polaroid Corp., Cambridge, MA).

Room temperature in the laboratory was
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maintained between 23 and 26° C. Isothermic areas on the photographic images were
calculated using a digitizing tablet and computerized area integration program
(SigmaScan, Jandel Corp., San Rafael, CA). Each isothermic area was expressed as
a percent of the total photographed area and the overall temperature of the joint was
calculated. For each horse, post-injection data were expressed as a percent change
from baseline in order to minimize variance between horses in basal joint
temperatures.
4. Synovial fluid analysis
a.

Clinical pathology

Fluid was kept at 4° C and warmed to room temperature (20-22° C) before
analysis. Fluid was analyzed for cellularity, protein and quality of hyaluronic acid.
The total number of nucleated cells (neutrophils, large mononuclear cells,
lymphocytes, eosinophils and basophils) and red blood cells per y\ were determined
by a multispecies automated hematology analyzer (Baker 9000, Baker Instrument Co.,
Allentown, PA). Samples with total nucleated cell counts of less than 500 cells//d
were reanalyzed by the direct hemocytometer method [382]. The overall quality of
the hyaluronic acid in the synovial fluid was determined by the mucinous precipitate
quality test (MPQ). This serves as a reliable qualitative measure of the concentration
and polymerization of synovial fluid hyaluronic acid [376]. Synovial fluid (0.5 ml)
was added to 5 ml of 5% acetic acid and mixed thoroughly. The resultant precipitate
was subjectively graded as: 1) good- tight ropy mass in clear solution; 2) fair- soft
mass with some shreds; or 3) poor- shredded, small, soft masses in a turbid solution
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[75].

Synovial fluid protein concentration was analyzed after centrifugation

(Hemofuge™, American Scientific, manufactured by Heraeus-Christ, Osterod, West
Germany) at 12,000 rpm for 4 minutes and was determined by a hand held
refractometer (TS Meter, American Optical, Keene, NH). Values below 2.5 g/dl
were not determined. These determinations were performed by the Louisiana State
University, School of Veterinary Medicine, Clinical Pathology Laboratory.
Differential leukocyte counts were made from direct and concentrated synovial
fluid smears. For samples with total nucleated cell counts less than 7,500 cells/^1,
5 drops of synovial fluid were concentrated on a glass slide by centrifugation at 1,000
rpm for 6 minutes (Cytospin 2, Shandon Southern Products, Astmoor Runcorn,
Chesire, England). Samples with elevated nucleated cell counts (>7,500 cells/jd)
were examined directly on glass slide smears. Slides were air dried and stained with
modified Wright’s stain (Hema-Tek™, Miles Laboratory, Inc., Elkhart, IN) using an
automatic stainer (Hema-Tek™ slide stainer, model 4480, Ames Co.; Miles
Laboratory, Inc., Elkhart, IN). A standard light microscope with 10X, 40X and 100X
oil immersion objective lenses was used for all synovial fluid cell counts (Ernst Leitz
Wetzlar, Germany).

Slides were examined for neutrophils, lymphocytes, large

mononuclear cells (monocytes and macrophages [382]), eosinophils and basophils.
100 cells were counted for every 30,000 nucleated cells//d.
b.

Bacterial culture

Synovial fluid remaining in the collecting syringe after aliquoting for the other
assays was diluted with sterile 0.9% saline and cultured in duplicate on blood agar
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plates and in thioglycollate broth tubes. Cultures were incubated at 37° C for 3 days
and were examined visually for bacterial or fungal growth every 24 hours.
c. Eicosanoid determination
i. Extraction
Synovial fluid (0.5 ml) was extracted before LTB4 determination by ELISA.
In order to stay within the range of ELISA quantitation for PGE2 (10-5000 pg/ml),
synovial fluid volumes of 0.25, 0.125, 0.0625 or 0.01 ml were extracted depending
on the anticipated concentration of PGE^ Further, synovial fluid obtained from some
horses at times 6 , 9 and 12 hours was diluted with water acidified to pH 3 with 1 N
HC1 (1:10 and 1:100) and the diluted sample was then extracted. Sep-Pak Plus™
cartridges containing 360 mg of Clg (Millipore Corporation, Milford, MA) were
washed and cleaned according to methods described in Chapter 3. The synovial fluid
was acidified to pH 3.5 using 1 N HC1 in a polypropylene centrifuge tube. One-half
ml of pH 3 water was added and the sample was vortexed for 15 seconds before being
transferred to the cartridge reservoir. The sample was allowed to flow through the
cartridge slowly under slight vacuum pressure (< 5 inches of mercury). After the
sample was evacuated, 6 ml of pH 3 water was added under vacuum followed by 6
ml of hexane. The eicosanoids were eluted from the cartridge with 6 ml of ethyl
acetate using gentle pressure applied with the syringe plunger. The ethyl acetate was
then evaporated under a stream of nitrogen gas.
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ii. ELISA

Quantitation of plasma and synovial fluid eicosanoids was achieved by
commercially available PGE2 and LTB4 ELISA kits

(Advanced Magnetics,

Cambridge, MA). These assays were based on the principle of a competitive ELISA
where PGEz or LTB4 in the sample competed with fixed amounts of alkaline
phosphatase labelled PGEj or LTB4 for binding to a limited number of sites on the
specific rabbit antibody (anti-PGEj or LTB4) bound to the microtiter well.
Absorbance (optical density) was read at 410 nm by a microtiter plate reader
(Dynatech MR5Q00, Dynatech Laboratories, Alexandria, VA).

Samples with the

greatest color development or optical density values (ODs) contained the least PGEj
or LTB4. Absorbance was correlated with concentration by means of a standard curve
ranging from 10 to 5000 pg/ml. All sample concentrations were then corrected for
extraction efficiency. For a complete description of the ELISA procedure, refer to
Chapter 3.
5. Hematology
All blood samples were kept at 4° C then warmed to room temperature before
analysis. Total leukocyte (WBC) and red blood cell (RBC) counts were determined
by the hemocytometer method [383,384] using the Unopette™ micro-collection system
(WBC- model

5853; RBC- model 5850, Becton, Dickinson and Company,

Rutherford, NJ). Determination of whole blood packed cell volume (PCV%) was
accomplished by centrifugation of glass capillary tubes at 11,700 to 13,700 rpm for
5 minutes (Autocrit™ II, model 0574, Clay Adams; Becton, Dickinson and Company,
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Parsippany, NJ) [384]. Plasma obtained from the centrifuged capillary tubes was
analyzed for protein (g/dl) by a hand held refractometer method (TS Meter, American
Optical, Keene, NH). Plasma fibrinogen was determined by heating these centrifuged
capillary tubes for 4 minutes at 56° C and then centrifuging again for 5 minutes [384].
Protein in the heated plasma was determined by the refractometer. Fibrinogen (g/dl)
was calculated by subtracting the heated plasma protein concentration from the
original plasma protein value and multiplying by 1,000. Blood smears were prepared
on glass slides for differential leukocyte counts, air dried and stained with modified
Wright’s stain (Hema-Tek™, Miles Laboratory, Inc., Elkhart, IN) using an automatic
stainer (Hema-Tek™ slide stainer, model 4480, Ames Co.; Miles Laboratory, Inc.,
Elkhart, IN).

Cells (100) were differentiated into neutrophils, lymphocytes,

monocytes, eosinophils and basophils.

Platelets were also enumerated from the

stained blood smears. A standard light microscope with 10X, 40X and 100X oil
immersion objective lenses was used for all hematological counts (Ernst Leitz,
Wetzlar, Germany).
6. Study design and statistical analysis
Twenty-four horses received ketoprofen (2.2 mg/kg and 3.63 mg/kg),
phenylbutazone (4.4 mg/kg) and saline intravenously according to a Latin Square
design [385]. Each treatment was administered to 6 horses and each horse was used
only once. Treatments assigned to horses were coded before the initiation of the
study. All drug administrations, tests and analyses were performed by individuals
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unaware of the treatment code. The treatment code was broken at the end of the
study.
All data except for eicosanoid concentrations were analyzed using one-way
analysis of variance (ANOVA) for repeated measures [386,387]. When indicated by
the ANOVA, multiple comparisons were performed using Tukey’s w procedure [388].
Differences between treatments at each time were considered significant when P <
0.05.
PGEj and LTB4 synovial concentration data were analyzed independently using
an analysis of variance for a split plot design with repeated measures where treatment
constituted the main plot and the time by treatment interaction was the subplot
[386,389]. The paucity of synovial fluid available for eicosanoid assay at some time
points resulted in missing data.

This precluded the use of the ANOVA as this

procedure excludes all the data from a particular horse if only one time point is
missing. Instead, data were analyzed initially by a univariate approach for overall
treatment, time, and time by treatment interaction effects. Where indicated by the
univariate analysis, treatment means (averaged over time) were compared using
Tukey’s w procedure. Eicosanoid concentrations (averaged over treatments) were
compared at times 0, 1,3, 6 , 9, 12, 24 and 48 hours by Tukey’s w procedure. Post
treatment times that were found to have significantly (P < 0.05) different eicosanoid
concentrations than baseline were analyzed for differences between individual
treatments by pairwise Student’s t tests, using the least squares means procedure to
adjust for missing data [388,386]. Differences between treatments at each time were
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considered significant when P < 0.05. Multiple comparisons of treatments were thus
preplanned, i.e. performed only at times indicated by the Tukey’s w procedure, so as
to not inflate the comparisonwise error rate [388].

C. Results
Before initiation of this project, a pilot study was performed on 2 horses in
order to refine sampling techniques and assay procedures and to ensure that the
synovitis was transient with no lasting articular damage. The experimental protocol
was similar except that these 2 horses were not administered systemic NSAIDs at the
time of carrageenan induction.

The first horse was humanely euthanized for an

unrelated hindlimb musculoskeletal disorder 72 hours after carrageenan induction.
The articular cartilage of the intercarpal joint (third and intermediate carpal bones) of
this horse was grossly and histologically normal.

Upon gross examination, the

synovium was slightly hyperemic and thickened.

Histologically, the synovial

membrane showed a minimal non-suppurative inflammatory response with hypertrophy
and hyperplasia of the synovial cells resulting in increased folding of the synovial
villi.

Lameness subsided in both of these horses by 24 hours.

Synovial fluid

collected from the second horse 5 months after induction was determined to be normal
upon clinical pathology analysis. Based on the pilot study results, it was determined
that the synovitis was transient and many of the parameters returned to near baseline
by 48 hours.
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Overall treatment effects for all parameters tested in the 24 carrageenan treated
horses are listed in Table 12. For the clinical parameters, there was a significant
difference among treatments for synovial fluid volume, lameness grade, carpal
effusion grade and carpal thermography. For the synovial fluid clinical pathology
parameters, significant treatment effects were observed for protein and PGEj
concentrations. For the hematological parameters, only the number of eosinophils and
basophils showed a significant treatment effect.
1. Synovial fluid volume and appearance
The volume (mean + standard error (SEM)) of synovial fluid in 24 horses
obtained from the left intercarpal joint at baseline was 4.54 ml ± 0.24. The volume
of synovial fluid increased over time in all horses after induction.

However,

phenylbutazone significantly reduced the volume of synovial fluid as compared to
saline at 1, 9 and 12 hours after administration (Figure 11A).

Further,

phenylbutazone significantly reduced the synovial fluid volume as compared both to
doses of ketoprofen at 9 and 12 hours. The remaining treatments failed to affect
synovial fluid volume significantly.
No significant treatment effects for subjective grade of hemorrhage were
obtained. However the mean hemorrhage grade for all horses increased over time
with a peak at 12 hours. When data were averaged over all horses, the hemorrhage
grade ranged from 0.83 ± 0.19 at baseline to 3.29 ± 0.19 at 12 hours post-induction
(Table 13). Synovial fluid samples often contained visible amounts of yellowish
fibrin. This was removed from the sample before analysis. A few samples with

Table 12: Statistical analysis of overall treatment effects.
CLINICAL PARAMETERS

P

SYNOVIAL FLUID
CLINICAL
PATHOLOGY

P

HEMATOLOGY

P

SYNOVIAL FLUID VOLUME
(ml)

0.0092*

NUCLEATED
CELLS/M

0.3611

WBC//il

0.0908

SYNOVIAL FLUID
HEMORRHAGE GRADE

0.7151

RBC/jtl

0.4862

RBC/jtl

0.7829

LAMENESS GRADE

0.0015*

MPQ grade

0.1296

PCV (%)

0.7261

MAX. FLEXION ANGLE (°)

0.1601

PROTEIN (g/dl)

0.0064*

PROTEIN (g/dl)

0.8187

JOINT CIRCUMFER. (cm)

0.3469

NEUTROPHILS

0.8492

FIBRINOGEN (g/dl)

0.8644

CARPAL EFFUSION GRADE

0.0432*

MONO. CELLS/M

0.3681

NEUTROPHBLS/mI

0.4993

RECTAL TEMP. (°C)

0.1848

LYMPHOCYTES/pl

0.8936

MONOCYTES//tl

0.4000

HEART RATE (bpm)

0.3653

EQSINOPHILS/fd

0.2448

LYMPHOCYTES//1I

0.4235

RESPIRATORY RATE (bpm)

0.9279

BASOPHILS/^!

0.2670

EOSINOPHILS//*!

0.0047*

CARPAL THERMOGRAPHY
(°C)

0.0072*

PGEz (pg/ml)

0.0056*

BASOPHELS/mI

0.0375*

LTB4 (pg/ml)
ROOM TEMP. (°C)
0.7151
PLATELETS/jtl
0.0603
P = Probability estimate obtained from analysis of variance, treatments include phenylbutazone (4.4 mg/kg),
ketoprofen (3.63 mg/kg), ketoprofen (2.2 mg/kg) and saline.
^Statistically significant at P < 0.05
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Figure 11: Effect of NSAIDs and saline on (A) lameness grade and (B) volume of synovial fluid obtained at each
arthrocentesis. Statistically significant treatment means as compared to saline are indicated by (*). Carrageenan
and NSAIDs were administered at time 0 (n=6).

Table 13: Means* (± SEM) of non-significant clinical parameters.
TIME
0

1

3

6

9

12

24

48

HEMORRHAGE
GRADE

0.83
±0.19

2.17
±0.25

2.54
±0.26

2.63
±0.27

2.75
±0.26

3.29
±0.19

3.09
±0.23

2.57
±0.25

MAX. FLEXION
ANGLE (°)

21.08
± 1.01

22.94
±0.92

26.13
±1.34

28.63
±1.55

27.58
±1.41

30.21
±2.26

27.22
±1.80

24.00
± 1.01

JOINT
CIRCUMFERENCE
(cm)

28.72
±0.25

28.81
±0.27

28.85
±0.26

29.24
±0.27

29.41
±0.27

29.55
±0.27

29.47
±0.32

29.37
±0.31

RECTAL
TEMPERATURE (°C)

37.85
±0.06

37.81
±0.07

37.70
±0.07

37.90
±0.09

38.18
±0.07

38.30
±0.08

37.98
±0.08

37.80
±0.07

HEART RATE (bpm)

29.29
±0.70

29.67
±0.76

28.75
±0.71

30.42
±0.75

30.63
±0.61

31.71
±0.71

29.83
±0.74

28.87
±0.75

RESPIRATORY RATE
(bpm)

10.79
±0.57

8.29
±0.40

8.50
±0.40

10.96
±1.05

11.17
±0.85

13.54
±1.56

11.83
±1.35

9.48
±0.70

*Since there were no significant treatment effects for the above parameters, values reported above represent
averages over 24 horses.
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hemorrhage grades of 4 contained evidence of coagulation. These clots would often
dissolve upon gentle inversion of the EDTA tube.
2. Lameness grade
All horses but five (3 with phenylbutazone, 4.4 mg/kg; 1 with ketoprofen, 2.2
mg/kg; and 1 with ketoprofen, 3.63 mg/kg) became lame after carrageenan
administration.

The remaining horses returned to soundness by 48 hours after

induction (Figure 11B). Ketoprofen (3.63 mg/kg) significantly reduced the lameness
score as compared to saline at 3 hours post dose. Ketoprofen (2.2 mg/kg) similarly
reduced lameness at 3 hours and at 6 hours. Phenylbutazone (4.4 mg/kg) reduced the
lameness score as compared to saline at 6 , 9 and 12 hours after administration.
Further, phenylbutazone significantly reduced lameness as compared to both doses of
ketoprofen at 12 hours post dose.
3. Maximum flexion angle
There were no significant treatment effects for the maximum flexion angle as
determined by radiography of the carpus held in rigid flexion by the examiner.
However, the flexion angle increased over time with a peak at 12 hours. When data
were averaged over all treatments, the maximum flexion angle ranged from 21.08°
± 1.10 at baseline to 30.21° ± 2.26 at 12 hours after induction (Table 13).
4. Joint circumference and effusion grade
There were no significant treatment effects for the circumference of the
intercarpal joint (Figure 12A). The mean circumference ranged from 28.72 cm ±
0.25 at baseline to 29.55 cm + 0.27 at 12 hours post-induction (Table 13).
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Figure 12: Effect of NSAIDs and saline on (A) intercarpal joint circumference and (B) carpal effusion grade.
Statistically significant treatment means as compared to saline are indicated by (*). There were no significant
treatment effects on joint circumference. Carrageenan and NSAIDs were administered at time 0 (n=6).
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Both doses of ketoprofen reduced the subjective grade of joint effusion at 3
hours as compared to saline. The high dose of ketoprofen also reduced joint effusion
at 6 hours as compared to saline (Figure 12B). There were no significant effects
associated with phenylbutazone administration.
5. Temperature, heart and respiratory rates
There were no significant treatment effects for rectal temperature, heart rate
or respiratory rate (Table 13). Rectal temperature ranged from 37.85° C ± 0.06 at
baseline to 38.30° C ± 0.08 at 12 hours. Heart rate ranged from 29.29 bpm ± 0.70
to 31.71 bpm + 0.71 at 12 hours. Respiratory rate ranged from 10.79 bpm + 0.57
at baseline to 13.54 bpm ± 1.56 at 12 hours.
6 . Carpal thermography

Joint temperature increased over time in the saline treated animals with a peak
at 9 to 12 hours. Phenylbutazone significantly reduced the overall joint temperature
as compared to saline from 3 to 48 hours after administration (Figure 13A).
Phenylbutazone also significantly reduced joint temperatures as compared to
ketoprofen (3.63 mg/kg) at 3 hours and ketoprofen (2.2 mg/kg) from 6 to 24 hours.
A graph of room temperature is included for comparison in Figure 13B.

Room

temperature was constant over time and there were no significant treatment effects.
7. Synovial fluid clinical pathology
There were no significant treatment effects for total number of nucleated cells
per ix1, red blood cells per /*1, MPQ grade and the number of neutrophils, large
mononuclear cells, lymphocyte, eosinophils and basophils per fx\ (Table 14). Further,
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Figure 13: Effect of NSAIDs and saline on (A) joint temperature as expressed as % change from baseline. The
graph of room temperature (B) indicates corresponding ambient temperature changes over time. Statistically
significant treatment means as compared to saline are indicated by (*). There were no significant treatments
effects of room temperature. Carrageenan and NSAIDs were administered at time 0 (n= 6).

Table 14: Means* (± SEM) of non-significant synovial fluid clinical pathology parameters.

SYNOVIAL FLUID
CLINICAL
PATHOLOGY

TIME 0

1

3

6

9

12

24

48

NUCLEATED CELLS x
ltfV

0.40
±0.08

3.43
±0.30

9.75
± 1.88

155.41
±13.2

155.59
±8.64

101.89
±8.13

52.51
±3.42

15.02
±1.72

RED BLOOD CELLS x
itfV

121.64
±54.87

417.08
±116.40

575.63
±172.29

562.08
±118.13

517.12
±76.80

542.67
±89.08

413.70
±90.02

318.04
±81.27

MPQ GRADE

1.17
±0.08

1.38
± 0.12

2.58
± 0.12

2.63
±0.13

2.56
±0.14

2.63
±0.14

1.87
±0.14

1.87
±0.16

NEUTROPHILS x
lO3/^!

0.16
±0.05

1.90
± 0.22

9.45
±1.87

144.98
±12.07

145.26
±8.24

91.70
±8.07

38.20
±3.06

8.75
±1.35

MONONUCLEAR
CELLS x 103 //d

0.13
± 0.02

0.89
± 0.21

0.14
±0.03

8.45
±1.79

10.53
±1.83

8.58
±0.83

11.58
± 1.20

5.36
±0.48

LYMPHOCYTES
x lO2/^ 1

0.79
±0.17

5.73
±0.75

1.47
±0.43

12.45
±6.08

8.87
±1.99

6.12
±1.35

25.89
±11.62

6.46
±1.16

EOSINOPHILS/^1

18.01
±10.18

110.67
±30.86

10.48
±5.63

594.04
±378.45

116.92
±84.24

0.00
± 0.00

34.96
±34.96

0.00
± 0.00

0.42
±0.42

5.17
±3.67

0.00
± 0.00

41.83
±41.83

0.00
± 0.00

0.00
± 0.00

0.00
± 0.00

0.00
± 0.00

BASOPHn.S/jd

*Since there were no significant treatment effects for the above parameters, values reported above represent averages
over 24 horses.

there were no significant treatment effects when the differential cell counts were
expressed as a percent of the total nucleated cell count. There was a significant
treatment effect on protein concentrations (g/dl). The phenylbutazone-treated horses
had significantly increased synovial fluid protein concentrations at 12, 24 and 48 hours
as compared to saline.

At 24 hours, phenylbutazone increased the protein

concentration as compared to both doses of ketoprofen (Figure 14A). The mean
synovial fluid protein concentrations at baseline were 2.51 g/dl ± 0.01. The peak
levels occurred at 9 hours for all treatments except phenylbutazone which peaked at
24 hours.

Synovial protein in normal horses as determined by the refractometer

method is generally reported to be low (less than 2.5 g/dl) [75] as synovial fluid is
considered a dialysate of blood plasma with hyaluronic acid [74].
The mean number of nucleated cells per /xl of synovial fluid ranged from 0.40
± 0.08 x 103 at baseline to 155.59 ± 8.64 x 103 at 9 hours (Table 14). Horses
administered saline had peak levels occurring at 6 hours 202.13 ± 15.22 x 103 while
the NSAID treated horses tended to have peak levels at 9 hours (Figure 14B).
Normal levels for the horse are generally reported to be less than 500 cells//fi [382].
The cells were predominantly neutrophils from 1 hour to 48 hours with an increasing
percentage of large mononuclear cells at 24 and 48 hours. There was also an increase
in the number of red blood cells in the synovial fluid with peak in cell numbers at 3
hours (Table 14). There was considerable variation in the number of red cells in
synovial fluid at all time points. The was a moderate decrease in the MPQ grade after
carrageenan administration with values returning to near baseline at 48 hours. The
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Figure 14: Effect of NSAIDs and saline on (A) synovial fluid protein concentration and (B) nucleated cells.
Statistically significant treatment means as compared to saline are indicated by (*). There were no significant
treatment effects on the number of nucleated cells. Carrageenan and NSAIDs were administered at time 0 (n=6).

137
mean MPQ grade ranged from 1.17 ± 0.08 at baseline to 2.63 ± 0.13 and 2.63 ±
0.14 at 6 and 12 hours, respectively (Table 14).
Microscopic examination of synovial fluid smears often revealed protein
folding and degenerating or dead cells in varying stages of cellular breakdown from
3 through 24 hours after induction. Vacuolation of large mononuclear cells and
neutrophils was often seen from 6 to 12 hours. Occasionally, clumps of platelets and
synovial lining cells were noted.
8. Bacterial cultures
Examination of blood agar plates and thioglycollate broth tubes revealed no
bacterial growth in any of the carrageenan cultures. Broth tubes and agar plates of
a few synovial fluid samples contained evidence of bacterial or fungal growth.
However, the growth was not consistent between duplicates or subsequent samples.
Based on these inconsistencies and the clinical signs of the horses, these samples were
most likely contaminated with non-pathogenic flora from the air or person performing
the microbial culture.
9. Synovial fluid eicosanoid concentrations
The mean baseline concentration of PGEj was 0.42 ng/ml + 0.07 (Figure
15A). The concentrations of PGEj increased dramatically over time with peak levels
occurring at 9 hours (79.19 ng/ml ± 33.83) in horses administered saline. For all
horses, concentrations returned to near baseline levels by 48 hours. There was a
significant overall treatment effect for PGEz when data was analyzed over all sampling
times according to the univariate procedure.

Results from the Tukey’s multiple
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Figure 15: Effect of NSAIDs and saline on synovial fluid (A) PGE2 and (B) LTB4 concentrations. Statistically
significant treatment means as compared to saline are indicated by (*). There were no significant treatment
effects (P = 0.0603) on LTB4 concentration. Carrageenan and NSAIDs were administered at time 0 (n=6).
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comparison procedure indicated that ketoprofen (2.2 mg/kg) and phenylbutazone
reduced the PGE2 concentrations as compared to saline. Tukey’s procedure was then
used to compare eicosanoid concentrations (averaged over treatments) at each post
dose time to baseline, in order to determine when the concentrations were different
from baseline. The results indicated that means for time 6 , 9 and 12 hours were
significantly different from baseline means. Based on the significant time effect,
individual treatment means at 6 , 9 and 12 hours were compared using the Student’s
t tests. At 6 hours, phenylbutazone and ketoprofen (2.2 mg/kg) significantly reduced
the PGEj concentrations as compared to saline. At 9 hours post administration, both
doses of ketoprofen and phenylbutazone reduced PGEj as compared to saline. At 12
hours after administration, only phenylbutazone reduced levels when compared to
saline. Ketoprofen (3.63 mg/kg) produced PGE2 concentrations significantly greater
than phenylbutazone and ketoprofen (2.2 mg/kg) at 6 and 9 hours.
LTB4 concentrations were associated with no significant (P = 0.0603) overall
treatment effects (Figure 15B). The mean baseline concentration was 0.04 pg/ml ±
0.01. Levels peaked at 3 hours post-dose (1.26 pg/ml + 0.37) and returned to near
baseline values by 9 hours.
10. Hematology
No treatment effects were obtained for WBC count, RBC count, plasma protein
(g/dl), fibrinogen (g/dl), PCV (%) or platelet count (Table 15). However there was
a significant treatment effect for the number of eosinophils and basophils per /il
(Figure 16A and B). At 1 hour post-dose, eosinophils in phenylbutazone treated

Table 15: Means* (± SEM) of non-significant hematological parameters.
TIMED

1

3

6

9

12

24

48

HEMATOLOGY
WHITE BLOOD CELLS
x ltfVjtL

9.64
+0.51

9.08
±0.44

9.83
± 0.38

10.28
±0.43

11.99
±0.65

12.58
±0.56

10.06
±0.36

9.64
±0.38

RED BLOOD CELLS
x 1Q6/jiL

8.40
± 0.20

7.48
±0.27

8.20
±0.26

7.95
± 0.22

7.94
±0.19

8.02
± 0.20

7.85
±0.29

7.94
±0.14

PROTEIN (g/dl)

7.36
±0.09

7.12
±0.08

7.32
± 0.11

7.20
± 0.11

7.18
± 0.11

7.20
± 0.10

7.26
±0.08

7.42
±0.09

287.50
±32.03

250.00
±20.85

233.33
±18.71

237.50
±13.20

279.17
±28.22

250.00
±21.70

308.70
±22.59

334.78
±30.55

PCV (%)

38.08
±0.97

34.58
±0.77

37.58
±0.98

37.29
±0.71

36.63
±0.85

37.79
±0.76

36.35
±0.79

36.04
±0.55

NEUTROPHILS x 1 0 V

5.70
±0.36

5.83
±0.40

6.30
±0.36

6.83
±0.40

8.58
±0.59

8.44
±0.43

6.28
±0.28

5.90
±0.25

MONOCYTES x l t f V

0.36
±0.05

0.33
±0.05

0.32
±0.05

0.40
±0.07

0.37
±0.05

0.51
±0.08

0.37
±0.05

0.23
±0.03

LYMPHOCYTES x lO3/ ^

3.16
±0.26

2.60
±0.16

2.96
±0.18

3.11
±0.36

2.74
± 0.22

3.36
±0.26

3.18
±0.24

3.13
± 0.22

198.25
±14.85

196.75
±13.52

198.31
±16.54

192.83
±16.98

188.33
±15.54

194.79
±13.49

192.48
±9.92

203.17
±12.78

FIBRINOGEN (g/dl)

PLATELETS x HP/pl

*Since there were no significant treatment effects for the above parameters, values reported above represent averages
over 24 horses.
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TIME (Hours)

TIME (Hours)

□ KETOPROFEN 3.63 m g /k g

v PHENYLBUTAZONE 4 .4 0 m g /k g

■ KETOPROFEN 2.20 m g /k g

▼ SALINE

Figure 16: Effect of NSAIDs and saline on the number of blood (A) eosinophils and (B) basophils. Statistically
significant treatment means as compared to saline are indicated by (*). Carrageenan and NSAIDs were
administered at time 0 (n=6).
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horses were greater than saline and both doses of ketoprofen.

At 6 hours,

phenylbutazone treated horses had higher eosinophil counts than ketoprofen (2.2
mg/kg) and saline. At 9 and 12 hours, phenylbutazone also was associated with
higher numbers of eosinophils than saline.

At 12 hours, basophils in horses

administered phenylbutazone were higher than both doses of ketoprofen and saline.
However, the eosinophil and basophil numbers were not outside of the normal ranges
(eosinophils- 0.0-0.8 x 103 cells//xl; basophils- 0.0-0.3 x 103 c e l l s / [390]. Mean
peripheral blood WBC counts were within normal ranges except at 12 hours when the
mean count rose to 12.58 x 10’ cells//xl + 0.56 (normal range for the horse is 6-12
x 10’ cells//xl [390]). This leukocytosis was due to a mature neutrophilia in most
horses.

The mean neutrophil count at this time was 8.44 x 103 + 0.43 cells/^1

(normal range for the horse is 3-6 x 103 cells//xl [390]). Further, although the total
WBC counts were not increased, many horses were neutrophilic at 3, 6 , 9 and 24
hours after induction. No other hematologic abnormalities were noted.

D. Discussion
Carrageenan-induced synovitis has been used previously in the horse to isolate
leukocytes from an inflammatory exudate, but the clinical effects and eicosanoid
concentrations in synovial fluid were not described [52]. A pilot study was performed
initially to determine the clinical effects of intra-articular carrageenan and to refine
methodology. The pilot study showed that the carrageenan-induced synovitis produced
no articular damage 72 hours after administration, although there was still evidence
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of synovial inflammation. No synovial fluid abnormalities were noted 5 months after
induction.

Horses with carrageenan synovitis (n=24) appeared clinically normal

within 2 weeks following induction with no lameness, heat, effusion or palpable
thickening of the joint capsule or synovial membrane. These results indicate that the
horses experienced a transient synovitis that resulted in no obvious lasting damage to
the joint.

Thus our initial objective of inducing self-limiting inflammation was

achieved.
The volume of synovial fluid obtained from the left intercarpal joint and the
size of these joints (effusion grade and joint circumference) rose dramatically after
induction of synovitis. Phenylbutazone reduced the synovial fluid volume at the time
of peak inflammation (9-12 hours) to a greater extent than either dose of ketoprofen.
However, phenylbutazone did not reduce the subjective grade of effusion while both
doses of ketoprofen produced significant reduction at 3 hours and there was no
significant treatment effect on joint circumference. These parameters all measure joint
distension, but they have subtle qualitative differences which may account for the
discrepancies in treatment effects.

An increase in effusion grade accounted for

increases in subcutaneous and periarticular edema as well as synovial fluid distension,
whereas the volume of synovial fluid reflected the amount of synovial fluid obtained
from the intercarpal joint only. The circumference of the intercarpal joint appeared
to be a less sensitive estimate of joint distension than the effusion grade and synovial
fluid volume, due to presence of bony protuberances on the equine carpus. The
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swelling and effusion associated with synovitis in the early stages of development
often occurred between these prominences and thus were not directly measurable.
Carrageenan-induced synovitis produced a variable degree of lameness: 5
horses out of 24 did not show lameness at any time post-induction and while a few
horses became markedly lame, others were only slightly effected.

Despite this

variability, there were significant treatment effects. Phenylbutazone more effectively
relieved lameness than either dose of ketoprofen. There appeared to be no clear
ketoprofen dose related effect, as the high dose (phenylbutazone molar equivalent
dose) of ketoprofen had a short lived effect at 3 hours and the therapeutic dose
reduced lameness from 3 to 6 hours.
Phenylbutazone reduced the overall temperature of the joint in the early stages
of the inflammatory process with effects lasting to 48 hours after administration. This
effect was greater than the therapeutic dose ketoprofen for most of the times tested.
As the surface temperature of the joint is related to blood flow to the region, these
results may indirectly reflect that phenylbutazone inhibits carrageenan-induced
vasodilation over an extended period.

A similar time course has been observed

previously for phenylbutazone in a carrageenan-induced subcutaneous inflammation
model [325].
The number of nucleated cells in synovial fluid rose dramatically with peak
levels occurring at 6 to 9 hours.

This primarily neutrophilic exudate was likely

attributable to the increase in the synovial fluid concentration of the potent chemotactic
agent, LTB4 [27,28]. In addition, PGEj has been shown to be chemotactic for equine
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neutrophils and both of these eicosanoids play a significant role in the recruitment of
neutrophils to the site of inflammation [20].

These results are similar to leukocyte

numbers from tissue cage studies with carrageenan. However, the number of cells
obtained from joint fluid were an order of magnitude higher than the tissue cage [67].
Cellular migration was likely impeded in the tissue cage model as compared to the
synovitis model by the presence of fibrous tissue around and within the polypropylene
device. Synovitis accompanying clinical cases of degenerative joint disease in the
horse results in nucleated cell counts of up to 10,000 cells//xl [75]. Nucleated cell
counts in excess of 50,000 cells//w.l with a predominance of neutrophils in clinical
equine cases usually indicates septic arthritis [75,94]. Based on the cell count, protein
concentration and the MPQ grade, this model of experimentally-induced synovitis
appeared to be quite similar to clinical cases of equine joint infection [114].
There were no significant treatment effects associated with the number of
nucleated cells in the inflamed synovial fluid or any of the other clinical pathology
parameters except for protein concentration. The effects of NSAIDs on leukocyte
numbers in inflammatory exudate are contradictory and have not been correlated with
cyclooxygenase inhibition [15]. Ketoprofen when administered within the therapeutic
dose range has been shown to reduce leukocyte counts in other carrageenan-induced
inflammation models [15,299]. Phenylbutazone (4.4 mg/kg) did not affect leukocyte
numbers in an equine model of subcutaneous inflammation as compared to control
[323], while low doses of phenylbutazone and other NSAIDs stimulated leukocyte
migration [50]. Phenylbutazone increased the synovial fluid protein concentration in
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the late stages of the inflammatory process. This unexpected effect is likely due to
the significant reduction in synovial fluid volume associated with phenylbutazone
treatment.
Erythrocytes are not usually found in normal synovial fluid unless
contamination occurred during arthrocentesis (iatrogenic hemorrhage) [376].
However, hyperemia of the synovial membrane during synovitis greatly increases the
potential for hemorrhage into the joint [75].

Further, joints in this study were

aspirated 8 times over a 48 hour period which increased the likelihood of hemorrhage
into the joint cavity. The iatrogenic hemorrhage in these joints most likely contributed
to the total nucleated cell counts [382]. The eosinophils and basophils noted in the
synovial fluid are likely the result of intra-articular hemorrhage as eosinophils are rare
constituents of synovial fluid and basophils have not been reported to be present in
non-hemorrhagic synovial fluid [376]. In addition, blood contamination of synovial
fluid could have contributed to eicosanoid production (refer to data described in
Chapter 6). However, this probably had little impact on the treatment effects of these
parameters as the grade of hemorrhage was not significantly different among
treatments.
There was no bacterial growth in the carrageenan cultures and synovial fluid
cultures. Joint infection in these horses cannot be ruled out definitively as it is not
uncommon for synovial fluid from infected joints to culture negatively [75].
However, the rapid reversal of lameness and the decrease in the number of synovial
fluid nucleated cells over time in all horses would indicate non-septic synovitis.
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There was a dramatic increase in PGEj concentrations in the synovial fluid
after carrageenan administration.

The peak concentration in horses administered

saline was approximately 200 times the baseline level at 9 hours.

The LTB4

concentrations also increased markedly in all horses. Peak levels were 14 times over
baseline concentrations at 3 hours in horses administered saline. The peak levels of
PGEj and LTB4 in control animals were similar to those found in subcutaneous
models of carrageenan-induced inflammation [69-72]. The LTB4 levels were in the
range of reported concentrations from carrageenan-induced arthritis in dogs [123] and
clinical osteoarthritis in man [136]. However, the PGE2 levels were generally higher
in this study than those reported in polycation-induced arthritis [118] and clinical joint
diseases in man [143] and the horse [134]. PGEj levels from carrageenan models are
apparently higher than those in other forms of inflammation. In vitro research on
cells from humans with rheumatoid arthritis indicates that activated synovial lining
cells produce PGEj whereas LTB4 originates mainly from synovial fluid neutrophils
[142], although monocytes from patients with rheumatoid arthritis have also been
shown to produce large amounts of LTB4 [139].

In the horse, chondrocytes and

synovial cells secrete PGEj with very little contribution from PGE, [391]. Studies in
other inflammatory exudates have also shown that the primary arachidonic acid
products of neutrophils are leukotrienes [7,392].
There was considerable variability in the magnitude in the peak eicosanoid
levels after carrageenan administration in these horses. Despite the variability among
and within horses, there were significant treatment effects at 6 , 9 and 12 hours for
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PGE2, but not for LTB4. Phenylbutazone apparently inhibited cyclooxygenase activity
longer than ketoprofen in this model of acute inflammation. Studies have indicated
that phenylbutazone is more potent in producing cyclooxygenase inhibition and
reducing carrageenan-induced edema than ketoprofen [8,64], In contrast, others have
shown that ketoprofen is more potent in producing cyclooxygenase inhibition [290],
and in carrageenan-induced inflammatory models [44,63] and pain models [44], In
this study, the therapeutic dose of ketoprofen reduced PGE2concentrations longer than
the high dose. This lack of a dose-response effect with ketoprofen may in part be due
to the small difference between the two doses chosen coupled with the large degree
of variability associated with PGE2 concentrations. Unexpectedly, at 6 and 9 hours
the 3.63 mg/kg dose of ketoprofen resulted in higher PGE2 concentrations than the
therapeutic dose.

Perhaps the high dose of ketoprofen decreases prostaglandin

degradation thereby resulting in apparent potentiation of prostaglandin formation.
Several NSAIDs inhibit the 15-hydroxy prostanoate dehydrogenase enzyme that
oxidizes and inactivates PGE^ and PGF2o, at concentrations that are generally higher
than for cyclooxygenase inhibition [393,394]. Perhaps the high dose, but not the
therapeutic dose of ketoprofen has activity against this degradative enzyme in the joint
thereby leading to a net increase in the concentration of PGEj in the synovial fluid.
There were no significant treatment effects on synovial fluid LTB4
concentrations for ketoprofen or phenylbutazone. Previous studies have indicated that
ketoprofen inhibits rabbit neutrophil [250,293] and human lung [292] lipoxygenase
activity, while others have found no effect [290,293]. Lipoxygenase inhibition data
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varies considerably depending on the source of the enzyme and the species tested
[293,295],

Although not significant, most NSAIDs appeared to increase the LTB4

concentrations as compared to saline at 3 hours. Phenylbutazone appeared to have the
greatest potentiation followed by the high dose of ketoprofen. This effect has been
reported previously for diclofenac, ketoprofen and aspirin in the guinea pig [293] and
for indomethacin, ibuprofen and aspirin in man [392] and has been attributed to a
diversion of arachidonic acid substrate after cyclooxygenase inhibition to the
lipoxygenase pathway.

The apparent

of 5-lipoxygenase for arachidonic acid is

comparable to that of cyclooxygenase. Since most cells with 5-lipoxygenase activity
also contain cyclooxygenase, it is thought that the activated enzymes compete for
arachidonic acid substrate in the same cell types [ 10].
Many horses were neutrophilic from 3 to 24 hours with a slight leukocytosis
occurring at 12 hours. This effect most likely represented a mobilization of mature
neutrophils from the marginal blood pool and the bone marrow maturation pool in
response to the synovitis [395]. The reason for the effect of phenylbutazone on blood
eosinophil and basophil numbers is unclear.
basophil numbers per
clinical limits.

However, the mean eosinophil and

for horses treated with phenylbutazone were within normal

This effect is most likely artifactual as there are no reports of

phenylbutazone increasing these white cells.

On the contrary, toxic doses of

phenylbutazone produce leukopenia in the horse [396,397].
Phenylbutazone was more effective than ketoprofen in alleviating many of the
signs of pain and inflammation in this model of synovitis. These results are consistent
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to those obtained in models of carrageenan-induced subcutaneous inflammation where
peak reduction in PGE^ exudate levels occurred at 6 hours [323]. High doses of
phenylbutazone in the dog have been effective in both preventing and suppressing the
inflammatory response from urate-induced joint inflammation [101]. Ketoprofen was
effective in alleviating inflammation in this model, but did not result in inhibition of
the leukotriene pathway as determined by the measurement of LTB4 in the synovial
fluid.

CHAPTER 5
PHARMACOKINETICS AND SYNOVIAL FLUID LEVELS OF
KETOPROFEN IN NORMAL HORSES AND HORSES
WITH ACUTE SYNOVITIS

A. Introduction
Ketoprofen or (±)-2(3-benzoylphenyl)propionic acid is a nonsteroidal anti
inflammatory drug (NSAID) of the propionic acid family that includes ibuprofen,
naproxen, benoxaprofen, fenoprofen and carprofen. This agent has been used in
human medicine in the treatment of arthritis and mild-to-moderate pain since its
introduction in France in 1973. Ketoprofen, at an intravenous dose of 2.2 mg/kg, was
approved by the United States Food and Drug Administration for alleviation of
musculoskeletal pain and inflammation in the horse in 1990.
The plasma or serum pharmacokinetics of ketoprofen has been studied in
humans [282,398], rabbits [287], rats [289], dogs [399], and horses [283,286].
Synovial fluid levels of ketoprofen have been measured in humans with various forms
of arthritis [280,297,400,401]. Peak synovial fluid concentrations of total (plasma
protein bound and free) ketoprofen in humans with arthritis are lower and occur later
than do peak plasma concentrations [280].

However, the peak synovial fluid

concentrations often exceed corresponding plasma levels after an equilibrium has been
established.
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Water and small solutes, including most NSAIDs, cross the synovial membrane
from plasma principally by diffusion through the intercellular, interstitial matrix of the
synovium.

This diffusion by small molecules is considered bi-directional [402].

Compounds that are lipid soluble may also cross the membrane through transcellular
diffusion [402]. The extravascular pharmacokinetics of a particular drug depend on
the agent’s molecular weight, lipid solubility, protein binding, plasma half-life and
pKa. For example, ketoprofen (C16H 140 3, molecular weight 254.29) has an octanolbuffer partition coefficient at pH 7.4 of approximately 1 with a pKa of 5.02 and a high
percentage of plasma protein binding [399]. However, this pKa results in ionization
of ketoprofen at a physiological pH.

In contrast to ketoprofen, phenylbutazone

(C19H20N2O2, molecular weight 308.37) has a similar pKa (4.8) and degree of protein
binding, but is much more lipid soluble with an octanol-buffer partition coefficient of
5.01 at a neutral pH and would be expected to cross biological membrane to a greater
extent than ketoprofen [162].
Evidence indicates that synovial NSAID concentrations are higher in patients
with joint inflammation than those in normal joints [403]. This is due to the increase
in vascular permeability and blood flow, loss of endothelial integrity and hemorrhage
that allows for the exudation of plasma proteins with the bound drug.

Normally,

only the free drug is able to diffuse freely between plasma and synovial fluid, but
with inflammation, bound drug may enter into the synovial fluid [402]. In contrast
to small molecules, plasma protein diffusion into the synovial fluid is a one-way
transport mechanism [258].

Plasma protein concentrations in synovial fluid are
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normally low, but the permeability increases with joint inflammation [402,404], The
increased protein concentration and drug receptor binding at the site of action may
serve to increase the joint drug concentration of highly bound drugs [258,402],
The purpose of this study was to compare the pharmacokinetics of ketoprofen
in healthy horses and those with experimentally-induced acute synovitis.

More

importantly, this study was designed to evaluate the concentration of ketoprofen at its
site of action in animals with joint disease. Synovial fluid levels of ketoprofen in
inflamed joints were compared to levels in normal joints in order to determine the
effect of acute joint inflammation on the magnitude and duration of ketoprofen
synovial fluid concentrations.

B. Materials and methods
1. Experimental animals
a. Normal horses
Three healthy geldings (2 American Quarter Horses and one Thoroughbred)
and one Thoroughbred mare weighing from 406 to 554 kg and ranging from 5 to 12
years of age were used. Horses were judged to be healthy and sound based on
physical examination and lameness evaluation.
b. Horses with experimentally-induced synovitis
Four geldings (one American Quarter Horse and 3 Thoroughbreds) weighing
from 437 to 509 kg and ranging from 8 to 12 years of age with carrageenan-induced
synovitis of the left intercarpal joint were used. Prior to induction, horses were judged
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to be healthy and sound based on physical examination, lameness evaluation, synovial
fluid analysis and radiographic examination of the left carpus.
All horses were vaccinated at least three weeks prior against eastern and
western equine encephalomyelitis, influenza, tetanus (Equi-Flu EWT™, Coopers,
Mundelein, IL) and rhinopneumonitis (Rhinomune™, SmithKline Beecham Animal
Health, Exton, PA).

The horses were dewormed with oxibendazole (Equipar™,

Coopers, Mundelein, IL). Horses were housed in 10.9 x 12.5 feet stalls and were
maintained on 5 pounds of a pelleted ration (Purina Horse Chow 100™, Purina Mills
Inc., St. Louis, MO) containing: a minimum of 10% protein; 2% fat; a maximum of
25 % fiber; and a vitamin/trace mineral supplement twice daily with mixed grass hay
(11% protein, 1.4% fat, 24% fiber) and water provided ad libitum.
2. Drugs and reagents
a. Drug solution for administration
Ketoprofen (Ketofen™) was obtained commercially from Aveco Company,
Inc., Fort Dodge, IA. Each ml of the sterile solution contained: 100 mg ketoprofen;
L-arginine, 70 mg; citric acid to adjust pH to approximately 7; and benzyl alcohol,
0.25 ml as a preservative.
b. Standard solutions
A stock solution of ketoprofen was prepared by dissolving 10 mg of the
compound in 10 ml of methanol.

The stock solution was serially diluted with

methanol to produce working standard solutions of 100 /ig/ml, 10 /xg/ml, and 1
(ig/ml. The working solution of fenoprofen was prepared by dissolving 10 mg of the
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compound in 10 ml of methanol. Ketoprofen and fenoprofen were obtained from
Sigma Chemical Co., St. Louis, MO.
c. Solvents
Liquid chromatography grade solvents were obtained from commercial sources.
Phosphate buffer (0.001M) for high performance liquid chromatography (HPLC)
mobile phase was prepared by placing 68.027 p\ of o-phosphoric acid (44.6N) in
triple distilled water sufficient to make 1 L total volume. The pH of this solution was
adjusted to 7.4 with sodium hydroxide (2.157 ml of 1 N).
d. Water
Triple distilled, filtered water was prepared by passing through a Modulab™
Polisher I water purification system (Continental Water Systems Corp., San Antonio,
TX).
3. Experimental protocol
a. Horse preparation
Each horse was shaved over the entire carpal region 24 hours prior to drug
administration.

Indwelling catheters (14 gauge, 5.7 cm) (Quick-Cath™, Baxter

Healthcare Corp., Deerfield, IL) were aseptically placed bilaterally in the jugular
veins of each horse before each session.
b. Blood collection
Ketoprofen (2.2 mg/kg) as Ketofen™ and detomidine (Dormosedan™, Norden
Laboratories, Lincoln, NE) were administered via the left jugular catheter. The right
jugular catheter was used for blood collection before drug administration and at 3, 5,
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10, 15, 20, 30, and 45 minutes and at 1, 1.5, 2, 3, 4, 5, 6 , 9, 12, and 24 hours after
drug injection for determination of plasma drug concentrations. The patency of each
catheter was maintained after each blood collection with 3 ml of 100 lU/ml of
heparinized saline. Before blood was collected, 2-3 ml was discarded to remove any
residual heparin from the catheter. Blood (14 ml) was collected with a 18 gauge, 1.5
inch needle and a 20 ml syringe and then placed immediately into 7 ml evacuated
glass tubes containing 10.5 mg of ethylenediamine tetraacetate K3 (EDTA) as an
anticoagulant (Vacutainer, Becton Dickinson, Rutherford, NJ).

Tubes were

immediately centrifuged at 2,000 rpm for 15 minutes (Dynac, Becton Dickenson and
Company, Parsippany, NJ).

Plasma was transferred into 15 ml polypropylene

centrifuge tubes (Sarstedt, Newton, NC) and stored at -20° C until analyzed.
Previous studies have shown that freezing does not affect ketoprofen concentrations
in biological matrices [280,405].
c.

Synovial fluid collection from normal horses

Horses received detomidine HC1 intravenously (10 /xg/kg for the first dose and
5.0 /xg/kg for subsequent doses) before each arthrocentesis as a sedative to reduce the
risk of iatrogenic joint hemorrhage and trauma. In addition, all horses were nose
twitched during arthrocentesis. Before each arthrocentesis the entire carpal area was
scrubbed with Hibiclens™ (Stuart Pharmaceuticals, Wilmington, DE) and alcohol at
least three times with a final scrub directly over the site for arthrocentesis. Sterile
needles (20 gauge, 1 inch), syringes (12 ml or 20 ml) and gloves were used during
each arthrocentesis. Synovial fluid was collected from the intercarpal joint before and
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at 1, 3, 6 , 9, 12, and 24 hours after drug administration for determination of
ketoprofen. Synovial fluid (approximately 3.5 ml) was obtained altematingly from
the left and right intercarpal joints due to the paucity of synovial fluid in these normal
joints. Synovial fluid was placed into 2 ml evacuated glass tubes containing 3 mg of
EDTA as an anticoagulant (Vacutainer, Becton Dickinson, Rutherford, NJ). The fluid
was immediately centrifuged at 4° C and 2,500 rpm for 15 minutes (Eppendorf
5415C, Brinkman Instruments, Westbury, NJ). The supernatant was stored in 1.5 ml
polypropylene micro-centrifuge tubes (Dot Scientific, Inc., Flint, MI) at 20° C until
analyzed.
d. Synovial fluid collection from horses with experimental synovitis
Arthrocentesis was accomplished as above except that acute inflammation was
induced in the left intercarpal joints of these horses by the injection of 0.3 ml of 1%
solution of sterile carrageenan at the same time as ketoprofen administration (time 0).
In these horses synovial fluid was obtained only from the inflamed left intercarpal
joint at the times designated above. At each time point, the maximum volume of
synovial fluid was withdrawn in order to reduce the degree of discomfort in the horse
caused by joint effusion. The amount of synovial fluid withdrawn ranged from 2.5
to 15 ml. Synovial fluid was processed as above.
4. Ketoprofen determination
The concentrations of ketoprofen in plasma and synovial fluid were determined
by high performance liquid chromatograph (HPLC) analysis of ethyl acetate extracts
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of acidified samples. Fenoprofen was added to the samples before extraction as an
internal standard.
Plasma and synovial fluid calibrators were prepared by adding ketoprofen and
fenoprofen standard solutions to drug-free equine plasma and synovial fluid. For
plasma, concentrations of 0.1, 0.5, 1, 10, and 40 fig of ketoprofen/ml of plasma were
prepared. Ketoprofen was added to synovial fluid to make concentrations of 1, 0.5,
0.1, 0.05, and 0.025 fig/ml. These calibrators were prepared and analyzed daily in
duplicate with each set of unknown samples.
a. Extraction
For plasma samples, 25 fil of 1000 /xg/ml fenoprofen was added to 500 fi\ of
sample to achieve a final concentration of 50 fig/ml. For synovial fluid samples, 5
fil of 1000 fig/ml of fenoprofen was added to 500 fil of sample to achieve a final
concentration of 10 fig/ml. Plasma or synovial fluid samples were acidified with 0.5
ml 1 N HC1 and 2.0 ml of ethyl acetate was added. Samples were vortexed for 30
seconds, then centrifuged at 2,000 rpm for 15 min (Dynac, Becton Dickenson and
Company, Parsippany, NJ). The ethyl acetate extraction was repeated. The upper
organic layers were transferred to a separate tube and evaporated to dryness without
heat under a flow of nitrogen. Samples were reconstituted in 250 fil of mobile phase
solvent mixture, vortexed and filtered through a 0.45 fim teflon syringe filter (Poretics
Co., Livermore, CA) into to a 2.0 ml HPLC autosampler vial. The injection volume
was 10 fil.
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b. Chromatography
All analyses were performed using a Hewlett Packard 1090 high performance
liquid chromatograph equipped with a variable volume auto-injector and a photodiode
array detector set at 256 nm (10 nm bandwidth) with a reference spectrum of 550 nm
(100 nm bandwidth). Instrument control, data acquisition, and peak integration were
accomplished with Hewlett-Packard HPLC ChemStation software (Waldbronn,
Germany). A 100 x 4.6 mm reversed phase column packed with 3 fim octadecylsilyl
derivatized silica particles (Spherosorb™ ODS-2, 80 A pore) equipped with 10 x 4
mm guard column (5 f i m , 300 A pore) from Keystone Scientific (Bellefonte, PA)
maintained at ambient temperature was used for all analyses.
The mobile phase consisted of 0.001 M phosphate buffer (pH 7.4) and
acetonitrile delivered at a ratio of 85:15 or 82.45:17.55. The mobile phase was
filtered through a 0.45 fim membrane filter (FP Vericel™, Gel man Sciences, Inc.,
Ann Arbor, MI) and degassed with helium immediately before use. A 10 fi\ aliquot
of synovial fluid or plasma extract was injected at a rate of 833.3 /d/minute for
analysis. The analyte and internal standard were eluted at a flow rate of 1 ml/minute
The total run time was 8.5 minutes.
c. Linearity o f response
Plasma and synovial fluid concentrations were calculated by determining the
peak height ratio of ketoprofen to the internal standard, fenoprofen for each incurred
sample and calibrator. Five point calibration curves for ketoprofen in plasma and
synovial fluid were prepared by plotting the peak height ratios against concentration
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using data derived from the average of duplicate injections. The slope, intercept and
correlation coefficients for each of the calibration curves were determined before each
analytical session.
d. Recovery
Relative recovery of ketoprofen from synovial fluid and plasma was evaluated
by comparison of analyte peak heights of 5 injections of non-extracted standard
solutions to peak heights of 5 extracted fortified samples. Percent recovery was
determined for the lowest and highest concentrations of ketoprofen tested in synovial
fluid and plasma.
e. Intra-assay variability
The within run precision was determined by replicate injections of the same
sample run under identical conditions during the same analytical session. This was
determined for fortified samples of the lowest and highest concentrations of ketoprofen
tested in synovial fluid and plasma. The intra-assay variation of each concentration
in each matrix was defined as the coefficient of variation of triplicate injections of the
same sample run in duplicate so that n = 6 per concentration. The coefficient of
variation of each concentration was calculated from the mean and standard deviation
of the peak height ratios.
f. Inter-assay variability
The between day precision was determined from samples of the same
concentration extracted and analyzed under identical conditions during different
analytical sessions. This was determined for fortified samples of the lowest and
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highest concentrations of ketoprofen tested in synovial fluid and plasma. The inter
assay variability at each concentration in each matrix was defined as the coefficient
of variation of 5 duplicate injections analyzed during 5 different analytical sessions.
The overall inter-assay variation for each matrix was obtained from averaging the
coefficient of variations from each concentration examined.
g.

Plasma pharmacokinetic analysis

The plasma ketoprofen concentration versus time data for each horse were
analyzed by an automated curve-stripping procedure using the RSTRIP™ computer
program (MicroMath Scientific Software, Salt Lake City, UT). This provided initial
estimates of pharmacokinetic parameters and the best exponential disposition function
to fit the data. These initial estimates were then used to generate a best fit by
nonlinear least-squares regression analysis with equal weighting of the data using the
MINSQ™ computer program (MicroMath Scientific Software, Salt Lake City, UT).
Visual inspection of the fitted curves, examination of the plot of the residuals versus
calculated concentration [406], and application of a modified Akaike’s information
criterion [407] were used to determine the number of exponential terms required to
describe the data. For the 2-compartment open model, the equation was:
Cp = A-e^1™' + B-e'BTimc
where Cp is the plasma concentration, A = distribution phase intercept, a =
distribution phase rate constant, B = elimination phase intercept, B = elimination
phase rate constant.

The MINSQ™ computer program calculated the following

dependent variables: area under the plasma concentration versus time curve (calculated
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to infinity), AUC; the elimination rate from the central compartment, K^,; the transfer
rate from the first compartment to the second compartment, K12; the transfer rate from
the second compartment to the first compartment, K21; the half-life of a , t,Aa; and the
half-life of j8 , tm . The following parameters were derived from standard kinetic
formulas [408].
The total plasma clearance was calculated from:
CLx = Dose/AUC
where dose = dose of ketoprofen in fig/kg and AUC = A/a + B/B.
The volume of the central compartment was calculated from the dose and the
area under the curve:
Vc = Dose/AUC
The volume of distribution based on the area method was determined by the
total clearance and elimination rate constant:
Vd(area) = CLj/B
The volume of distribution at steady state or the whole body estimate of the
volume of distribution was calculated as follows:
Vd„ = Dose-AUMC/AUC2
The elimination half-life (tl/iB) was determined by the elimination rate constant:
t&e = ln(2)/B
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A noncompartmental method was used to determine the statistical moments
[409]. The area under the first moment curve ( j Cp t-dt) was calculated from the
intercepts and rate constants:
AUMC = A/a 2 = B/B2
The first statistical moment of the drug concentration time curve is the mean
residence time (MRT) and is analogous to the half-life of compartmental analysis.
This value represents the time for 63.2% of the dose to be eliminated and was
calculated from the area under the curve and the area under the first moment curve
[409]:
MRT = AUMC/AUC
h.

Synovial fluid pharmacokinetic analysi

The limited number of time-concentration data for synovial fluid in normal
horses (3 points) and synovitis horses (4 points) did not allow for a calculation of a
complete pharmacokinetic profile.

However, the area under the curve and time-

concentration data for each horse were calculated. The area under the time versus
concentration curve (AUC) was determined for each horse by the Pharmacologic
Calculation System computer program (Microcomputer Specialists, Philadelphia, PA)
using the trapezoidal rule [410].
Plasma Statistical analysis
The elimination half-life (t1/4B) was expressed as an arithmetic mean of four
horses. In addition the half-life was expressed as the harmonic mean (Ht,A) based on
the mean elimination rate constant. The harmonic is the more appropriate estimate
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of the half-life and always produces a lesser value than the arithmetic mean [411].
The harmonic mean is calculated as follows:
= H / ( l / t i ABji +

+

l/ti4B,n)

or
Htv4 = ln(2)/B“
where B* = the mean elimination rate constant of four horses. The pseudo standard
deviation (pSD) of the harmonic half-life was based on the jackknife variance and was
estimated by the following:
PSD = V [(n -l)E (H r HtV2)2]
where H; = the harmonic mean of n-1 values which is calculated n times deleting a
different half-life value each time. Estimates of half-life, volume of distribution,
AUC and Cp° (time 0 plasma concentration) are not considered to be normally
distributed [412].

Therefore, all pharmacokinetic parameters were compared for

normal horses and those with acute synovitis by the Mann-Whitney rank sum test
[413] using SigmaStat (Jandel, Corp., San Rafael, CA). All results were considered
significant when P < 0.05.
k. Synovial fluid statistical analysis
Values for AUC from both groups of horses were compared by the MannWhitney rank sum test. Synovial fluid concentrations from both groups of horses
were compared at each time using the Mann-Whitney rank sum test. Within each
group, synovial fluid concentrations were compared to corresponding plasma
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concentrations with paired Student’s t tests [414] using SigmaStat (Jandel, Corp., San
Rafael, CA). All results were considered significant when P < 0.05.

C. Results
1. Chromatography
The mobile phase composition reported by Satterwhite and Boudinot [405] of
0.01 M phosphate buffer and acetonitrile (82.5:17.5) did not achieve adequate
resolution of the analyte and the reported internal standard, naproxen when used with
the 3 f i m octadecylsilyl column. Several other internal standards were also tested
using this system without success including, oxyphenbutazone, phenylbutazone and
ibuprofen.

Fenoprofen was determined to have adequate chromatography and a

unique retention time as compared to the analyte when a mobile phase of 0.001
phosphate buffer and acetonitrile was used with a ratio of 85:15 or 82.45:17.55. The
latter mobile phase ratio was found to be optimal for some sessions using a newly
purchased column. The limits of quantitation of ketoprofen in this system were 0.025
f i g / ml in synovial fluid and 0.1 ^g/ml in plasma.

Chromatograms of blank plasma and synovial fluid are shown in Figures 17
and 18.

Chromatograms of plasma and synovial fluid from horses administered

ketoprofen are shown in Figures 19 and 20. All chromatograms are expressed as
milliabsorbance units (mAU) versus time. The retention time of ketoprofen in both
fluids was 1.75 minutes. The retention time of fenoprofen varied slightly from 1.90
to 2.20 minutes. As can be seen from the blank chromatograms in Figures 17 and 18,
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Figure 17: Liquid chromatogram of extracted plasma containing no drug.
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Figure 18: Liquid chromatogram of extracted synovial fluid containing no drug.
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Figure 19: Liquid chromatogram of extracted plasma from a horse administered ketoprofen. The calculated
ketoprofen (KETO) concentration was 11.89 ^g/ml. The sample was fortified with fenoprofen (FENO) at 50
jig/ml as an internal standard.
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Figure 20: Liquid chromatogram of extracted synovial fluid from a horse administered ketoprofen. The
calculated ketoprofen (KETO) concentration was 0.53 /xg/ml. The sample was fortified with fenoprofen (FENO)
(10 /ig/ml) as an internal standard.
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there were no interfering substances eluting near the retention times for ketoprofen or
fenoprofen in plasma or synovial fluid. The ultraviolet (UV) absorbance spectra of
ketoprofen from non-extracted standards and incurred samples are shown in Figures
21 and 22. Comparison of the UV spectra of ketoprofen from standards and incurred
samples indicates excellent peak purity. The UV absorbance spectrum of fenoprofen
is shown in Figure 23. Thus, ketoprofen and fenoprofen were differentiated based on
both the unique retention time and UV absorbance spectrum of each compound.
a. Linearity o f response
Calibration curves of ketoprofen fortified plasma and synovial fluid were
obtained using the mean peak height ratio values of duplicate injections. These curves
were linear over the range of concentrations used (0.1 to 40 /ig/ml for plasma, and
0.025 to 1.0 /xg/ml for synovial fluid) for each analytical session with correlation
coefficients (r) ranging from 0.9964 to 0.9989.
b. Recovery
The mean relative recoveries of ketoprofen as determined by comparison of
peak heights of five injections of standard solutions to five injections of extracted
fortified samples were 100.2% ± 10.0 and 92.1% + 6.5% for synovial fluid samples
containing 0.025 /xg/ml and 1.0 ptg/ml, respectively, with an overall mean recovery
of 96.2 %. Mean relative recoveries of ketoprofen from fortified plasma samples were
109.4% ± 13.4% and 89.8% ± 12.5% for samples containing 0.1 /ig/ml and 40.0
/ig/ml, respectively, with an overall mean of 99.6% (Table 16). The extraction
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Figure 21: UV absorbance spectrum of ketoprofen from a liquid chromatogram of a non-extracted standard
solution.
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Figure 22: UV absorbance spectrum of ketoprofen from a liquid chromatogram of an extracted incurred plasma
sample.
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Figure 23: UV absorbance spectrum of fenoprofen from a liquid chromatogram of an extracted plasma sample.

Table 16: Recovery of ketoprofen as determined by the comparison of peak heights from 5
standard solutions and extracted fortified samples. Percent recovery is reported ± SD.

CONCENTRATION
(/tg/ml)

RECOVERY
(%)

CONCENTRATION
0 tg/ml)

RECOVERY
(%)

0.025

100.2 (± 10.0)

0.10

109.4 (± 13.4)

1.000

92.1 (± 6.5)

40.0

89.8 (± 12.5)

OVERALL

96.1

OVERALL

99.6
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technique used showed excellent recoveries for synovial fluid and plasma and were
similar to other methods using diethyl ether [405] and dichloromethane [283].
c. Intra-assay variability
The intra-assay variances for synovial fluid as expressed as the coefficient of
variation ranged from 5.2% for the 1.0 ^g/ml concentration to 11.0% for the 0.025
^g/ml level. The plasma values were 3.5% for the 0.1 /ig/ml concentration and 4.6%
for samples containing 40.0 /tg/ml of ketoprofen (Table 17).
d. Inter-assay variability
The between session variability based on the coefficient of variation of five
samples run during subsequent analytical sessions ranged from 8 .0 % for fortified
plasma samples containing 0.1 fig/ml of ketoprofen to 10.3% for fortified synovial
fluid containing 0.025 fig/ml of ketoprofen (Table 17).
2. Plasma pharmacokinetics
Ketoprofen disposition in plasma for normal horses and those with acute
synovitis was best described by a bi-exponential equation, except in one normal horse
and one horse with acute synovitis which were better fitted to a mono-exponential or
one-compartment model.

These unusual animals were force-fitted to a two-

compartment model which permitted comparison between horse groups.

The bi

exponential equation, Cp = A-e'“'T,me + B-e'BTime, was used to determine the
pharmacokinetic parameters of all horses where Cp = plasma concentration, A =
distribution phase intercept, a = distribution phase rate constant, B = elimination
phase intercept, and B = elimination phase rate constant. The individual coefficients

Table 17: Intra-assay variability as represented by the CV of 6 injections. Inter
assay variability as represented by the CV of 5 injections.

SYNOVIAL FLUID
CONCENTRATION
Oig/ml)

INTRA
ASSAY
(CV)

INTER
ASSAY
(CV)

0.025

11.0

14.2

1.000

5.1

9.2

OVERALL

8.1

11.7

PLASMA
0.1

3.5

8.0

40.0

4.6

9.5

OVERALL

4.1

8.8

Ill

of determination (correlation coefficient2 or r2) ranged from 0.96217 to 0.99753. This
value is a measure of the fraction of the total variance accounted for by the model.
The mean total plasma ketoprofen concentration versus time curve for normal
horses and horses with acute synovitis are shown in Figures 24 and 25 and the derived
pharmacologic parameter values are outlined in Tables 18 and 19. The mean ±
standard deviation (SD) plasma concentration of normal horses 3 minutes after dosing
was 33.72 ± 0.43. The corresponding concentration in horses with acute synovitis
was 23.61 + 1.96. The distribution phase intercept (A) of normal horses was 41.31
+ 17.08. This value was significantly higher (P = 0.029) than the corresponding
value in horses with acute synovitis, 24.65 ± 4.90. Both groups had a similar rapid
distribution phase followed by slower elimination phase. At 4 hours post-dose plasma
levels were 0.36 /ig/ml + 0.02 in normal horses and 0.16 /ig/ml ± 0.06 in horses
with acute synovitis.

Plasma ketoprofen concentrations were below the limit of

quantitation by 5 hours. The harmonic plasma half-life (tV^B) + the pseudo standard
deviation of the horses with acute synovitis was 0.55 hour + 0.21. This harmonic
half-life was shorter (P = 0.029) than that of the normal horses, 0.88 hour ± 0.35.
All other plasma pharmacokinetic parameters were not statistically different between
horse groups.
3. Synovial fluid pharmacokinetics
Ketoprofen disposition in synovial fluid in normal horses was minimal with
mean peak levels ± SD of 0.39 /xg/ml + 0.03 occurring at one hour with levels
falling to 0.08 /j.g/ml + 0.04 by 6 hours (Figure 26). Concentrations were below the

TIME ( h o u r s )

Figure 24: Plasma disposition curves of intravenous ketoprofen (2.2 mg/kg) in 4 normal horses. Mean
ketoprofen concentrations in /xg/ml are presented as + standard deviations (SD). Inset graph represents
the natural log of plasma concentrations versus time.
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Figure 25: Plasma disposition curves of intravenous ketoprofen (2.2 mg/kg) in 4 horses with acute
synovitis. Mean ketoprofen concentrations in ng/m\ are presented as + SD. Inset graph represents the
natural log of plasma concentrations versus time.
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Table 18: Plasma pharmacokinetic parameters of intravenous ketoprofen (2.2 mg/kg) in normal horses and horses
with acute synovitis.

NORMAL HORSES
PARAMETER

MEAN

ST.DEV.

MEAN

ST.DEV.

41.31

17.08

31.06-66.82

24.65

4.90

18.36-30.24

a (1/hr)

6.86

2.89

4.57-10.92

9.47

3.74

3.95-11.88

> 0.10

B (/tg/ml)

5.10

3.40

2.02-9.18

9.29

5.26

2.99-15.80

> 0.10

0 (1/hr)

0.79

0.31

0.42-1.10

1.27

0.49

0.67-1.83

> 0.10

Cp° (/tg/ml)

46.16

20.07

33.78

7.26

26.44-40.11

> 0.10

(1/hr)

3.73

1.05

2.84-5.25

3.37

0.56

2.62-3.83

> 0.10

K 12 (1/hr)

2.44

1.45

1.33-4.47

3.67

1.93

0.99-5.58

> 0.10

Kn (1/hr)

1.47

0.78

0.67-2.28

3.69

2.03

1.01-4.51

> 0.10

A (/tg/ml)

P = Probability estimate
’Statistically significant at P < 0.05

RANGE

SYNOVITIS HORSES

33.08-76.04

RANGE

P
0.029*

Table 19: Plasma pharmacokinetic parameters of intravenous ketoprofen (2.2 mg/kg) in normal horses and horses
with acute synovitis.
NORMAL HORSES
PARAMETER

MEAN

ST.DEV.

SYNOVITIS HORSES

RANGE

MEAN

ST.DEV.

RANGE

P

t%«* (hr)

0.11

0.04

0.06-0.15

0.09

0.06

0.05-0.17

> 0.10

Up (hr)

1.02
0 . 88"

0.47
0.35b

0.62-1.65

0.63
0.55"

0.29
0 .21b

0.37-1.03

> 0.10
0.029"*

0.20

0.05

0.13-0.24

0.23

0.04

0.18-0.26

> 0.10

MRT (hr)

0.76

0.25

0.56-1.11

0.62

0.13

0.57-0.75

> 0.10

AUC„ (/tg®hr/ml)

12.06

1.64

10.75-14.46

10.10

1.00

8.70-10.94

AUMC. (Kg'hrVml)

9.07

2.64

7.49-12.99

6.25

1.63

4.87-8.26

CLj (ml/hr®kg)

184.72

22.70

152.08-204.48

219.55

23.25

201.02-252.68

Vc (ml/kg)

52.67

16.50

28.93-66.48

66.55

12.40

54.83-77.80

> 0.10

Vd(area) (ml/kg)

276.30

139.16

138.20-319.16

195.27

77.46

112.51-299.04

> 0.10

Vds, (ml/kg)

142.30

52.53

85.63-211.74

134.79

27.21

94.24-151.74

> 0.10

(hr)

P = Probability estimate
"Harmonic mean
bPsuedo Standard Deviation
’Statistically significant at P < 0.05

0.057
> 0.10
0.057
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Figure 26: Mean plasma and synovial fluid ketoprofen concentrations in jig/ml (+ SD) following
intravenous ketoprofen (2.2 mg/kg) in 4 normal horses. Significantly different synovial fluid and plasma
concentrations are indicated by (*).
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limit of quantitation in all normal horses by 9 hours.

Synovial fluid ketoprofen

concentrations at one hour were below (P = 0.015) corresponding plasma levels.
Synovial fluid levels at 3 hours were not different from the corresponding plasma
concentrations.
In contrast, synovial fluid disposition of ketoprofen in horses with acute
synovitis was extensive with peak concentrations (2.53 /tg/ml + 0.39) occurring at
one hour with levels falling to 0.06 /tg/ml + 0.02 by 9 hours. Concentrations were
below the limit of quantitation by 12 hours. Although not significant, synovial fluid
levels at 3 hours appeared greater than the corresponding plasma concentrations (P =
0.09). In contrast to the normal horses, synovial fluid concentrations at one hour
were not statistically different from one hour plasma levels (Figure 27). The average
AUC for normal horses (1.37 /tg-hr/ml ± 0.38) was less (P = 0.029) than that of
horses with acute synovitis (6.24 /tg-hr/ml + 2.41). At one hour post-dose, synovial
fluid levels of ketoprofen in horses with acute synovitis were 6.5 times greater (P =
0.017) than normal horses. There was no difference in synovial fluid concentrations
between the two groups at 3 or 6 hours.

D. Discussion
The harmonic means of plasma elimination half-lives of ketoprofen in both
groups of horses were between 0.5 and 1 hour. This was expected based on the
polarity of ketoprofen, as most polar compounds are rapidly excreted. The plasma
half-life is proportional to the volume of distribution and inversely proportion to total

100 1

■ PLASMA
□ SYNOVIAL FLUID

10
&o
3

NT

2
o

<
K

1

E2

W
U
2
O
U

0.1

3

4

5

6

7

8

TIME ( h o u r s )

Figure 27: Mean plasma and synovial fluid ketoprofen concentrations in ng/ml (+ SD) following
intravenous ketoprofen in 4 horses with acute synovitis.
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clearance.

The three volumes of distribution for both groups were less than or

approximately equal to the extracellular volume (200 ml/kg), which would also be
expected for a polar drug.

The steady state volume of distribution is largely

dependent on the intravascular albumin binding which for most NSAIDs results in
limited distribution volumes [415].
The mean harmonic plasma half-life of normal horses (0.88 hours + 0.35)
was significantly higher than that of horses with acute synovitis (0.55 hours + 0.21).
This may be due to the increased penetration of ketoprofen into the inflamed joint,
particularly from 1 to 3 hours post-dose as compared to the normal joints.

In

addition, the inflamed joints of these horses may have acted as a sequestered site of
elimination, as the synovial fluid withdrawn from horses with acute synovitis ranged
from 2.5 to 15 ml as compared to approximately 3.5 ml in normal horses. However,
this cannot be confirmed as elimination data from concurrent urinary and fecal
ketoprofen levels were not obtained in this study. To date, there are two published
studies on the plasma kinetics of ketoprofen in the horse. In the study by Sams et
ah, 1993, the reported harmonic mean of the half-life after one dose of 2.2 mg/kg of
intravenous ketoprofen was 1.6 hours with a range of 1.18 to 2.65 hours. After five
daily intravenous doses the harmonic mean of the half-life was 1.3 hours with a range
of 0.76 to 1.86 hours [283]. The half-life in normal horses in the present study
ranged from 0.62 to 1.65 hours.

Several differences in study design and

pharmacokinetic analysis are evident in these two studies. There may be a breed
difference in the pharmacokinetics of ketoprofen as most of the horses in the previous
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study were standardbreds weighing from 465 to 660 kg whereas most horses in this
study were Thoroughbreds weighing from 406 to 554 kg. The ketoprofen disposition
was described as a tri-exponential equation in the previous study whereas the data in
this study were best described by a bi-exponential equation. In addition, blood was
sampled in this study more often than in the Sams study, particularly during the early
stages (17 times versus 13). Further, all three volumes of distribution and the total
clearance values were lower in the present study as compared to data collected by
Sams. Again, these differences may be accounted for in part by the larger horses
used in the Sams study as these parameters are known to change in proportion to body
weight [416].
The distribution phase intercept (A) of normal horses (41.31 /ig/ml + 17.08)
was significantly greater than that of horses with acute synovitis (24.65 /xg/ml ±
4.90).

The significance of this effect is unknown.

However, the other

pharmacokinetic values were not different between groups with the exception of the
harmonic half-life. This may be due to the effect of an outlier in the normal horse
group with a particularly high distribution phase intercept value (66.82 /xg/ml).
Ketoprofen is a chiral compound with the center of asymmetry at C2.

The

commercial preparation is a racemic mixture of the R and S enantiomers. Upon
administration many species show conversion of the biologically inactive R enantiomer
to the active S enantiomer [417,418]. In humans, the there is an approximately 10%
inversion of the R enantiomer to the S after oral administration with little
stereoselectivity in the pharmacokinetics of these enantiomers.

Therefore,
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nonstereospecific assays may be used to explain the pharmacokinetics of the individual
enantiomers in man [284].

In a recent study by Jaussaud et ah, the plasma

pharmacokinetics of ketoprofen enantiomers in the horse were evaluated after
administration of the racemate by means of a stereoselective HPLC technique [286].
The plasma disposition curves were fitted to a bi-exponential equation. In contrast to
humans, the ratio of the S to R enantiomer increased over time and attained a 70:30
ratio at 50 minutes in the horse. The elimination half-lives of the enantiomers were
not significantly different statistically but the clearance rate and initial concentration
of the S enantiomer were lower than that of the R enantiomer. The total ketoprofen
disposition curve closely paralleled the S enantiomer curve. Further, these authors
noted a short elimination half-life (0.29 to 0.47 hours) as compared to the present
study, which may be accounted for by their relatively short sampling interval of 90
minutes.
Synovial fluid ketoprofen levels in normal horses were lower than plasma
levels at one hour, but the drug reached an equilibrium between the joint and systemic
circulation by 3 hours as synovial fluid levels approximated plasma concentrations at
this time. In contrast, ketoprofen synovial fluid and ketoprofen levels in horses with
acute synovitis reached equilibrium at one hour post-administration. In these horses
with acute synovitis, synovial fluid concentrations at 3 hours tended to be higher than
the corresponding plasma levels. In humans with arthritis this effect is common as
synovial levels often exceed plasma levels after the equilibrium time [280]. This
results from the relative sequestration of the drug in the synovial fluid with the lack
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of significant elimination occurring from the joint [402],

In horses with acute

synovitis the amount and persistence of ketoprofen in synovial fluid was greater than
in normal horses.

This was based on the significantly larger AUC, higher

concentration at one hour and longer duration of synovial fluid ketoprofen quantitation
for the horses with joint disease.
The effect of increased penetration of an NSAID into inflamed joints versus
normal ones has been reported in several species. In humans, NSAID joint levels
were higher in patients with synovial inflammation than normal non-inflamed joints.
NSAIDs reached levels in inflamed chicken joints that were three times higher than
in control joints. The inflamed joint levels approximated the corresponding plasma
levels at 2 hours post-dose [265].
Distribution of a drug to the peripheral tissues depends on the physicochemical
properties of the drug, the concentration of the drug in the plasma and tissue, the
blood flow to the tissue, percentage of plasma protein binding and the affinity of the
drug for the particular tissue [399,416]. Only free (unbound to plasma proteins) drug
is available to penetrate the endothelium and enter the synovial fluid. However, in
cases of synovitis, the damaged endothelial barrier allows transudation of plasma
proteins along with frank hemorrhage into the joint space leading to the accumulation
of albumin bound drug in the synovial fluid. NSAIDs bound to albumin are thought
to be released by the degradation of albumin by lysosomal enzymes in sites of
inflammation [257]. This one way flow of albumin serves to increase the tissue
concentration of the drug [258]. Also the lowered pH of the inflamed environment
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serves to keep these planar, anionic molecules unionized and thus increase membrane
permeability [247].

Ion trapping is postulated to occur intracellularly as the

environment inside the cell is relatively alkaline compared to the acidic inflamed tissue
[260,261,419].
The effects of protein binding on pharmacokinetics are greater for drugs that
are highly bound to plasma proteins and are bound in a concentration dependent
manner. For these drugs, small changes in binding often result in marked alterations
in drug disposition [420]. In the horse, ketoprofen is greater than 90.0% bound to
plasma proteins and this binding is constant over the range of therapeutic drug levels
[283]. Plasma and synovial fluid protein binding was not determined in the present
study. However, due to the reported linear protein binding in the horse, these data
obtained from total drug analytical methods were used as an estimate of free drug
kinetics. In addition, in humans there does not appear to be any difference in the
degree of protein binding between plasma and synovial fluid for ketoprofen [280].
Certain drugs have a high affinity for tissues and undergo sequestration or
depot formation.

These drugs may reversibly or covalently bind to subcellular

organelles, nucleic acids or cellular proteins and lipids. In cases of covalent binding
the drug release is dependent on the cell life span [416].

The R-enantiomer of

profens acts as a substitute for endogenous fatty acids and forms hybrid
triacylglycerols.

The drug may then be bound to lipid membranes for extended

periods of time [236,417]. Data from rat studies based on unbound drug disposition
suggest that ketoprofen has dose-dependent binding to tissue components [415]. This
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tissue binding may account for the low reported urine recovery of ketoprofen (57.2%)
in horses [283].

CHAPTER 6
EFFECT OF KETOPROFEN AND PHENYLBUTAZONE ON CHRONIC
PAIN AND DIGITAL VEIN EICOSANOID LEVELS
IN LAMINITIC HORSES

A. Introduction
Laminitis has been cited as one of the major causes of chronic hoof pain in the
horse [198]. Laminitis is classified as chronic after 48 hours of continual pain from
a laminitic episode or when ventral deviation or rotation of the distal phalanx occurs
[200]. It is associated with debilitation, hypertension, lameness and hoof pain which
may last for the life of the animal. The complex syndrome of equine laminitis has
multiple etiologies with a complex and poorly understood pathophysiology [199]. The
pathology within the foot is a manifestation of a systemic metabolic disorder that
affects the cardiovascular, endocrine and renal systems.
This disease is no longer defined as inflammation of the laminae of the foot,
but is more precisely defined as a peripheral vascular disease [200] characterized by
ischemic necrosis of the epidermal laminae, microvascular thrombosis, epithelial
hyperplasia, and hemorrhage [220,224-226]. It has been hypothesized that the laminar
ischemia develops acutely due to decreased capillary perfusion from opening of
arteriovenous shunts and vasoconstriction [220].
Bacterial endotoxin has been implicated as an inciting cause in laminitis. Many
horses with endotoxemia develop laminitis [220] and horses with carbohydrate
191
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overload-induced laminitis have increased plasma endotoxin levels and lameness [221].
Endotoxemia is associated with increased plasma levels of leukotriene B4(LTB4) [222],
prostaglandin Ej (PGEj) as well as other eicosanoids.

The administration of

nonsteroidal anti-inflammatory drugs (NSAIDs) prevents many of the effects of
experimentally induced endotoxemia [223].

Eicosanoids have been implicated as

mediators in laminitis due to the powerful vaso- and venoconstriction produced by
PGF^ and thromboxane [217] along with the well known hyperalgesic effects ofPGEj
[157,158] and LTB4 [166]. However, the association between endotoxin-induced
eicosanoid production and the development of laminitis remains a theory due to the
inability to produce laminitis following endotoxin administration.

Further,

concentrations of eicosanoids have not been measured in horses with acute or chronic
laminitis [220].
NSAIDs are commonly administered to reduce the pain and suffering
associated with laminitis and allow the animal to more comfortably stand and
ambulate, thereby promoting blood flow to the foot and reducing the adverse effects
of long term recumbency. According to Hood [199], horses that are treated with
analgesics early in the course of the disease have a lower incidence of rotation of the
distal phalanx than those treated later. NSAIDs are thought to be particular useful in
treating the coagulopathy within the foot because of their inhibitory effects on
eicosanoid formation and platelet function [199,234]. Previously, phenylbutazone (4.4
mg/kg) has been regarded as the single most important therapeutic agent in treating
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laminitis [231,233]. The effects of the recently approved NSAID, ketoprofen have
not been evaluated in horses with laminitis.
The purpose of this study was to determine if horses with chronic laminitis
have increased digital vein levels of PGE2 and LTB4 as compared to normal horses.
An increase in the concentration of eicosanoids in the venous drainage of the foot
would lend further evidence that these metabolites play a role in mediating the pain
and pathology within the foot. The digital vein was chosen as a sampling site due to
the difficulty in obtaining laminar tissue for eicosanoid level determination in live
horses. Horses were evaluated both at rest and after a brief exercise period in order
to determine if eicosanoids are released into the circulation after mild concussion to
the laminitic foot.
Provided that there were higher eicosanoid concentrations in laminitic versus
normal horses, the severity of hoof pain in these laminitic animals was to be
correlated with the eicosanoid concentrations. These horses were then to receive
ketoprofen and phenylbutazone in order to determine the magnitude and time course
of the eicosanoid inhibitory effects of these NSAIDs in animals with chronic laminitis.
Further, this study objectively quantitated and compared the analgesic effects of
phenylbutazone and the newly approved NSAID, ketoprofen in horses with chronic
hoof pain by means of an electronic hoof tester. The approved therapeutic doses of
ketoprofen (2.2 mg/kg) and phenylbutazone (4.4 mg/kg) were used. In addition, the
phenylbutazone molar equivalent dose of ketoprofen (3.63 mg/kg) was tested in the
laminitic animals in order to compare the potency of ketoprofen and phenylbutazone.
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B. Materials and methods
1. Experimental animals
a. Normal horses
Six healthy Thoroughbred mares ranging from 7 to 18 years of age were used
to determine digital vein PGEj and LTB4 concentrations. Horses were judged to be
healthy and sound based on physical examination and lameness evaluation.
b. Horses with chronic laminitis
Six horses (4 geldings, 2 mares; 4 American Quarter Horses, 1 Thoroughbred,
and 1 Morgan) diagnosed with chronic laminitis ranging from 3 to 22 years of age
were used for the collection of digital venous blood for determination of PGEj and
LTB4 concentrations. Seven horses with chronic laminitis (4 mares, 3 geldings; 5
Quarter Horses, 1 Thoroughbred and 1 Morgan) ranging from 3 to 18 years of age
were used in determining the analgesic effects of ketoprofen and phenylbutazone. The
diagnosis was based on: 1) degree of lameness as evaluated at a walk, trot and while
turning on a concrete surface; 2) hoof abnormalities associated with chronic laminitis
such as diverging hoof growth patterns with wider growth rings at the heel, subsolar
or mural abscesses, a convex shaped sole, and the presence of a ’seedy toe’ or an
abnormally large white line [200]; 3) radiographic evidence of laminitis such as
ventral deviation or rotation of the third phalanx as determined by Stick’s method
[228] (mean rotation + standard error, 13.75° ± 2.25), and osteolysis with
demineralization of the distodorsal aspect of the third phalanx [234]; 4) response to
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the hoof tester, particularly over the sole midway between the apex of the frog and
the toe; and 5) clinical history of a laminitic episode [231].
All horses were vaccinated at least three weeks prior against eastern and
western equine encephalomyelitis, influenza, tetanus (Equi-Flu EWT™, Coopers,
Mundelein, IL) and rhinopneumonitis (Rhinomune™, SmithKline Beecham Animal
Health, Exton, PA).

The horses were dewormed with oxibendazole (Equipar™,

Coopers, Mundelein, IL). Horses were housed in 10.9 x 12.5 feet stalls and were
maintained on 5 pounds of a pelleted ration (Purina Horse Chow 100™, Purina Mills
Inc., St. Louis, MO) containing: a minimum of 10% protein; 2% fat; a maximum of
25 % fiber; and a vitamin/trace mineral supplement twice daily with mixed grass hay
(11% protein, 1.4% fat, 24% fiber) and water provided ad libitum.
2. Drugs and reagents
a.

Drug solutions for administration

Ketoprofen (Ketofen™) was obtained commercially from Aveco Company,
Inc., Fort Dodge, IA. Each ml of the sterile solution contained: 100 mg ketoprofen;
L-arginine, 70 mg; citric acid to adjust pH to approximately 7; and benzyl alcohol,
0.25 ml as a preservative. Phenylbutazone (Butazolidin™) was obtained commercially
from Coopers Animal Health, Inc., Kansas City, KS. Each ml of the sterile solution
contained: phenylbutazone, 200 mg; sodium hydroxide to adjust pH to between 9.5
and 10.0; and benzyl alcohol, 10.45 mg as a preservative.
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3. Experimental protocol
a. Collection o f blood from digital veins
Blood was collected from 6 normal horses and 6 horses with chronic laminitis
before and after trotting for 5 minutes on a concrete surface. The lateral region of
the metacarpophalangeal joint of each normal and laminitic horse was shaved and
scrubbed with a povidone-iodine preparation and alcohol before each venipuncture.
Horses were restrained in a stanchion and nose twitched during venipuncture. Blood
was collected from the digital vein at the level of the metacarpophalangeal joint with
a 20 gauge, 1.0 inch needle. One to 2 ml of blood were discarded before collection
of 10 ml into chilled evacuated siliconized glass tubes (Vacutainer, Becton Dickinson,
Rutherford, NJ) containing 3.3 /tg/ml of BW755C (Wellcome Research Laboratories,
Beckenham, Kent, England) as an inhibitor of ex vivo eicosanoid synthesis and 10
mg/ml of the anticoagulant, disodium ethylenediamine tetraacetate (EDTA) purchased
from Sigma Chemical Company, St. Louis, MO. Tubes were immediately centrifuged
at 2,000 rpm for 15 minutes at 4°C (Beckman J21-B, Palo Alto, CA).

The platelet

poor plasma was transferred into 15 ml polypropylene centrifuge tubes (Sarstedt,
Newton, NC) and stored at -20°C until analyzed.
b.

Quantitation o f nociceptive thresholds in horses with chronic

laminitis
Ketoprofen (2.2 mg/kg and 3.63 mg/kg), phenylbutazone (4.4 mg/kg) and
saline as a control were administered via the left jugular vein to 7 horses with chronic
laminitis.

The following methods were used to evaluate analgesia before
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administration of NSAIDs (baseline) and at 3, 6 and 24 hours post-treatment.
Nociceptive or pain thresholds were determined in the test animals using a calibrated
electronic hoof tester according to the method of Kamerling, et al., [421-423]. This
device is a standard hoof tester equipped with a load cell welded to the tip of one jaw.
The tension/compression load cell (Sensotec Model 31, Columbus, OH) had 10 V
excitation, 2 mV/V output and a load capacity of 250 pounds. The calculated full
scale accuracy was 0.15% with 0.15% linearity and hysteresis.
The hoof tester was manually applied to the solar surface of each forefoot in
the traditional fashion [377]. Gradually increasing force over 2 seconds was applied
at 16 separate loci on the solar and posterior surfaces of each forefoot (Figure 28).
The force in Newtons required to produce a hoof withdrawal response by the
laminitic horse was designated the hoof compression threshold (HCT). A ’response’
to hoof compression was considered painful when the hoof was withdrawn from the
examiner’s hand or a contraction of the antebrachial musculature was noted by the
examiner and an independent observer. The examiner terminated hoof compression
at the initiation of the withdrawal response to avoid tissue damage. Loci that did not
result in hoof withdrawal or muscle contraction by the end of the 2 second
compression were deemed ’non-responsive’. The peak analog output (mV) of the hoof
tester transducer was converted to Newtons and recorded for each locus by a computer
(Commodore 64, England) equipped with customized software designed to test
nociceptive thresholds.

Left Hoof

LATERAL

R ig h t H o o f

MEDIAL

LATERAL

Figure 28: Diagram showing the position of the 16 loci tested on the solar surface of the left and right forefeet
of the laminitic horses. Locus 16 is tested by applying the hoof tester to the medial and lateral heel bulbs.
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During baseline hoof testing sessions, the computer recorded the peak force
applied to each locus and an independent observer entered (into the computer) whether
the locus was ’responsive’ or ’non-responsive’. All loci were tested again at 3, 6 and
24 hours after drug (or saline) administration. However, in the responsive loci, HCTs
were elicited using a compression cutoff of 50% above baseline. This was calculated
by the computer for each baseline locus which was ’responsive’ to hoof compression.
The computer was equipped with an audible bell that signaled when 50% above
baseline HCT had been reached so that the examiner could terminate compression.
Therefore, post-treatment compression in the ’responsive’ loci was terminated either
when a withdrawal response was initiated by the horse or the cutoff value was
reached. ’Non-responsive’ loci received approximately the same pressure on post
treatment sessions as baseline, unless the loci became responsive in a post-treatment
session. In that case compression was terminated when a withdrawal response was
initiated.
The number of responsive (pain sensitive) loci on each foot was recorded
during each hoof test session and expressed as a percentage of the total number of loci
tested per horse. A subjective assessment of the hoof withdrawal response following
hoof compression was made by the examiner. A subjective grade of 0 to 4 was used
to indicate the weakest to strongest response as follows:
Grade 0: No response to hoof compression.
Grade 1:

The horse contracted the antebrachial musculature with mild

extension of the shoulder, but the foot was not moved appreciably.
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Grade 2: The horse extended the shoulder and briefly attempted to withdraw
the foot from the examiners grasp.
Grade 3: Moderate excursion of the limb and foot occurred, but the foot was
not removed from the examiners grasp.
Grade 4: The horse quickly and forcefully withdrew the limb and attempted
to place the foot on the ground.
c.

Evaluation o f lameness in laminitic horses

Lameness was assessed {lameness score) immediately before each hoof test
session according to a modified Obel scale [200] as follows:
Grade 1: The horse exhibited a normal gait at a walk. The trot showed a
shortened stride with an audible cadence abnormality, but showed even head
and neck lifting for each foot.
Grade 2: The walk was stilted, but showed no abnormal head or neck lifting.
The trot showed obvious lameness with uneven head and neck lifting. A
forefoot could be lifted off the ground easily.
Grade 3: The lameness was obvious at a walk and trot. The horse resisted
attempts to have a forefoot lifted and was reluctant to move.
Grade 4: The horse experienced difficulty bearing weight at rest or was very
reluctant to move.
Preliminary studies indicated that this scale was not sensitive to subtle changes in
lameness that occur over time in laminitic horses e.g., head and neck lifting becoming
more/less pronounced. Further, numerical rating scales consisting of only 4 lameness
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grades are known to be less sensitive compared to other grading schemes [424].
Consequently, the above enumerated scale was expanded to include 3 divisions per
grade by adding a 4- or - to each lameness grade to indicate the degree of severity
associated with the score. Therefore, this modified lameness scale ranged from 0
(sound) to 12 (non-weight bearing).
4. Eicosanoid determination
a. Extraction
Plasma obtained from digital venous blood was extracted using a liquid/liquid
extraction technique prior to determination of PGE2 and LTB4 by enzyme-linked
immunosorbent assay (ELISA) [333]. Four ml were extracted for both the LTB4 and
PGE2 assays. All samples were processed in duplicate. Plasma was acidified and
then three volumes of ethyl acetate were added to extract the eicosanoids. After
vortexing, centrifugation and separation of aqueous and organic layers, the ethyl
acetate was evaporated under nitrogen. Samples were then dissolved in phosphate
buffer just prior to the ELISA procedure. For a more complete description of the
extraction procedure and recovery information refer to Chapter 3.
b. ELISA
Quantitation of plasma eicosanoids was achieved using commercially available
PGE2 and LTB4 ELISA kits (Advanced Magnetics, Cambridge, MA) [425]. These
assays were based on the principle of a competitive ELISA where PGEj or LTB4 in
the sample competed with fixed amounts of alkaline phosphate labelled PGE2 or LTB4
for binding to the specific rabbit antibody bound to the microtiter well. Results were
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determined by means of a Dynatech MR5000 ELISA micro-titer plate reader
(Dynatech Laboratories, Alexandria, VA).

Absorbance (read at 410 nm) was

correlated with concentration by means of a standard curve ranging from 10 to 5000
pg/ml. Quantitation of unknown samples was achieved by averaging the absorbance
of sample duplicates and calculation of the concentration from the standard curve. All
sample concentrations were then corrected for extraction efficiency. For a more
complete description of the ELISA procedure see Chapter 3.
5. Statistical design and data analysis
a. Eicosanoid concentrations
PGE2 and LTB4 plasma concentration data were analyzed using a univariate
analysis of variance for a split-plot design [389] where group (normal or laminitic)
constituted the main plot and status (resting digital vein or post-exercise digital vein)
was the subplot [386,387]. When indicated, multiple comparisons between groups or
status categories were performed using a Tukey’s w Procedure [388]. Differences
between groups or status categories were considered significant when P < 0.05.
b. Nociceptive thresholds and lameness grade
Each laminitic test subject received ketoprofen (2.2 mg/kg and 3.63 mg/kg),
phenylbutazone (4.4 mg/kg) and saline intravenously according to a Latin square
design [385]. Horses received one treatment per week for four weeks. The study was
performed in a double-blind fashion as neither the person performing the analgesic
tests nor the injector were aware of the treatment.
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To minimize variance in pain thresholds over experimental days, all data were
expressed as percent change from baseline for each horse at each post-treatment time
within a given session. In addition, HCT (for responsive loci) and subjective grade
of hoof withdrawal reaction data were expressed as an average over all baseline
responsive loci for each horse at the post-treatment times. Data were analyzed using
one-way analysis of variance (ANOVA) for repeated measures [386,387]. When
indicated by ANOVA, multiple comparisons were performed using a Tukey’s w
Procedure [388].

Differences between treatments at each time were considered

significant when P < 0.05.

C. Results
1. Digital vein eicosanoid concentrations
Mean digital vein PGE2 and LTB4 concentrations are shown in Figure 29.
Within each group (normal and laminitic), there were no differences in resting and
post-exercise PGEz digital vein concentrations.

Between groups, there were no

differences in digital vein concentrations of PGEj.

The mean PGE^ digital vein

concentration for the two groups was 187.18 pg/ml.

For the LTB4 digital vein

concentrations, there were no differences in resting and post-exercise levels within
groups (normal and laminitic). As with PGEj, there were no differences in digital
vein concentrations of LTB4 between groups.
concentration for the two groups was 74.71 pg/ml.

The mean LTB4 digital vein
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Figure 29: Mean plasma PGEj and LTB4 concentrations in pg/ml (± SEM) obtained from digital vein of 6
normal and 6 laminitic horses at rest and after exercise.
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2. Nociceptive thresholds and lameness grade
The effect of NSAIDs and saline on HCTs in horses with chronic laminitis is
shown in Figure 30. Ketoprofen (3.63 mg/kg) significantly increased the HCT as
compared to saline at 3 and 6 hours post-treatment. At 3 and 6 hours after treatment,
the horses administered this dose of ketoprofen tolerated an average increase in
compressive force (as compared to baseline) of 19.74% and 23.35%, respectively.
Even though there were significant effects as compared to saline, there were no
differences between NSAIDs at 3 or 6 hours.
In order to determine the degree of variation in compression applied to a nonresponsive locus over the course of time, the coefficient of variation (CV) of nonresponsive loci HCT’s elicited during the experimental day was determined. This
value was obtained for each of 4 non-responsive loci in 4 horses by obtaining the
mean and standard deviation of HCTs elicited at hoof test sessions before treatment
and at 3, 6 and 24 hours after treatment. An overall CV was calculated by averaging
all individual CVs across horses. Non-responsive locus CVs for an experimental day
ranged from 1.18% to 9.50%. The overall average CV for a total of 16 loci in 4
horses was 3.81% with a standard deviation of 2.30.
The percentage of responsive loci per horse was unaffected by any treatment
at 3 hours after drug dosing (Figure 31). However, at 6 hours all NSAIDs produced
a lower percentage of responsive loci as compared to the saline control (29.49%). By
24 hours, ketoprofen at 3.63 mg/kg (-3.87%), and phenylbutazone (-2.50%) continued
to produce a significantly lower percentage of responsive loci as compared to saline
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Figure 30: Effect of NSAIDs and saline on mean hoof compression thresholds (+ SEM) in 7 laminitic
horses. Dissimilar superscripts indicate statistically significant differences in treatments at P < 0.05.
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Figure 31: Effect of NSAIDs on mean percentage of responsive or pain sensitive loci (+ SEM) in 7
laminitic horses. Dissimilar superscripts indicate statistically significant treatment differences at P <
0.05.
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(30.48%), with apparent recovery in the horses treated with 2.2 mg/kg of ketoprofen
(7.19%). There were no differences among NSAIDs at 6 or 24 hours. The number
of responsive loci in horses administered saline increased over time while there was
very little change in horses administered NSAIDs.
The 3.63 mg/kg dose of ketoprofen (-8.25%) reduced the subjective grade of
hoof withdrawal response at 3 hours when compared to saline (9.89%). All NSAIDs
reduced this grade at 6 hours (Figure 32). By 24 hours, only the 3.63 mg/kg dose of
ketoprofen (-9.63%) had reduced the grade of withdrawal response as compared to
saline (11.64%). There were no differences among NSAIDs at any of the times
tested.
At 3 hours post-treatment, there were no significant effects on the lameness
grade (Figure 33). By 6 hours, only the 3.63 mg/kg dose of ketoprofen (-21.43%)
reduced the lameness grade when compared to saline (14.29%).

There were no

significant differences between individual NSAIDs. This effect continued through the
24 hour post-treatment period.

D. Discussion
In the 7 horses with chronic laminitis, the digital vein concentrations of PGE2
and LTB4 were not significantly different from corresponding concentrations in the 6
normal horses. Further, there was no difference in the digital vein concentrations of
PGE2 and LTB4 after a brief exercise period in any of the horses. These results show
that horses with hoof pain and lameness from chronic laminitis do not have an
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Figure 32: Effect of NSAIDs and saline on mean subjective grade of hoof withdrawal response (± SEM)
in 7 laminitic horses. Dissimilar superscripts indicate statistically significant treatment differences at P <
0.05.
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increase in the plasma eicosanoids in the venous drainage of the foot as compared to
normal horses even after mild concussion to the foot. These data do not support the
hypothesis that eicosanoids play a role in mediating the pain and pathology of chronic
laminitis. However, it must be noted that eicosanoids were not measured in laminar
tissue which is the site of pathology within the foot. It may be that tissue
concentrations were not sufficiently elevated to increase levels in the venous blood.
Other researchers have been able to demonstrate increased circulating levels of
eicosanoids with a local disease state. An increased plasma leukotriene concentration
has been reported in children with asthma as compared to healthy subjects [426].
Similarly, significantly higher than normal venous plasma prostaglandin and
thromboxane levels have been described in calves [427] and humans with lung disease
[428].

Further, plasma PGEj [140] and serum LTB4 [141] levels of patients with

rheumatoid arthritis are reportedly higher than normal controls and the time course
of changes of PGEj in blood plasma levels reflects the disease dynamics [140]. It is
possible that eicosanoids may play a role only in the acute phase of the laminitis
where hoof pain and the circulatory changes are more pronounced [220].
The overall average PGE2 level in the digital veins of normal and laminitic
horses was 187.18 pg/ml. Plasma PGE^ levels obtained from other species which
range from 14.35 to 517 pg/ml [333,349,427,429]. The mean LTB4 level in digital
plasma as determined in normal and laminitic horses was 74.71 pg/ml.

This is

approximate to the plasma levels in humans which are reported to be less than 100
pg/ml [430]. It should be noted that eicosanoid concentrations vary considerably
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depending on the sampling site, species, extraction and method of quantitation. It is
theorized that actual circulating eicosanoid levels do not exceed 2 pg/ml [24].
Therefore, even minor trauma occurring during collection of blood plasma may result
in ex vivo formation of eicosanoids which accounts for the wide range of
concentrations reported [24].

These reported values then cannot be regarded as

absolute and should only be used for comparison when obtained under identical
circumstances.
One of the objectives of this study was to correlate the severity of hoof pain
in these laminitic animals with the eicosanoid concentrations, provided that there were
higher eicosanoid concentrations in laminitic versus normal horses. These horses
were then to be administered ketoprofen and phenylbutazone in order to determine the
magnitude and time course of the eicosanoid inhibitory effects of these NSAIDs. This
objective could not be accomplished due to the lack of significant eicosanoid
differences in laminitic versus normal horses
Although the pain and lameness in these laminitic horses could not be
definitively attributed to eicosanoids, both effects were reduced by the systemic
administration of NSAIDs.

Statistically significant overall treatment effects were

observed for all measures of nociceptive threshold and lameness.

However,

ketoprofen at a dose of 3.63 mg/kg (1.65 times the approved therapeutic dose)
produced a more pronounced and longer lasting reduction in most of the objective and
subjective indices of pain and lameness. For lameness grade and HCT, the high dose
of ketoprofen produced the only significant treatment effects that were different from
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saline upon multiple comparison. This dose of ketoprofen produced effects even at
24 hours for 3 of the 4 pain tests, including lameness grade. However, it should be
noted that there were no significant differences between the NSAIDs at any of the
times for all 4 tests. These treatment means were within + 20% of one another. The
hoof is somewhat limited in terms of sensitivity as a bioassay for analgesia. This
device is better at demonstrating the pain relieving effects of potent central analgesics
[425].
In this study, horses that were administered saline became progressively more
lame and the number of responsive loci along with the grade of withdrawal response
increased over the course of the hoof test session as compared to horses administered
NSAIDs.

This would indicate that these animals were becoming hyperalgesic

(excessive sensitivity to mechanical stimuli) and hyperpathic (an abnormally
exaggerated subjective response to painful stimuli) [155]. It is known that NSAIDs
usually do not completely block pain, but primarily reverse the hyperalgesia associated
with painful conditions [163]. These agents reduce the peripheral afferent discharge
from hyperalgesic regions [197,266], and also have central anti-hyperalgesic effects
[272,305] that may not be dependent on eicosanoid inhibition [258,276]. The results
of this study indicate that NSAIDs reduced the hyperalgesia associated with chronic
laminitis.
Ketoprofen is approved at a intravenous dosage rate of 2.2 mg/kg, once daily.
This dose of ketoprofen did not produced any significant effects on hoof pain or
lameness at 24 hours. This would not support the recommended once daily dosing
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interval for ketoprofen at the 2.2 mg/kg dose. It appears that laminitic horses might
benefit from a slightly increased dosage rate of ketoprofen.

This dose was not

associated with any apparent clinical toxicity in the animals in this study. Although
more extensive toxicity studies are needed, one study has shown that up to five times
the therapeutic dose (11.0 mg/kg,IV) produced no evidence of toxicity after 15 days
[309].
This study also served to further evaluate the electronic hoof tester and the
model of chronic pain in horses. There was close agreement among the data from all
4 pain tests which supports the accuracy and validity of the subjective measures of
hoof pain and lameness (subjective grade of hoof withdrawal, lameness score) as
compared to the objective measures (HCT, number of responsive loci). The degree
of variation in compression applied to a non-responsive locus as determined by the
CVs of non-responsive loci HCT’s elicited during the experimental day was minimal.
This indicates that the compression applied to a particular loci was consistent over
time.

CHAPTER 7
GENERAL CONCLUSIONS

Carrageenan-induced synovitis of the equine carpus proved to be self-limiting
and reproducible model of acute inflammation. The synovitis was associated with
quantifiable increases in prostaglandin

(PGE2) and leukotriene B4 (LTB4)

concentrations in synovial fluid along with other measurable joint inflammatory
responses.

PGE2 concentrations rose dramatically over time with peak levels

occurring at 9 hours, with gradual decreases to near baseline at 48 hours. LTB4
concentrations in synovial fluid peaked early in the inflammatory process at 3 hours
then quickly returned to baseline. The primarily neutrophilic cellular influx into the
synovial fluid was extensive, with peak levels occurring from 6 to 9 hours. These
findings are consistent with other forms of carrageenan-induced inflammation. The
inflammation was apparently non-septic and transient as horses returned to soundness
by 48 hours with no subsequent clinical signs of degenerative joint disease.
Phenylbutazone decreased the concentrations of PGE2from 6 to 12 hours post
dose, whereas the therapeutic and equi molar doses of ketoprofen were associated with
more short lived prostaglandin inhibitory effects. There was no ketoprofen doseresponse relationship observed for prostaglandin concentrations or any of the other
parameters.

Further, the therapeutic dose of ketoprofen inhibited prostaglandin

production to a greater extent than the higher dose at 6 and 9 hours post-dose. This
may in part be due to the small difference in the two doses chosen and the variability
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associated with PGE2 measurement. Future studies using ketoprofen at doses of 4.4
mg/kg and higher, and perhaps in vitro experiments on the effect of ketoprofen on
prostaglandin

metabolizing

enzymes,

would

possibly

clarify

this

effect.

Although ketoprofen and phenylbutazone had no significant influence on
synovial fluid LTB4 concentrations, all drugs appeared to elevate the levels as
compared to saline at the time of peak increases. Phenylbutazone appeared to have
the greatest potentiation followed by the therapeutic dose of ketoprofen. This effect
has been reported for many nonsteroidal anti-inflammatory drugs (NSAIDs) and has
been attributed to a diversion of arachidonic acid substrate after cyclooxygenase
inhibition to the lipoxygenase pathway. Based on these experiments in this study,
ketoprofen was not an inhibitor of lipoxygenase. Other reports have both confirmed
and refuted these results, as inhibition of cyclo- and lipoxygenase enzymes by
NSAIDs varies depending on the dose, species, metabolite measured and the model
of inflammation. These studies do support data from other species suggesting that
leukotrienes are involved in joint inflammation, and development of drugs which
inhibit their synthesis may be of therapeutic value.
Phenylbutazone was more effective than ketoprofen in alleviating many of the
clinical signs of pain and inflammation in this model of acute synovitis.
Phenylbutazone had activity lasting as long as 24 and 48 hours post-dose for some of
these measures of joint inflammation.
The plasma half-life of the therapeutic dose of ketoprofen was less than one
hour. Horses with acute synovitis had significantly shorter plasma half-lives than
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normal horses.

This can be attributed to the significantly higher synovial fluid

concentration of ketoprofen in horses with acute synovitis. In addition, ketoprofen
may have been sequestered in the inflamed joint as the synovial fluid levels were
greater than plasma concentrations at 3 hours post-administration. Synovial fluid
levels of ketoprofen in horses with acute synovitis were detectable from 1 to 9 hours
post-dose while this dose produced significant anti-inflammatory activity from 3 to 9
hours. Data from other studies suggest that ketoprofen and other NSAIDs may bind
to tissue components for substantial lengths of time in a dose-dependent manner. Such
data may help to explain the relatively long duration of action in comparison to the
short plasma half-life of these drugs.
Digital vein eicosanoid concentrations were not different between horses with
chronic laminitis and normal horses. These data do not support the hypothesis that
eicosanoids play a role in mediation of the pain and pathology of chronic laminitis.
However, eicosanoids may play a role locally in the laminar tissue without producing
measurable concentrations in the digital vein. Alternatively, these compounds may
be released during the acute phase of the laminitis where hoof pain and circulatory
changes are more pronounced. Although the pain and lameness in the laminitic horses
could not be attributed to eicosanoids, both effects were reduced by the systemic
administration of NSAIDs at doses which reduced PGEz in synovial fluid. The high
dose of ketoprofen produced a more pronounced and longer lasting reduction in most
of the measures of hoof pain and lameness than the other NSAIDs.

This dose

produced effects lasting for 24 hours for most of the pain tests, including lameness

218
grade. The therapeutic dose of ketoprofen was effective in 2 of the 4 pain tests at 6
hours.

Horses administered saline became progressively more lame and had

increasing hoof pain over the course of the experimental session as compared to
horses administered NSAIDs.

These results indicate that rather than producing

analgesia, these NSAIDs reduced the hyperalgesia associated with chronic laminitis.
This effect has been well documented for NSAIDs and may be independent of
eicosanoid inhibition.

The severity of hoof pain could not be correlated with

eicosanoid concentrations in the horses with chronic laminitis due to the lack of
significant differences in normal and laminitic horses.
Procedures for extraction and measurement of PGE2 and LTB4 equine plasma
and synovial were evaluated. The solid phase extraction procedure that was developed
resulted in adequate recovery for both compounds from equine biological samples.
An enzyme-linked immunosorbent assay (ELISA) was used for quantitation of LTB4
and PGEz that had not been previously documented in the horse.

Available

information suggested that considerable cross reactivity with PGEj occurred in the
PGE2 ELISA while the LTB4 was very specific. The results from the validation
procedures for the PGEj ELISA indicated that the assay was specific for this
compound in equine synovial fluid.
In conclusion, the results of these studies indicate that NSAIDs differ in
potency and efficacy depending on the type of pain and inflammation present. In
acute experimentally-induced synovitis, where the duration of clinical signs lasted
approximally 48 hours, phenylbutazone was more potent in relieving the joint
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inflammation and pain than either the therapeutic or the equimolar dose of ketoprofen.
In naturally occurring chronic laminitis, where horses experience pain and pathology
within the foot for months or years, the high dose of ketoprofen was more potent than
either the therapeutic dose of ketoprofen or the equimolar dose of phenylbutazone.
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